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MODULATION OF THE PLASMINOGEN SYSTEM BY THROMBIN  ACTIVATABLE 






 Thrombin activatable fibrinolysis inhibitor 
Thrombin activatable fibrinolysis inhibitor (TAFI, EC 3.4.17.20) was 
discovered at the end of the 80s, when two groups identified independently 
an unstable carboxypeptidase present in serum preparations. They named 
it carboxypeptidase R [1] and carboxypeptidase U [2], respectively. Another 
group [3] was studying the mechanism of the antifibrinolytic action of 
thrombin in tissue-type plasminogen activator (tPA)-mediated plasma clot 
lysis. They spent the following years searching for the “de Fouw Factor”, 
which was responsible for this effect. Still, this puzzle only started to 
be unveiled [4] when TAFI was identified as a contaminant during the 
purification of α2-antiplasmin and named plasma procarboxypeptidase B 
[5]. Finally in 1995, the protein was rediscovered when seeking to explain 
the profibrinolytic effect of activated protein C (APC) [6]. The protein was 
named TAFI because it could be activated by thrombin and when active 
inhibited fibrinolysis.
TAFI has been suggested to circulate in a complex with plasminogen [5,7] 
but this seems to be based only on its affinity for plasminogen in a purified 
system and direct evidence is still missing. TAFI was shown to bind to 
plasminogen, which was immobilised on a Sepharose column and, using a 
BIAcore system, it was found that the affinity of TAFI for Lys-plasminogen 
was 10-fold higher than for Glu-plasminogen (Kd - 0.035 µM and Kd - 0.3 
µM, respectively) [7].
TAFI is a basic procarboxypeptidase, which is synthesised in the liver 
and released into the circulation as a single-chain glycoprotein of 60 kDa 
(Fig.1). Four of the five potential N-linked glycosylation sites are located on 
the activation peptide with the carbohydrates accounting for about 20% 
of the zymogen total mass [5,8-10]. As a result, the activation peptide 
migrates as a broad band on SDS-PAGE, which is difficult to visualise with 
standard staining procedures such as Coomassie brilliant blue (Chapter 
2). The N-glycosylation site located in the catalytic domain (Asn219) was 
also found in an unglycosylated form. This suggests that TAFIa exists in 
both a glycosylated and unglycosylated variant [9]. The disulphide pattern 
of TAFI, composed of three intrachain disulphide bonds, is homologous to 
that of pancreatic carboxypeptidase B (CPB) [9] as previously predicted 
[11]. Therefore the disulphide pattern of TAFI was unable to explain the 




TAFI has also been identified in platelets where it is stored intracellularly 
and seems to be synthesised during the intermediate and late stages of 
megakaryocytopoiesis [12]. This TAFI pool can be secreted upon platelet 
activation increasing the local TAFI concentrations within the fibrin mesh.
The proenzyme TAFI requires proteolytic cleavage at Arg-92 (Fig.1) in order 
to release the activation peptide and uncover the active site, generating the 
active enzyme (TAFIa, 36 kDa). Thrombomodulin (TM), a transmembrane 
glycoprotein receptor of thrombin required for the activation of protein C 
(PC) was found to work as a cofactor for thrombin in the activation of TAFI 
Figure 1. Schematic depiction of the activation and inactivation of TAFI.
The proenzyme TAFI (60kDa) consists of 401 amino acids and contains 5 N-
glycosylation sites located on the activation peptide (Asn22, Asn51, Asn63, Asn86) 
and on the catalytic domain (Asn219). Activation occurs by a single cleavage at 
Arg92 which results in the formation of TAFIa (36kDa) and release of the activation 
peptide. The complex between thrombin/thrombomodulin is seen as a likely 
activator in vivo though plasmin might also behave as a physiological activator of 
TAFI. Due to thermal instability TAFIa will undergo a conformational change and 
become inactive (TAFIai, 36kDa). This inactive form is in turn more susceptible to 
proteolytic cleavage at Arg302 by thrombin leading to the formation of degraded 
TAFIai (25kDa). Plasmin is capable of cleaving TAFI and TAFIa at additional sites 




[6,13,14]. When the complex between thrombin and thrombomodulin, in 
the presence of calcium [15], is formed the activation of TAFI and PC are 
enhanced 1250-fold [13] and 1000-fold [16], respectively. However, when 
PC is bound to the endothelial protein C receptor (EPCR), an additional 
stimulation of the activation by thrombin/thrombomodulin complex is 
accomplished (20-fold) [16]. The active enzymes, TAFIa and APC, have 
opposing effects on the haemostatic balance with one resulting in the 
down-regulation of fibrinolysis while the other down-regulates coagulation. 
The preference for TAFI or PC activation depends on the thrombomodulin 
concentration with low TM concentrations (< 5 nM) favouring TAFI activation 
and higher TM concentrations (~10 nM) leading preferentially to the 
activation of PC [17]. Interestingly, different domains of thrombomodulin 
are required for the activation of either TAFI or PC. Epidermal growth factor 
(EGF)-like repeats 4-6 of TM provide normal cofactor function for effective 
activation of PC by thrombin while TAFI in addition to the EGF-like domains 
4-6 also requires a part of the EGF-like domain 3 [18-20]. Thrombomodulin 
has been detected in a variety of cells and tissues and TM expression is 
known to fluctuate on the endothelium according to the vessel size with 
larger vessels, such as arteries, bearing lower TM concentrations than 
smaller ones, such as capillaries. In addition, the presence of soluble TM in 
the circulation is used as a prognostic marker of endothelial cell membrane 
injury [21].
Activation of TAFI can also be mediated by trypsin or by plasmin by a single 
cleavage at Arg-92 in analogy to the activation mediated by thrombin 
[5,22]. The efficiency of TAFI activation by plasmin increases around 15-
fold in the presence of heparin or other glycosaminoglycans (GAGs) [23]. 
These GAGs are synthesised by endothelial cells and are present in the 
extracellular matrix and on the cell surface [24].
The mechanism of TAFI in the inhibition of fibrinolysis
After the formation of a thrombus, the fibrinolytic system starts off by 
binding plasminogen and tissue-type plasminogen activator (tPA) to the 
fibrin mesh. This binding is mediated by specific interactions between 
internal lysines in fibrin and lysine-binding sites in plasminogen and tPA 
[25]. This first phase of plasmin generation slowly initiates fibrin degradation 
creating new C-terminal lysine residues, which during the second phase 




is able to hydrolyse these C-terminal lysines from partially degraded 
fibrin, restricting plasminogen binding and plasmin generation and thus 
inhibiting fibrinolysis (Fig.2) [6,15,28]. Correspondingly, treatment of 
fibrin degradation products with TAFIa reduced their cofactor activity in 
DSPA and tPA-mediated plasminogen activation [29]. Moreover, plasmin 
bound to C-terminal lysine residues is more resistant to inactivation by 
its naturally occurring inhibitors [30,31]. It has been shown in a purified 
system that TAFIa was able to abrogate this protection by removing these 
C-terminal lysines forcing plasmin to remain in solution where it is rapidly 
inhibited by α2-antiplasmin [32].
Besides the role of these C-terminal lysine residues during thrombus 
resolution, C-terminal arginine and lysine residues were shown to mediate 
other extracellular protein-protein interactions, which are important during 
wound healing [33], control of inflammation [34-36], cellular migration 
[33,37], cellular adhesion [35,38] and in the regulation of cellular 
fibrinolysis [39] [40-43](Fig.2).





Regulation of TAFIa activity - role of stability and inhibitors
So far, TAFIa has no known physiological inhibitor and regulation of TAFIa 
activity occurs by a spontaneous temperature-dependent process, which 
results in a conformational change and in the generation of inactivated 
TAFIa (TAFIai). This has been schematically depicted in figure 1. Hence, 
TAFIa activity is highly sensitive to temperature with the half-life of TAFIa 
increasing from about 10 min at 37oC, 45 min at 30oC to stable at 0oC 
[8,10,44]. In addition, TAFIa is stabilised in the presence of a substrate or 
of a competitive inhibitor [45]. After TAFIa undergoes the conformational 
change it becomes more prone to proteolysis [7] by thrombin at Arg302 
(Fig.1) [10,23,44]. Besides being able to activate TAFI (Arg92), plasmin is 
capable of inactivating TAFI and TAFIa by proteolytic cleavage at Arg327 
and Arg330 [46]. Interestingly, epsilon-amino caproic acid (ε-ACA) is able 
to protect TAFI from plasmin-mediated cleavage at Arg327 and Arg330 
but not at Arg92 [46]. Similarly, ε-ACA is also able to limit the proteolytic 
cleavage of TAFI by trypsin [7].
Given that TAFIa is a zinc-containing metallocarboxypeptidase [47], zinc-
chelating agents [5], such as 1,10-phenantroline result in inhibition. Other 
inhibitors of TAFIa have also been described such as, ε-ACA, guanidinoethyl-
mercaptosuccinic acid (GEMSA) and DL-2-mercaptomethyl-3-guanidinoethyl
thiopropanoic acid (MERGETPA) [2,7,48,49]. Still, in most in vitro work and 
in in vivo animal experimental models, potato carboxypeptidase inhibitor 
(PCI, also referred to as PTCI and CPI) has been used as a specific TAFIa 
inhibitor. At the concentration used, PCI specifically inhibits TAFIa but not 
carboxypeptidase N (CPN), the other basic carboxypeptidase present in 
plasma [50]. CPN is constitutively active and shows a preference for C-
terminal lysines over C-terminal arginines. On the contrary, TAFIa displays 
greater substrate specificity for C-terminal arginines [22]. Recently, 
PCI and GEMSA were demonstrated to be able to inhibit or enhance the 
antifibrinolytic activity of TAFIa depending on the concentration of inhibitor 
as well as the concentrations of tPA and TAFIa [45,51].
TAFI function - insights from animal models
Although the in vivo relevance of TAFIa as a regulator of fibrinolysis is not 
yet clearly established, convincing data are available from several animal 




The potential role for TAFI as a natural anti-inflammatory agent (Fig.2) 
by inactivating inflammatory mediators, such as the complement-derived 
inflammatory peptides C3a and C5a and bradykinin, has also been 
investigated. Both in vitro and some in vivo evidence is available that 
corroborates a role for TAFI in the regulation of inflammation [34-37].
Recently, TAFI knock-out mice have been generated by different groups 
[33,37,58]. These mice did not present a clear phenotype displaying 
normal embryonic development and normal life expectancy. The mice 
were fertile with pregnancies carried out to full term and no differences 
were found either in the haemostatic parameters or in liver and kidney 
functions. TAFI knock-outs were also subjected to a number of acute 
Figure 3. Schematic representation of the genomic organisation of the 
human TAFI gene and of the TAFI gene polymorphisms. (A) The TAFI gene is 
composed of 11 exons represented as numbered boxes (length in bases) separated 
by introns (length in kbases) [61]. The part in white on exon 1 represents the 
signal peptide, composed of 22 amino acids, which is removed intracellularly. The 
exons depicted in grey represent the sequences encoding for the TAFI protein with 
the activation peptide spanning from exon 1-3b, where the activation site (R92) 
is located. A putative C/EBP binding site has been identified between positions -
53 and -40 of the promoter as well as a glucocorticoid response element (GRE) 
between nucleotides -92 and -78 [62]. (B) The location of TAFI polymorphisms 
identified in the promoter (5’-Flanking region in white) [68,69], in the coding 
region [70,71] represented by the exons and in the 3’-untranslated region (3’-




challenges aiming to invoke a phenotype. Both models for venous and 
arterial thrombosis were employed with similar responses in knock-out and 
control animals. In addition, TAFI deficiency did not produce any advantage 
in thrombin-induced thromboembolism, factor X coagulant protein-induced 
thrombosis or endotoxin-induced disseminated intravascular coagulation 
and did not alter kaolin-induced disseminated intravascular coagulation. 
Notwithstanding, a recent paper [37] demonstrated a clear role for TAFI 
as a modulator of the plasmin(ogen) system in vivo by combining TAFI 
deficiency with a plasminogen heterozygous deficiency background. Of 
special interest was the fact that TAFI inhibited not only the fibrinolytic 
functions of plasminogen but also its cell migratory functions. This new 
role for TAFI as a modulator of cell-migrating and/or -invading functions 
seems to extend to other cell types. Another recent report has found a 
mild wound-healing defect in TAFI knock-out mice, which points to an 
involvement of TAFI in tissue repair processes [33].
Genomic organisation of the TAFI gene
The TAFI gene was mapped to chromosome 13q14.11 [59,60] and consists 
of 11 exons, spanning about 48 kb of genomic DNA [61] (Fig.3A). The 
TAFI promoter lacked a consensus TATA sequence resulting in the initiation 
of translation from multiple sites [61]. Three distinct polyadenylation sites 
were identified in the 3’-untranslated region (3’-UTR) of the TAFI gene 
[61] (Fig.3A).
The promoter sequences between nucleotides -141 and -73 were found 
to be crucial for liver-specific transcription [61]. In this region, a putative 
CCAAT/enhancer-binding protein (C/EBP) binding site was identified 
between positions -53 and -40 of the promoter as well as a glucocorticoid 
response element (GRE) between nucleotides -92 and -78 [62].
TAFI was shown to be an acute-phase protein in mice as injection of these 
animals with bacterial lipopolysaccharide (LPS) led to an increase both 
in TAFI plasma concentrations and in TAFI mRNA abundance in the liver 
[63]. By contrast, intravenous injection of LPS in healthy male volunteers 
brought about a decrease in TAFI antigen levels [64]. Still, in humans the 
plasma concentration of TAFI, C-reactive protein (CRP) and haptoglobin 
were correlated [65].




in HepG2 cells [66]. IL-1 and IL-6 administration in combination induced 
a decrease in TAFI mRNA abundance, which was related to changes in 
the stability of the TAFI mRNA transcript. Alternative polyadenylation can 
result in rapid changes in transcript abundance by altering, for instance the 
mRNA stability. In agreement, the TAFI 3’-untranslated region was found 
to contain a cis-acting instability element that determines the stability of 
the TAFI transcripts [67].
TAFI gene polymorphisms
The TAFI gene has been scrutinised for single nucleotide polymorphisms 
(SNPs) in the promoter, coding and 3’-untranslated regions (Fig.3B). In 
the literature, nine SNPs were accounted for in the promotor (5’-flanking 
region) of the TAFI gene (-152 A/G; -438 G/A; -530 C/T; -1053 T/C; -
1102 G/T; -1690 A/G; -1925 T/C [68] and -2345 2G/1G; -2599 C/G [69]) 
with several of these SNPs being localised in the proximity of transcription 
regulatory elements. One group of SNPs identified in the TAFI promotor, 
namely -1925 T/C, -530 C/T and -152 A/G, was in complete linkage 
disequilibrium (LD) while a second group of SNPs (-1690 A/G, -1102 G/T, 
-1053 C/T and -438 A/G) was in almost complete LD [68,69] In the coding 
region of the TAFI gene three SNPs have been reported in the literature, 
namely the +505 G/A (Ala147Thr), the +678 C/T (Asp226Asp) [70] and 
the +1040 C/T (Thr325Ile) [71]. Additionally, two SNPs were reported for 
the 3’-untranslated region (UTR) (+1542 C/G and +1583 A/T) [69].
Functional studies with four recombinant TAFI variants expressing either 
the residues 147Ala or 147Thr and either the residues 325Thr or 325Ile 
were carried out [72]. As expected from the previous characterisation of 
the TAFI 147Ala and 147Thr isoforms [70] no functional differences were 
found between variants containing this modification. In contrast, clear 
differences were observed between the TAFI Thr325Ile variants. The 
presence of an isoleucine at position 325 (TAFI 325Ile) nearly doubled the 
thermal stability of the active enzyme while the kinetics of activation of 
the isoforms by thrombin/thrombomodulin complex remained identical. 
Moreover, TAFIa 325Ile displayed a greater antifibrinolytic effect (30-60% 
increase) that arose from the increased ability of this isoform to release 
lysine residues from partially degraded fibrin. To date this SNP (1040C/T -





Figure 4. Schematic representation of the methods for antigen 
determination of TAFI. TAFI antigen levels can be determined in plasma using 
a variety of immunological assays with different principles. The figure contains 
information about product origin (commercial or developed in house), antibody 
reactivity and certain differences in antibody preparations (species immunised, 
polyclonal or monoclonal). Some of these assays were used in population-based 
studies and in such case references are provided.
Furthermore, information has been collected by distinct genome projects 
such as Ensembl [73] and HapMap [74] where several additional SNPs 
have been reported for the 5’- and 3’-flancking regions and coding region 







































































































































































































































































































































(not shown Fig.3B) have been reported in the coding region of the TAFI 
gene (Asp97Asp, Asp142Asp, Pro221Pro, Ile251Ile). This information can 
be found on web-based databases.
Measurement of TAFI and TAFIa in plasma
Seeking to establish the role of TAFI as a possible causative agent of 
or risk marker for cardiovascular events resulted in the development of 
different methods for the determination of TAFI plasma concentrations. 
These methods are based on two different principles: determination of 
antigen levels or quantitative conversion of TAFI into TAFIa, usually by 
the thrombin/thrombomodulin complex, followed by the measurement of 
the basic carboxypeptidase activity generated. For both principles different 
approaches are employed resulting in subtle but important differences in 
the TAFI levels that are being determined (Fig.4 and 5).
Due to their straightforward methodology and regular implementation 
in the clinical set-up, enzyme-linked immunosorbent assays (ELISAs) 
are often selected for the determination of TAFI antigen levels although 
a rocket immunoelectrophoresis method has also been described [75] 
(Fig.4). The specificity of these assays for TAFI fractions in plasma ranges 
either from determination of total TAFI antigen (commercial: Affinity 
Biologicals [71,76-94] also marketed by Milan Analytica [95-103]; American 
Diagnostica [104-107]; Hyphen [108-111]; Chromogenix [112-115] or in-
house [116] methods) to the determination of a particular fraction as for 
instance TAFIa/TAFIai [117], TAFI activation peptide [117] or just the TAFI 
proenzyme (commercial: Roche [118-120] or in-house [117,121,122] 
methods) (Fig.4). For some antigen assays the specificity has not been 
reported in the literature and therefore is marked as unknown (commercial: 
Calbiochem [123] or in-house [64,124-129] methods) (Fig.4).
Moreover, a variable immunoreactivity of some antibodies towards TAFI 
isoforms (Thr325Ile) has been demonstrated (Chapter 3 and [122]). For 
these antibodies the recognition of the TAFI 325Ile variant is impaired, 
leading to an underestimation in the determination of TAFI antigen levels 
of this variant and to a fictitious amplification of the genotype-related 
variation of TAFI concentration. This will be considered in more detail in 
the discussion of this thesis (Chapter 9). Nevertheless, using TAFI assays 




estimation of the weight of TAFI gene polymorphisms on the TAFI antigen 
levels was found to be 25% [120].
The alternative is to determine TAFI plasma levels using an activity-based 
assay. Also in this case different assays have been developed to determine 
either TAFI after conversion into TAFIa or TAFIa activity in plasma (Fig.5).
Recently, a fluorogenic assay was described for the determination of TAFIa 
activity in individual plasma samples [130]. This assay is based on the 
fact that TAFIa decreases the capacity of high molecular weight fibrin 
degradation products (HMW FDPs) to stimulate the plasminogen activation 
by DSPA and therefore, no correction is required for carboxypeptidase 
N (CPN). Another assay for the determination of TAFIa activity using a 
fluorogenic substrate for TAFIa has been made commercially available 
(Fig.5).
Other activity-based assays have been developed to exploit the specificity 
of TAFIa for carboxy-terminal lysines and arginines. Most of these assays 
rely on the conversion of TAFI into the active enzyme by thrombin/
thrombomodulin followed by the determination of the activity of TAFIa 
in the hydrolysis of a small synthetic substrate (furoylacroleyl alanyl-
arginine [131], anisylazoformyllysine [132,133], hippuryl-L-arginine 
[124,134,135], p-hydroxy-hippuryl-L-arginine [136,137] or unknown), as 
shown in Fig.6. These assays have been used in different epidemiological 
studies to evaluate the role of TAFI in cardiovascular disease (HPLC assay 
[138];[65,116,139-141] the chromogenic assay described by Mosnier 
et al. [84,124,125,128,142-144] and the Actichrome® assay [77-83,87-
89,93,111-113,115,145,146]).
The TAFI functional isoforms 325Thr and 325Ile were shown to have 
similar activation kinetics by the thrombin/thrombomodulin complex as 
well as identical hydrolysis of a synthetic substrate (anisylazoformyllysine, 
AAFK) [72]. This means that activity assays relying on the cleavage of 
such a small synthetic substrate will probably detect both TAFI variants 
equally well. The activity-based assays determine the concentration of the 
proenzyme (TAFI), which can be converted into the active enzyme (TAFIa). 
It is imperative to bear in mind that these assays demand a quantitative 
and standardised conversion of the proenzyme to the active form and the 
assay conditions should take this into consideration because of the limited 





TAFI functional activity has also been evaluated using other assays based 
on the ability of TAFIa to delay plasma clot lysis mediated by plasminogen 
activators (Chapter 6). The clot lysis time was shown to correlate with 
TAFI antigen [124]. However, these assays have as a downside the fact that 
other plasma components, such as plasminogen activator inhibitor-1 (PAI-1), 
α2-antiplasmin, antithrombin and plasminogen, affect the clot lysis time 
resulting in an ambiguous measurement [127]. Notwithstanding, ways 
have been devised to circumvent this problem (Chapter 4).
The pathophysiological role of TAFI
The pathophysiological role of TAFI has been extensively studied. It is 
nowadays recognised that TAFI establishes the long sought-for link between 
coagulation and fibrinolysis whereas the implications for thrombotic 
diseases are still under discussion.
The ability of TAFI to cleave inflammatory mediators and inflammatory 
peptides allowing inflammation management has inferred an inhibitory 
role for TAFI during inflammatory processes. However, inflammation has 
another aspect, namely its potential to induce the activation of coagulation. 
In particular, if it were confirmed that TAFI is an acute phase response 
protein it would mean that in circumstances governed by inflammation-
induced coagulation, TAFI might have a role in the development of a 
prothrombotic state.
In view of the antifibrinolytic function of TAFI, its involvement in thrombotic 
disease has been investigated. TAFI has been found to be a mild risk factor 
for venous thrombosis where increased TAFI antigen levels possibly lead 
to a hypofibrinolytic state. In contrast, in arterial thrombosis the results 
are conflicting. This is perhaps a consequence of the discrepancies in the 
TAFI assays (variable immunoreactivity of antibodies and/or deficient 
assay standardisation), which hamper interpretation of the results as well 
as the comparison between clinical data. These assays were also used to 
investigate the involvement of TAFI in other disease states such as diabetes, 
liver cirrhosis, kidney transplantation, nephrotic syndrome and dialysis. 
Efforts are now being made (Scientific Standardisation Committee of the 
ISTH) to compare assay performance and to achieve standardisation. This 




The scope of this thesis
The aim of this thesis is to shed additional light on the molecular mechanisms 
of TAFI and to further unravel the physiological and pathophysiological 
relevance of TAFI.
The contents are structured into three sections. The first section deals 
with the biochemical properties of TAFI. The second section describes 
the assessment of TAFI assays along with the development, validation 
and implementation of new methodology for the functional determination 
of TAFI in plasma samples. And finally, the third section examines the 
involvement of TAFI in the modulation of the plasminogen system during 
fibrinolysis and during pericellular proteolysis.
Upon purification of TAFI from plasma, we studied the migration and 
detection of the activation peptide of TAFI during SDS-PAGE and 
characterised the reactivity of monoclonal antibodies against distinct TAFI 
fragments (Chapter 2).
TAFI antigen levels exhibit a large interindividual variability, in which genetic 
control seems to play a strong role. We evaluated the determination of TAFI 
antigen levels using different assays focusing on the relationship between 
TAFI antigen and TAFI genotype, particularly the Thr325Ile functional 
polymorphism (1040C/T) (Chapter 3).
The functional TAFI variant (TAFI Ile325Ile) exhibits increased stability 
but decreases expression levels thus reinforcing the importance of the 
determination of TAFI functional activity for studying the role of TAFI in 
cardiovascular disease. Consequently, we developed a new functional 
activity-based assay that was validated in a group of healthy individuals 
(Chapter 4). Thereafter, the role of TAFI in ischaemic stroke was studied 
by determining TAFI functional activity levels as well as the genotype 
distribution in a case-control prospective study (Chapter 5).
The efficiency of thrombolysis is determined to a certain extent by 
the properties of the PA (enzyme kinetic parameters, fibrin cofactor 
dependence), the thrombus structure (composition, degree of retraction) 
and by the supply of plasminogen and PA to the boundary and interior of 
the thrombus (transport of proteins, PA-fibrin clot-binding characteristics). 
Although TAFI is nowadays regarded as a potent inhibitor of fibrinolysis, its 
effect on the above-mentioned parameters, which influence not only in vivo 




investigated plasma clot lysis mediated by increasing concentrations of a 
variety of PAs, which represent all major classes of thrombolytic drugs, 
under conditions in which lysis proceeds throughout the clot (internal 
lysis model) (Chapter 6). The inhibitory effect of TAFI was studied in 
this internal lysis model taking into consideration the role of the plasmin 
inhibitor. Furthermore, external plasma clot lysis, where lysis proceeds 
from the boundary to the interior of the plasma clot, was also studied 
using several models. In Chapter 7, the fibrinolytic efficacy of three PAs in 
these external lysis models was examined and the inhibitory effect of TAFI 
was evaluated.
In recent years, evidence suggesting the involvement of TAFI in other 
processes besides fibrinolysis and the ability of TAFI to behave as a broad 
modulator of the plasminogen system, is slowly growing. In Chapter 8, the 
involvement of TAFI in an in vitro model of capillary-like tube formation 
was investigated. This wound-healing angiogenesis model consists of a 
three-dimensional plasma clot matrix on top of which human microvascular 
endothelial cells (hMVECs) were seeded. The hMVECs upon combined 
stimulation with bFGF and TNF-α formed capillary-like structures. Due 
to the composition of the matrix, the results may be extrapolated to 
neovascularisation of a fibrinous exudate in vivo.
Finally, in Chapter 9 the results are discussed in association with recent 
insights from the literature in an attempt to provide a global view of the 
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 Summary 
Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen, 
which upon activation is capable of delaying fibrinolysis. We investigated the 
migration and detection of the activation peptide of TAFI during SDS-PAGE. 
Purified TAFI before and after activation by thrombin/thrombomodulin 
was electrophoresed on 4-20% polyacrylamide gels and stained with 
Coomassie Blue as well as Western blotting. Before activation, Coomassie 
Blue staining resulted in one main band of TAFI. After activation, a sharp 
band corresponding to TAFIa was observed. No distinct activation peptide 
was detected, in agreement with the literature. Western blotting using a 
polyclonal anti-TAFI antibody, on the other hand, showed one additional 
broad band with an Mr of about 33,000 after TAFI activation. N-terminal 
sequence analysis confirmed that this band represented the activation 
peptide of TAFI. In addition, we tested the reactivity of two anti-TAFI 
monoclonal antibodies (MA-T3D8 and MA-T18A8) towards TAFI before and 
after activation by Western blotting. Both monoclonal antibodies recognised 
TAFI. After activation of TAFI, MA-T3D8 reacted with TAFIa, while MA-T18A8 
reacted with the activation peptide.
We identify the 33,000 band as the activation peptide of TAFI and exemplify 
the use of this information for the characterisation of monoclonal antibodies 
against TAFI.
 Introduction 
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently discovered 
plasma inhibitor of the fibrinolytic system [1,2]. The activated form of TAFI 
(TAFIa) is a carboxypeptidase B, which removes carboxy-terminal lysine 
and arginine residues from partially degraded fibrin. Because these residues 
represent binding sites of plasminogen, TAFIa reduces the fibrin-binding 
of plasminogen and thereby the activation of plasminogen and eventually 
fibrinolysis [3-5].
TAFI is a glycoprotein of 401 amino acid residues and has an Mr of about 
60,000. The zymogen can be activated by thrombin, plasmin or trypsin, 
which cleave the protein between Arg-92 and Ala-93 [6]. The action of 
thrombin is strongly accelerated by thrombomodulin [7]. The activation 
results in a 92-amino acid activation peptide containing the four potential 
sites for N-glycosylation of TAFI and a 309-amino acid catalytic domain 
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with an Mr of about 36,000. TAFIa can be further degraded by thrombin at 
Arg-302, which results in two peptides with an Mr of 25,000 and 11,000, 
respectively [8,9]. A three-dimensional model of TAFI has been constructed 
on the basis of its homology with human pancreatic procarboxypeptidase B 
[10].
The activation peptide of TAFI has a theoretical Mr of 10,200 (without 
carbohydrate) and revealed after isolation by HPLC an Mr of 19,400 by 
mass spectrometry (with carbohydrate) [8]. The migration of the activation 
peptide during SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is not 
well documented and the literature about it is confusing.
Eaton et al [6] studied the activation of TAFI by using SDS-PAGE. They 
observed after prolonged incubation with trypsin a very faint band with 
an Mr of 15,000 and with the same amino-terminal amino acid sequence 
as the intact molecule, suggesting that the activation peptide migrated 
as a 15,000 protein. Bajzar et al [11] reported in their original paper on 
TAFI purification that SDS-PAGE of TAFI during a treatment with thrombin 
showed initially the appearance of 35,000 and 14,000 bands, followed by 
a 25,000 band. They suggested that TAFI was first cleaved to form 35,000 
and 14,000 fragments. Amino-terminal sequence data of the 35,000 band 
showed, however, that the 35,000 band was composed of two unresolved 
proteins, with respective sequences corresponding to those of the 60,000 
and the 25,000 proteins. The 14,000 band was not sequenced. Valnickova 
et al [12] studied the activation of TAFI by trypsin by using SDS-PAGE and 
also found two amino-terminal sequences in one sharp 36,000 band. They 
concluded that the activation peptide of TAFI co-migrated with TAFIa in the 
sharp protein band with an Mr of 36,000. Other investigators using either 
Coomassie Blue staining, silver staining, Western blotting or autoradiography 
of 125I-labelled TAFI failed to show the generation of a distinct activation 
peptide on SDS-PAGE [8,9,13-15].
Our experiments establish the migration behaviour of the activation 
peptide of TAFI during SDS-PAGE and demonstrate that the peptide can 
be detected by Western blotting. This knowledge will facilitate biochemical 
studies on the TAFI protein. Furthermore, we report the use of our findings 
to localise the epitopes of monoclonal anti-TAFI antibodies on either TAFIa 
or the activation peptide.
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 Materials and Methods 
Materials 
Human thrombin was acquired from Sigma and rabbit lung thrombomodulin, 
with a specific activity towards thrombin of 1.2 units/µg, from American 
Diagnostica Inc. TAFI was isolated from plasminogen-depleted plasma 
by using ammonium sulphate precipitation, plasminogen-Sepharose 
chromatography and gel filtration on Superdex 200, essentially as described 
by Eaton et al [6].
Activation of TAFI 
Purified TAFI (56 µg/ml - final concentration) was incubated at 22oC or 
37oC in the presence of 5 mM CaCl2, 2 unit/ml thrombin and 2 unit/ml 
thrombomodulin in 50 mM Hepes, 100 mM NaCl, 0.1 % (v/v) Tween 80, pH 
7.5. The incubation was carried out for 30 min and subsequently quenched 
by addition of the thrombin inhibitor D-Phe-Pro-Arg chloromethyl ketone 
(PPACK - 1 µM). Samples were immediately used for SDS-PAGE.
Migration of the activation peptide of TAFI during SDS-PAGE 
Precast 4-20% polyacrylamide Mini gels (iGels from Gradipore) were 
used for SDS-polyacrylamide gel electrophoresis. SDS was added to the 
samples containing TAFI before (0.22 µg) and after activation (0.44 µg) to 
a final concentration of 2 % (w/v). These were then heated for 2 min at 
100oC. Samples and the standard proteins (low molecular weight kit from 
Pharmacia) were electrophoresed at 150 V for about 1 hour 30 min using 
the Laemmli buffer [16] system under non-reducing conditions. The gel 
was then stained with Coomassie Brilliant Blue.
Detection of the activation peptide of TAFI by Western Blotting 
TAFI before activation (0.22 µg) and after activation (0.44 µg) as well as 
the activation components on its own were electrophoresed as described 
above. The gel was subsequently blotted onto nitrocellulose paper 
(Schleicher & Schuell) at 150 mA, overnight. Nonspecific binding sites were 
blocked by a 60 min incubation in block buffer (5% Nutrilon milk powder 
– Nutricia, in 7.5 mM Na2HPO4, 2.5 mM NaH2PO4, 145 mM NaCl pH 7.6). The 
blots were then incubated with a sheep anti-human TAFI HRP conjugated 
IgG (Affinity Biologicals - 0.5 µg/ml) in dilution buffer (20 mM Hepes, 150 
mM NaCl, 1% (w/v) BSA, 0.1% (v/v) Tween 20, pH 7.2) for 120 min. After 
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several washings with dilution buffer the blot was stained with BM blue POD 
substrate (Roche). The blotted standard proteins were stained separately 
with Ponceau S (Helena Laboratories).
N-terminal protein sequence analysis 
The N-terminal sequence analysis was performed by Edman degradation 
with an automated sequencer (Model 494 Procise, Applied Biosystems) 
[17]. The protocols, reagents and materials used were also from Applied 
Biosystems. Eurosequence bv (Groningen, The Netherlands) carried out 
the sequence analysis.
Reactivity of two Anti-TAFI monoclonal antibodies towards TAFI fragments 
Two different anti-TAFI monoclonal antibodies (MA-T3D8 and MA-T18A8), 
which were generated by Gils et al [18] were used for the immuno-staining 
of TAFI (73 ng) before and after activation. SDS-PAGE and Western blotting 
were performed as described above. As the monoclonal antibodies were 
not HRP conjugated the immuno-staining protocol was altered. Briefly, the 
blots were incubated with MA-T3D8 (0.3 µg/ml) or MA-T18A8 (0.01 µg/ml) 
or both (MA-T3D8 - 0.3 µg/ml, MA-T18A8 - 0.01 µg/ml) in dilution buffer 
for 120 min. The blot was extensively washed with dilution buffer and 
incubated for 60 min with a secondary HRP-conjugated goat anti-mouse 
antibody (GAM/Ig/PO - Nordic) diluted 1:5000 in dilution buffer. After 
washing the blot was again stained with BM blue POD substrate (Roche).
 Results 
Migration of the activation peptide of TAFI during SDS-PAGE 
TAFI before and after activation at 22oC was analysed by SDS-PAGE and 
stained with Coomassie Blue (Fig.1). Coomassie Blue staining revealed one 
main protein band of 65,000 before activation, and after activation a minor 
band of 65,000 representing some non-activated TAFI along with a major 
band of 37,000 of TAFIa. No distinct activation peptide was observed, in 
agreement with the literature.
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Detection of the activation peptide of TAFI by Western Blotting 
TAFI before and after activation at 22oC was also stained by Western 
blotting (Fig.1), showing in addition to the same protein bands seen with 
Coomassie Blue staining, a broad band with an Mr of about 33,000 for TAFI 
after activation. This band most likely represented the activation peptide. 
The slower migration than expected on the basis of its molecular weight 
and the heterogeneity are ascribed to its high carbohydrate content. The 
activation mixture was analysed under the same Western blotting conditions 
but no bands were observed (not shown). Moreover, a negative antibody 
control was also included, again without revealing any bands (not shown).
The activation of TAFI was also performed at 37°C instead of 22°C (not 
shown). TAFI was fully activated and the activation peptide appeared 
again on the Western blot as a broad band of 33,000, now between two 
sharp bands of respectively, 37,000 (TAFIa) and 25,000 (further degraded 
TAFIa).
Figure 1. SDS-polyacrylamide gel electrophoresis of TAFI before and after activation with 
thrombin and thrombomodulin. TAFI before activation (lane 1) and after activation 
(lane 2) along with molecular mass standards (lane 3) were electrophoresed in 
parallel on two 4-20% gels under non-reducing conditions. One gel was stained 
with Coomassie Blue and the other one was blotted onto nitrocellulose paper and 
immuno-stained using sheep anti-human TAFI IgG conjugated to peroxidase and 
BM blue POD substrate. Positions of molecular mass standards are indicated on 
the right (10-3 x Mr).
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N-terminal protein sequence analysis 
In order to support the hypothesis that the 33,000 band represented in 
fact the activation peptide of TAFI, a gel slice below the 37,000 band was 
cut from the Coomassie Blue-stained gel and subjected to amino-terminal 
sequence analysis. The results showed a mixture of the following amino 
acid residues: (Phe/Ala) – (Ser?/Gln?) – (Ala/Ser?) – (Gly/Ser?) – (Tyr/Gln) 
– (Val/Tyr) – (Glu/Leu). These results were compatible with the presence of 
the activation peptide (amino-terminal sequence Phe-Gln-Ser-Gly-Gln-Val-
Leu) and some material from the 37,000 band (TAFIa with amino-terminal 
sequence Ala-Ser-Ala-Ser-Tyr-Tyr-Glu) [6].
Reactivity of two Anti-TAFI monoclonal antibodies towards TAFI fragments 
Two monoclonal anti-TAFI antibodies (MA-T3D8 and MA-T18A8) were used 
to inspect their reactivity towards TAFI and TAFI fragments generated by 
incubation with thrombin/thrombomodulin (Fig.2). Before activation, both 
the MA-T3D8 and the MA-T18A8 recognised one single band of 65,000, 
corresponding to TAFI. Upon TAFI activation, however, the band pattern 
obtained with these monoclonal antibodies was altered. The MA-T3D8 
Figure 2. Western blot of TAFI before and after activation with two distinct 
monoclonal anti-TAFI antibodies. TAFI before activation (lane 1) and after 
activation (lane 2) with thrombin and thrombomodulin was electrophoresed 
under non-reducing conditions. The gel was blotted onto nitrocellulose paper and 
immuno-stained. Monoclonal anti-TAFI antibodies (MA-T3D8, MA-T18A8) were 
used as primary antibodies and HRP conjugated goat anti-mouse antibody as 
the secondary antibody. BM blue POD substrate was used for staining. Figures 
indicate 10-3 x Mr.
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revealed a very minor band of about 65,000, which represented some non-
activated TAFI, as well as a sharp band of 37,000, corresponding to TAFIa. 
In contrast, the MA-T18A8 recognised a broad band of 33,000 in addition to 
the minor band of 65,000. As we have shown, this broad band corresponds 
to the activation peptide. Combining both monoclonal antibodies resulted 
as expected in two distinct bands with an Mr of 37,000 (TAFIa) and 33,000 
(activation peptide). The weaker staining of the minor band of 65,000 in 
the activated TAFI preparation by MA-T3D8 as compared to MA-T18A8 
was due to the lower affinity of the former antibody (compare antibody 
concentrations in the Materials and Methods section).
 Discussion 
TAFI circulates as an inactive proenzyme. Upon activation, this carboxypeptidase 
B-like enzyme is cleaved between Arg-92 and Ala-93 resulting in a 92-amino 
acid activation peptide with four potential N-glycosylation sites. Several 
studies have characterised TAFI migration on SDS-PAGE. Nevertheless, the 
activation peptide of TAFI has never been detected on gels and information 
regarding it is somewhat confusing.
In order to study the migration and detection of the activation peptide 
during SDS-PAGE, we analysed once more purified TAFI before and after 
activation and used Coomassie Blue as well as Western blotting for staining 
(Fig.1). The Coomassie Blue staining pattern was very similar to that 
described in prior reports. TAFI before activation could be spotted as a 
relatively broad band of 65,000 with the same holding true for Western 
blotting. This probably reflected the heterogeneous glycosylation of TAFI 
[8,19]. Under moderate activation conditions, some non-activated TAFI 
could still be perceived on the Coomassie Blue and the Western blotting 
staining, as well as a sharp band of 37,000, which corresponded to TAFIa. 
Again, these results were analogous to previous data. Yet, we identified 
an additional broad band of about 33,000 on the Western blot. N-terminal 
sequence analysis of the polyacrylamide gel confirmed that this was in fact 
the activation peptide of TAFI with amino-terminal sequence Phe-Gln-Ser-
Gly-Gln-Val-Leu. The migration of the activation peptide just ahead of TAFIa 
implies that the separation could be incomplete and that mixtures of TAFIa 
and the activation peptide could be found in sequence analyses [11,12]. In 
agreement with this, we found a second amino-terminal sequence Ala-Ser-
Ala-Ser-Tyr-Tyr-Glu that matched TAFIa.
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Our results explain most of the confusing data on the activation peptide in 
the literature. The high carbohydrate content probably prevents staining by 
Coomassie Blue and silver staining as well as the incorporation of 125Iodine, 
making the activation peptide invisible in various experiments. In addition, 
the sort of gradient used for SDS-PAGE will influence the migration of the 
different TAFI fragments, particularly of the activation peptide due to its 
carbohydrate content.
On the basis of our findings we set out to inspect the recognition of 
TAFI and TAFI treated with thrombin/thrombomodulin by two different 
monoclonal anti-TAFI antibodies [18] (MA-T3D8 and MA-T18A8). Both 
monoclonal antibodies reacted with TAFI before activation. After the 
digestion of TAFI with thrombin/thrombomodulin, MA-T3D8 recognised 
TAFIa, a sharp band of 37,000 while MA-T18A8 recognised a broad band 
of 33,000, which as we have shown corresponds to the activation peptide. 
These results localise the epitopes of the monoclonal antibodies on the 
TAFI molecule and, simultaneously, confirm that the 37,000 and 33,000 
bands represent distinct fragments of TAFI (i.e. TAFIa and the activation 
peptide, respectively).
The experiments described here establish the migration behaviour of the 
activation peptide of TAFI during SDS-PAGE and provide conditions for its 
detection by Western blotting. Moreover and as shown here this knowledge 
can aid in evaluating the reactivity of anti-TAFI antibodies towards TAFI 
fragments.
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Summary 
TAFI antigen levels exhibit a large interindividual variability in which genetic 
control seems to play a major role. However, recent reports have questioned 
the association between TAFI concentration and genotype. These reports 
suggest that variable antibody reactivity towards TAFI isoforms, particularly 
the Thr325Ile polymorphism (1040C/T), may lead to artefacts in TAFI 
antigen levels. In order to compare assay outcome we determined plasma 
TAFI levels in 92 healthy individuals making use of an ELISA (commercial 
antibodies) and an electroimmunoassay (home-made antibodies) as well 
as a commercial chromogenic assay (Actichrome® TAFI). Each individual 
was genotyped for the - 438A/G and 1040C/T polymorphisms in the TAFI 
gene. We found a significant association of TAFI levels and genotype with 
both antigen assays and with the chromogenic assay. All assays displayed 
significant correlations with each other. Linear regression and Bland-Altman 
agreement analysis in the genotype sub-groups showed that neither the 
genotype nor the concentration affected the relationship between the 
Actichrome® TAFI and the Electroimmunoassay.
In contrast, the ELISA/Actichrome® TAFI and the ELISA/Electroimmunoassay 
relationships were concentration and genotype-dependent. Our results 
demonstrate that artefacts may arise when measuring TAFI antigen levels 
by ELISA. Nevertheless, the Electroimmunoassay and the Actichrome® 
TAFI support a genotype-related variation of TAFI concentration.
Introduction 
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) has been described 
as a potent fibrinolysis inhibitor that is present in plasma as a basic 
procarboxypeptidase, the active form of which, (TAFIa), can be formed 
during coagulation [1-3]. TAFIa can inhibit fibrinolysis by removing carboxy-
terminal lysine and arginine residues from partially degraded fibrin leading 
to a decrease of plasminogen-binding sites on the fibrin surface [4-7]. Due 
to this, TAFI is also referred to as a link between coagulation and fibrinolysis. 
This confers an extra importance on the determination of TAFI plasma levels 
and activity as these may have both diagnostic and prognostic value for a 
number of diseases. Several reports have corroborated the involvement 
of TAFI in venous thrombosis [8-10], coronary artery disease [11-13], 
and myocardial infarction [14]. Although nowadays, several methods are 
CHAPTER 3
Association between TAFI genotypes and levels in plasma
51  
available for TAFI determination in plasma, evaluation and characterisation 
of the performance of these assays still remain a problem.
Several genetic polymorphisms have been identified in the TAFI gene and 
evidence has been gathered that points to a strong genetic control of 
plasma TAFI levels [15-17]. Recently, Brouwers et al [18] reported a new 
single nucleotide polymorphism (SNP), 1040C/T which is located in the 
coding region of the TAFI gene and results in the substitution of a threonine 
at position 325 by an isoleucine (Thr325Ile). This polymorphism was 
associated with TAFI antigen levels and in linkage disequilibrium with other 
TAFI SNPs. Simultaneously, Schneider et al [19] prepared TAFI variants 
with either a threonine or an isoleucine at position 325 and demonstrated 
that the Ile-325 variant had an increased stability and exhibited a greater 
antifibrinolytic effect than the Thr-325 variant.
TAFI plasma levels, in healthy individuals, have been shown to exhibit a 
large interindividual variability [15,17,20,21]. Recent reports have raised 
questions regarding the antibody reactivity of the different TAFI isoforms 
suggesting that the genotype-dependent variation of TAFI concentration 
may include assay artefacts (unpublished observations). The 1040C/T 
functional polymorphism seems to be especially involved. In order to evaluate 
assay agreement and to investigate genotype-related effects and possible 
assay-related artefacts, we compared three assays, i.e. Actichrome® 
TAFI activity assay, Electroimmunoassay and ELISA that rely on different 
methods. Actichrome® TAFI assay is a commercial chromogenic activity 
assay in which TAFIa is generated by thrombin/thrombomodulin. This 
chromogenic assay relies therefore on complete TAFI activation and on a 
similar activity of all TAFI isoforms towards the synthetic substrate. The 
Electroimmunoassay and the ELISA both depend on antibody reactivity, 
but are based on different principles and make use of different antibody 
preparations. We determined TAFI levels in citrated plasma from a group 
of 92 healthy individuals as well as the distribution of the - 438A/G and 
1040C/T polymorphisms. We demonstrate that the TAFI concentration 
exhibits an association with TAFI genotype, but we emphasise that the 
magnitude of this association may be influenced by the choice of assay.
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Materials and Methods 
Subjects
A group of 92 healthy individuals composed of 46 males and 46 females 
with a mean age of 46.5 years, ranging from 21 to 75 years, was gathered. 
Blood was collected into 0.1 volume of 0.106 mol/l trisodium citrate. The 
blood was centrifuged at 2000g for 30 min at 4oC. The plasma was stored 
at - 80oC in aliquots of 0.4 ml. The participants gave informed consent.
Pooled normal plasma
Blood was collected by venipuncture in plastic tubes containing into 0.1 
volume of 0.106 mol/l trisodium citrate. The blood was centrifuged at 2000 
g for 20 min at 20oC. The donors consisted of 30 males and 40 females 
with a mean age of 38.7 years. The platelet-poor plasma of 70 healthy 
individuals (women on oral contraceptives were excluded) was pooled and 
used as a calibrator for the Electroimmunoassay and for the ELISA. The 
pooled normal plasma was considered to contain 1U/ml of TAFI.
TAFI Concentration (TAFI Actichrome®)
A commercial chromogenic assay (Actichrome® TAFI Activity kit - Lot. No. 
022706 – instructions protocol October 2002; American Diagnostica) was 
used to determine the amount of activatable TAFI in plasma. This assay 
relies on the activation of TAFI by the thrombin/thrombomodulin complex 
to TAFIa, which then reacts with a chromogenic substrate. Plasma samples 
were diluted 25-fold in assay buffer. The diluted plasma sample (25 μl) 
was added to a well of a microtitre plate followed by 115 μl of an activation 
mixture containing thrombin, thrombomodulin and calcium ions or by 115 
μl of assay buffer (unactivated plasma control). Both the activated sample 
and unactivated sample were incubated for 20 min at room temperature 
on an orbital plate shaker without a clot being observed. Then, 10 μl of 
an activation stop reagent was added to each well. During the 20-min 
incubation step serial dilutions of the TAFIa standard, which was supplied 
in the kit, were prepared. The TAFIa substrate (50 μl) was then added to 
the wells. The enzymatic reaction was followed in time by measuring the 
optical density at 405 nm while incubating at 25oC and shaking. The inter-
assay variation coefficient was below 10% and the detection limit was 0.20 
µg/ml TAFIa.
CHAPTER 3
Association between TAFI genotypes and levels in plasma
53  
TAFI Antigen Concentration (Electroimmunoassay)
A rocket immunoelectrophoresis assay was used to determine TAFI antigen 
levels [8]. Briefly, 0.5% v/v of rabbit anti-TAFI IgG (6 mg/ml) was included 
in 1.0 % agarose (SeaKem LE, cat. No. 50 004; FMC BioProducts) gels in 
31.6 mmol/l tricine, 91.5 mmol/l Trizma base, 1 mmol/l EDTA, pH 8.8. 
Standards (0.25-1.0 U/ml) were prepared by diluting the pooled normal 
plasma in TAFI-deficient plasma [8]. Standards and 2-fold diluted samples 
(in TAFI-deficient plasma) were applied (4.5 μl) in wells with a diameter of 
2.5 mm. Plates were electrophoresed at 2 to 3 V/cm for 18 hours at 10oC 
to 15oC. After drying and staining the plates, the length of the precipitation 
peaks was measured and the TAFI concentrations computed from duplicate 
determinations. The Electroimmunoassay had an intra- and inter-assay 
variation coefficient of 6% and a detection limit of around 0.16 U/ml [8].
TAFI Antigen Concentration (ELISA)
A sandwich-type enzyme-linked immunosorbent assay (ELISA) was 
developed for the determination of TAFI antigen levels, using commercial 
sheep polyclonal antibodies against TAFI (Affinity Biologicals Inc.). The 100 
μl of H2SO4 (1 mol/l) were added. The optical density was measured at 450 
nm. TAFI plasma levels were calculated from duplicate measurements.
TAFI Genotyping
All individuals were genotyped for two previously identified polymorphisms, 
- 438A/G [16] and 1040C/T [18]. In order to determine the genotype of 
these two SNPs a duplex polymerase chain reaction (PCR) followed by a 
restriction fragment length analysis was performed. The following primer 
sequences were used: TAFI F4 (5’ CAG AGA TCC TGT AAT CAT CC 3’) and TAFI 
R2 (5’ CGC GAA GAC ATG CTG CTC AC 3’) for - 438A/G and TAFI-EX10-F (5’ 
TGC TTC CAG TCT CTA GTA GC 3’) and TAFI-EX10-R (5’ CAG TTG TAT TAC ATG 
TGA CC 3’) for 1040C/T. The PCR conditions used were: first denaturation 
step at 94oC for 4 min, followed by 35 cycles of 1 min denaturation at 
94oC, 1 min annealing at 58oC, 2 min elongation at 72oC and finally 10 
min at 72oC. The PCR products were digested with Hpy CH4 IV and SpeI, 
respectively, at 37oC for 4 hours and analysed on a 1.2 % agarose gel.
ELISA dilution profiles
Two separate plasma pools were prepared from individuals with the - 438 
G/G, 1040 C/C (CC pool) or the - 438 A/A, 1040 T/T (TT pool) genotypes. 
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Each pool was composed of 7 healthy individuals, which belong to the 
subjects described above. Both pools included 4 men and 3 women, with a 
mean age of 44.7 and 45.3 years for the CC and TT pool respectively. The 
mean TAFI antigen concentration with the Electroimmunoassay was 1.37 
and 0.94 U/ml for the CC and TT pool, respectively.
The pooled plasmas were diluted 5 to 1200-fold in dilution buffer and 
the TAFI ELISA was performed as described above. After addition of the 
TMB substrate, the development of the blue colour was followed in time by 
measuring the optical density at 620 nm every 30 s. The initial rates were 
obtained by linear regression analysis and expressed as delta OD620 nm / time 
(min -1) (mean of six repeats).
Statistical Analysis
Allele frequencies were calculated by gene counting and the genotype 
frequencies at both loci were in Hardy-Weinberg equilibrium (c2 analysis 
with 1 df). The linkage-disequilibrium coefficient, D and the Lewontin’s D’ 
were estimated as outlined by Devlin and Risch [22]. Values are expressed 
as mean ± SD. One-way ANOVA was computed to look at the relation 
between TAFI levels and TAFI genotype. Pearson’s correlation coefficients 
were calculated to study the associations between the assays (Actichrome® 
assay, ELISA and Electroimmunoassay). Linear regression analysis as well 
as Bland-Altman agreement analysis [23] were performed to evaluate the 
between-assay relationships in the entire sample group as well as in the 
1040C/T genotype subgroups. ANCOVA was employed to test for differences 
in linear regression analysis for the between-assay relationships in the 
genotype subgroups, and an F test to verify if slopes were significantly 
non-zero. P values < 0.05 were considered statistically significant.
Results 
TAFI Concentration and TAFI Genotyping
The genotype and allele frequencies of - 438A/G and 1040C/T TAFI single 
nucleotide polymorphisms were determined in 92 healthy individuals 
(Table I) and found to be in Hardy-Weinberg equilibrium (P< 0.001, c2 
analysis). The SNPs were, as previously described [18,24], in strong 
linkage disequilibrium (D = 0.73; D’ = 0.85) and associated with the 
TAFI antigen levels, as shown in table I. Not only the immunologic assays 
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Figure 1. Effect of genotype on 
the between-assay relationships. 
TAFI concentration was determined 
with the Actichrome® TAFI activity 
assay, Electroimmunoassay and 
ELISA for a group of 92 healthy 
individuals. A, Electroimmunoassay/
Actichrome® TAFI assay. B, ELISA/
Actichrome® TAFI assay. C, ELISA/
Electroimmunoassay. (□) 1040 
C/C, (●) 1040 C/T, (Δ) 1040 T/T. 
Depicted lines were obtained by 
linear regression analysis for each 
of the genotype sub-groups and 
table 2 provides detailed regression 
parameters.
(Electroimmunoassay and ELISA), but also the activity assay (Actichrome® 
TAFI assay) exhibited this association of genotype with concentration.
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Assay Evaluation by linear regression analysis
Statistically significant correlations were found both between the Actichrome® 
TAFI assay and the Electroimmunoassay (r = 0.68; P< 0.0001), between the 
Actichrome® TAFI assay and the ELISA (r = 0.55; P< 0.0001) and between 
the Electroimmunoassay and the ELISA (r = 0.64; P < 0.0001). Linear 
regression analysis revealed an intercept significantly different from zero 
for the relationships between the Electroimmunoassay and the Actichrome® 
TAFI assay and between the ELISA and the Electroimmunoassay (Table 
II).
To look for genotype-specific effects and/or possible assay-related artefacts 
we constructed plots of the Electroimmunoassay versus Actichrome® TAFI, 
ELISA versus Actichrome® TAFI and ELISA versus Electroimmunoassay 
for the 1040C/T-genotype sub-groups. Linear regression analysis, for 
each of these sub-groups, is shown in figure 1 and table II. For the 
Electroimmunoassay/Actichrome® TAFI plot we found that the regression 
lines obtained for the genotype sub-groups can be considered equal (fig. 
1A) (by ANCOVA, P = 0.249). The ELISA/Actichrome® TAFI plot (fig.1B) and 
the ELISA/Electroimmunoassay plot (fig.1C) however, exhibit three distinct 
lines for the genotype sub-groups (by ANCOVA, P <0.0001 and P < 0.0001, 
respectively). The results suggest that both the Actichrome® TAFI assay 
and the TAFI Electroimmunoassay are assays free of genotype-dependent 
artefacts. The ELISA on the other hand is dependent on the genotype and 
amplifies differences in TAFI concentrations in a genotype-related manner. 
This suggests distinct recognition of the TAFI variants in the two antigen 
Figure 2. TAFI ELISA dilution 
profiles of the CC and TT 
pools (- 438G/G, 1040C/C and - 
438A/A, 1040T/T respectively). 
The ELISA was performed as a 
kinetic assay and the delta OD 
620nm / time plotted against 
the TAFI concentration obtained 
with the Electroimmunoassay 
(U/ml). () CC pool, () TT 
pool. Each point results from 
six repeats.
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assays, which could arise from the different IgG preparations or from the 
different principles of the immunologic assays.
Assay Evaluation by Bland-Altman agreement analysis
Bland-Altman difference plots were constructed from the results by plotting 
the differences between TAFI concentrations determined with two different 
assays against the average TAFI concentrations in these two assays (not 
shown). This statistical method can be used to assess agreement between 
two assays and is particularly useful when no reference method is available, 
as for TAFI determination.
For the whole group, concentration-dependent effects did not affect the 
agreement between the Electroimmunoassay and the TAFI Actichrome® 
(by F test, P = 0.457) while, for combinations involving the ELISA a 
concentration-dependent effect was encountered (by F test, P < 0.0001). 
Subsequently, Bland-Altman difference plots were constructed for the 
genotype sub-groups. Neither the 1040C/T genotype nor the TAFI 
concentration affected the agreement between the Electroimmunoassay 
and the TAFI Actichrome®. The agreement between the ELISA and the 
Electroimmunoassay or the TAFI Actichrome® however, was genotype-
dependent and concentration-dependent.
ELISA dilution profiles
In order to study the ELISA response of the two TAFI variants in a greater 
detail, two different plasma pools (CC and TT pools) were serially diluted 
and tested in the ELISA. Figure 2 shows the delta OD620 nm / time values 
plotted against the TAFI concentration in U/ml, as determined with the TAFI 
Electroimmunoassay and therefore not affected by the genotype.
The TT and CC pools showed distinct responses in the TAFI ELISA. The 
results suggest that the TT pool led to a lower maximal value than the CC 
pool, pointing to an impaired recognition of the 325Ile variant (- 438A/A, 
1040T/T) in the ELISA.
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Discussion 
At present, it is not fully understood which TAFI single nucleotide 
polymorphism (SNP) or group of SNPs causes the high variability in TAFI 
levels and whether these can predict the risk of thrombosis. Several 
polymorphisms have been identified in the TAFI gene [10,16,18,25] and 
found to be in strong linkage disequilibrium. Recently, a SNP (1040C/T) 
was identified that results in an amino acid substitution at position 325 
(Thr325Ile) [18]. Recombinant TAFI variants with either Ile325 or Thr325 
were prepared and found to have a similar sensitivity to activation by the 
thrombin/thrombomodulin complex [19]. The hydrolysis of a synthetic 
substrate (anisylazoformyllysine - AAFK) by the activated TAFI variants 
was also identical. However, Thr325Ile is known to be a functional 
polymorphism with the variant Ile325 displaying enhanced stability and 
increased antifibrinolytic potential [19], but apparently lower antigen levels 
[18]. These opposing effects may hamper the interpretation of studies 
based solely on genetic association [24,26].
In the meanwhile, it was suggested that anti-TAFI IgG preparations might 
have a variable affinity towards different TAFI isoforms of the Thr325Ile 
SNP (1040C/T) (unpublished observations). If it would be confirmed that 
different IgG preparations or assays generate different results, the outcome 
of clinical studies may possibly depend on the assay methodology. This 
could aid the elucidation of the controversial results suggesting that high 
TAFI antigen in plasma is both protective against myocardial infarction 
[14,27] and angina pectoris [28], and a risk factor for venous [8-10] and 
arterial thrombosis [11-13]. Therefore, we set up a study to compare assay 
agreement in a group of 92 healthy individuals.
To do so, we selected three distinct assays to determine TAFI levels in 
plasma and genotyped the individuals. The results allowed us to discriminate 
between the outcome of the assays in the whole group and in the 1040 
C/C, C/T and T/T sub-groups. We confirmed the significant association 
between the TAFI polymorphisms and plasma TAFI concentration for the 
two immunological assays (ELISA and Electroimmunoassay), although 
the genotype-dependence of the TAFI concentration was much more 
pronounced for the ELISA than for the Electroimmunoassay. Furthermore, 
we showed a similar association for the Actichrome® TAFI assay, which 
established that this association is not limited to immunological assays. It 
is relevant to stress at this stage that the Actichrome® TAFI assay relies 
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on the activation of the pro-enzyme and on the activity of TAFIa towards a 
synthetic substrate both of which seem to be identical for the TAFI 325Thr 
and TAFI 325Ile [19]. Hence, the Actichrome® TAFI assay is expected to 
detect the two TAFI variants equally well.
For the 92 healthy volunteers statistically significant correlations were 
encountered in all combinations of the assays. Furthermore, the relationships 
between both the Electroimmunoassay and the Actichrome® TAFI assay, and 
the ELISA and the Electroimmunoassay exhibited intercepts, which differed 
from zero. This may well arise from the fact that the Electroimmunoassay 
determines total TAFI antigen, which will comprise not only TAFI but also 
might include different TAFI fragments.
When the individuals where subdivided per genotype, a clear shift in 
response was seen for the relationships involving the ELISA. Regression 
analysis of the ELISA/Actichrome® TAFI and the ELISA/Electroimmunoassay 
relationships showed that the 1040 T/T sub-group resulted in the 
lowest regression line followed by the 1040 C/T and the 1040C/C sub-
groups (fig.1). We confirmed these results with Bland-Altman agreement 
analysis where different responses were also encountered for the CC, 
CT and TT genotypes. The performance of the same analysis for the 
Electroimmunoassay/Actichrome® TAFI relationship produced identical 
responses. We concluded that these two assays are free of genotype-
related artefacts while the ELISA involves a concentration and genotype-
dependent effect that enhances erroneously the observed concentration 
differences between the genotype sub-groups. While the ELISA suggested 
that the TAFI levels in the C/C subgroup were 2-fold higher than in the T/T 
subgroup, the Electroimmunoassay and the Actichrome® TAFI indicated TAFI 
levels 1.2 to 1.3-fold higher in the C/C subgroup (Table I).
Dilution profiles of plasma pools composed of 1040C/C or 1040T/T 
individuals (Fig.2) confirmed that the response of the ELISA was variable 
for the two variants. The ELISA response for the pooled normal plasma 
used as calibrator was more similar to the CC pool than to the TT pool, due 
to the genotype frequencies (Table I). Altogether, this results in a variable 
estimation of TAFI concentration in individuals according to genotype but 
also according to the composition of the calibration pool.
After completion of this manuscript, Gils et al [29] described the 
development of a genotype 325-specific proCPU/TAFI ELISA. In addition, 
another combination of monoclonal antibodies was found to be completely 
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independent on the 325 genotype. The commercial antigen assays tested 
showed a variable dependence on the 325 genotype, which is in agreement 
with what we found using our ELISA. Furthermore, they completely 
attributed the genotype-related differences in TAFI concentration to the 
impaired reactivity towards the 325 genotype. This contrasts with our 
finding of a linear trend of TAFI concentration with the 325 genotype both 
for the Electroimmunoassay and for the Actichrome® TAFI assay. We believe 
that the authors have overlooked a small but significant genotype effect on 
TAFI levels that exists at least in human volunteers.
In conclusion, standardisation and better characterisation of the available 
TAFI assays and calibrators become increasingly important. We demonstrated 
that genotype-dependent artefacts might occur when measuring TAFI 
antigen levels by ELISA. As a result, one should exert caution in interpreting 
TAFI antigen levels given that comparison is only possible when the same 
method is used or when method characteristics are comparable. Moreover, 
it is also important to realise that as normal pooled plasma is usually used 
for ELISA calibration this may lead to additional discrepancies according to 
the composition of the pool. Nevertheless, based on the results obtained 
with the Electroimmunoassay and the Actichrome® TAFI assay, we support 
a genotype-related variation of TAFI concentration. 
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Summary
New TAFI assays are necessary for studying the role of this fibrinolysis 
inhibitor in cardiovascular disease. The identification of a functional SNP 
(1040C/T) leading to a TAFI-variant with increased stability but lower 
antigen levels has made the determination of functional activity even more 
essential. Therefore, we developed a new assay for the functional activity of 
TAFI in citrated plasma samples. This assay is based on the retardation of 
plasma clot lysis by TAFIa. TAFI activation was induced simultaneously with 
fibrin formation and lysis was mediated by rt-PA. The variability of other 
plasma components was minimized by a 20-fold dilution of the samples in 
TAFI-depleted plasma. Lysis times (-/+ potato carboxypeptidase inhibitor) 
and the TAFI-related retardation of clot lysis, the functional parameter of 
the assay, were determined in a group of 92 healthy volunteers, as well 
as TAFI antigen levels (Electroimmunoassay) and two TAFI SNPs (- 438A/G 
and 1040C/T). TAFI-related retardation was 19.8 ± 5.6 min (mean ± SD) 
and was correlated with the antigen level. The specific antifibrinolytic 
activity of TAFI was associated with the - 438A/G and 1040C/T genotypes. 
Individuals with the 325Ile-variant had on average a 34% higher TAFI-
specific antifibrinolytic activity than individuals with the 325Thr-isoform. 
The TAFI-related retardation in the two groups of individuals did not differ, 
as a lower level compensated for the higher specific antifibrinolytic activity 
of the 325Ile-isoform. This assay provides valuable information about the 
performance of different TAFI isoforms and constitutes a new method for 
studying the role of TAFI in cardiovascular disease.
Introduction
Thrombin activatable fibrinolysis inhibitor (TAFI) or plasma procarboxypeptidase 
B was discovered about a decade ago and constitutes a connection between 
the clotting and fibrinolytic pathways [1-3]. Proteolytic cleavage of TAFI 
after Arg-92 by thrombin, plasmin, trypsin or the thrombin-thrombomodulin 
complex forms the active enzyme (TAFIa) and the glycosylated activation 
peptide [4-6]. The antifibrinolytic effect of TAFIa in vitro is dependent on 
the concentration of TAFI [7,8] as well as on the type and concentration 
of the plasminogen activator used [9]. TAFIa removes C-terminal arginine 
and lysine residues present on partially degraded fibrin [7,10-12]. These 
residues have a pivotal role in plasminogen activation and in the lysis of a 
plasma clot. Consequently, TAFIa inhibits clot lysis.
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There is evidence that a single nucleotide polymorphism (SNP) in the TAFI 
gene, which results in the substitution of a Thr by an Ile at position 325 of the 
protein [13], is located in a region that is related to the thermal stability of 
TAFIa and therefore to its antifibrinolytic potential. Hence, an Ile at position 
325 in recombinant TAFI doubles its stability (half-life at 37oC increases 
from 8 min to 15 min) and results in an increased antifibrinolytic activity 
[14]. However, the same SNP (1040 C/T) was found to be associated with 
TAFI antigen levels in plasma with the T allele (which codes for the 325Ile-
isoform) being linked to lower antigen levels [13]. This probably arises from 
the fact that this SNP is in strong linkage disequilibrium with several other 
SNPs situated in the promoter region of the TAFI gene [13,15-17]. Indeed, 
the increased stability and activity of this isoform and its decreased antigen 
level pose a problem for the interpretation of results of TAFI assays.
Different methods have been employed for the determination of TAFI 
activity in plasma and recently, an assay was devised for the determination 
of endogenous TAFIa activity in plasma [18]. Some of the TAFI activity 
assays used clot lysis times [8,19,20]. However, most TAFI activity assays 
are based on the activation of TAFI zymogen and subsequent detection of 
TAFIa via the enzymatic cleavage of a small synthetic substrate [3,21-24].
Our aim was to develop an assay for the measurement of TAFI that would 
include TAFI activation, the limited stability of TAFIa as well as the removal 
of C-terminal lysines and arginines from partially degraded fibrin by TAFIa. 
This functional assay is based on the ability of activated TAFI to delay the 
lysis of a plasma clot mediated by r-tPA. A 20-fold dilution of the sample 
in TAFI-depleted plasma reduced the influence of other individual plasma 
components on lysis, which previously posed a problem for the specificity 
of lysis-based TAFI assays [20]. In addition, this predilution assured the 
measurement of TAFI activity in a concentration range, which produced a 
proportional increase in response. By determining TAFI antigen levels as 
well as genotyping for the functional TAFI SNP (1040C/T – Thr325Ile) and 
a SNP in the promoter region (- 438A/G) we were able to show that the 
response of the TAFI functional assay is dependent not only on the TAFI 
level but also on the stability and activity of the particular TAFI isoform.
In our view this novel TAFI functional assay can be used for the determination 
of potential TAFI activity in a variety of individual plasma samples and may 
be used for the identification and characterisation of TAFI molecules with 
altered activity as well as for testing new pharmaceutical approaches for 
the modulation of the antifibrinolytic activity of TAFIa.
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r-tPA (Actilyse) was kindly supplied by Boehringer Ingelheim (Ingelheim, 
Germany). Human thrombin was purchased from Sigma (St Louis, 
MO, USA) and both potato carboxypeptidase inhibitor (PCI) and human 
recombinant plasmin activator inhibitor 1 (PAI-1) were obtained from 
Calbiochem (La Jolla, CA, USA). For stability reasons, dilutions of the PAI-1 
stock were performed in 20 mM Hepes, 1 mM EDTA, pH 6.5. Rabbit lung 
thrombomodulin (TM), with a specific activity towards thrombin of 1.2 
units/μg, was acquired from American Diagnostica Inc (Greenwich, CT, 
USA). Plasmin inhibitor (previously α2 –antiplasmin) and fibrinogen were 
obtained from Biopool (Umeå, Sweden) and Enzyme Research Laboratories 
(South Bend, IN, USA), respectively. Plasminogen was purified from human 
plasma by lysine-Sepharose chromatography [25]. All the other reagents 
were from Merck (Darmstadt, Germany).
Pooled normal plasma
Blood was collected by venipuncture from 70 healthy individuals (30 men, 
40 women, mean age 38.7 years) in plastic tubes containing 0.1 vol of 
0.106 M trisodium citrate. Blood was centrifuged at 2000g for 20 min at 
20oC. Women on oral contraceptives were excluded. The platelet-poor 
plasmas were pooled and used as calibrator for the Electroimmunoassay 
[24,26]. The pooled normal plasma was considered to contain 1U/ml of 
TAFI.
Subjects 
A group of 92 healthy individuals (46 males and 46 females, mean age of 
46.5 years, range 21 to 75 years) was recruited among hospital personnel 
and their families. All subjects gave informed consent. Blood was collected 
into 0.1 vol of 0.106 M trisodium citrate and centrifuged at 2000g for 30 
min at 4oC. The plasma was stored at - 80oC in aliquots of 0.4 ml.
TAFI-depleted Plasma
TAFI-depleted plasma was prepared using an anti-TAFI IgG sepharose 
column as previously described by Van Tilburg et al [26]. Briefly, rabbit 
polyclonal anti-TAFI antibodies were coupled to CNBr-activated Sepharose-
4B (Amersham Pharmacia Biotech, Uppsala, Sweden) as described by the 
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manufacturer. Pooled normal plasma prepared from blood collected on 
citrate-phosphate-dextrose was applied to the anti-TAFI IgG sepharose 
column (10 mg IgG/mL sepharose) and the breakthrough fractions were 
tested for TAFI with a TAFI ELISA [24] and with the TAFI functional assay 
(see under). TAFI-depleted fractions were pooled and dialysed against 50 
mM Hepes, 100 mM sodium chloride, 20 mM sodium citrate (pH 7.4), in 
order to remove phosphate ions. The plasma was then aliquoted and frozen 
at -20oC. TAFI-depleted plasma was used to dilute samples both in the TAFI 
functional assay and in the Electroimmunoassay.
TAFI Functional Assay
Individual citrated plasma samples were diluted 20-fold in TAFI-depleted 
plasma (a single batch of TAFI-depleted plasma was used to determine all 
individual samples). The diluted plasma samples (100 µl) were added to 
the wells of a microtitre plate containing 25 µl of a reaction mix. The mix 
was composed of thrombin (3.3 NIH units/ml), TM (0.6 units/ml), r-tPA 
(0.10 µg/ml), CaCl2 (20 mM) and PCI (30 µg/ml where stated) in 50 mM 
Hepes buffer, pH 7.4 containing 0.1% w/v BSA. The concentrations between 
brackets refer to the final concentrations in the clotted plasma, which have 
been optimised as described previously [9]. The wells were immediately 
covered with paraffin oil (Merck – No.107162) and the microtitre plate was 
placed in the prewarmed (37oC) incubation chamber of a TECAN Sunrise® 
Microplate-reader (Giessen, The Netherlands). The optical density at 405 
nm was monitored every minute for 150 min. A control with PCI was used 
for each sample. Lysis time (LT) was defined as the time point corresponding 
to a 50% decrease in optical density and a sigmoidal regression was used 
for its determination. The TAFI-related retardation was determined for each 
sample by subtracting the lysis time in the presence of PCI (LT+PCI) from 
the lysis time in the absence of PCI (LT-PCI). Using this assay the intra- 
and inter-assay variability of the TAFI-related retardation of pooled normal 
plasma (20-fold diluted) were 7 % and 13 %, respectively (n = 30; using 
several batches of TAFI-depleted plasma).
TAFI Functional assay: dilution profile
Serial dilutions of citrated plasma in TAFI-depleted plasma were prepared 
and the TAFI-related retardation of clot lysis was measured as outlined 
above. The dilution profile was inspected for pooled normal plasma and for 
citrated plasma from two individuals who were homozygous for the - 438 A/G 
and 1040 C/T TAFI polymorphisms. One individual had the - 438 GG, 1040 CC 
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genotype and the other the - 438 AA, 1040 TT genotype.
TAFI antigen levels (Electroimmunoassay) and genotyping
Rocket immunoelectrophoresis [27] was used to measure TAFI antigen 
levels [26]. The Electroimmunoassay and genotyping were performed as 
described previously [24]. The Electroimmunoassay had an intra- and inter-
assay variation coefficient of 6% and a detection limit of around 0.016 
U/ml [26]. The distribution of the individuals in the genotype subgroups 
according to gender was normal.
Statistical Analysis
Values are expressed as mean ± SD or mean ± SEM as indicated. The 
normality of the distribution of each functional assay parameter was 
tested in the entire group and in the genotype subgroups using both 
parametric and nonparametric tests. One-way ANOVA with a post-test for 
linear trend was used to look at the relation between TAFI levels and the 
TAFI genotype. Pearson’s correlation coefficient was calculated to study 
Figure 1. Clot lysis profiles obtained by plotting the OD 405 nm against 
the incubation time (min) (typical example). TAFI in each plasma sample 
was activated during clotting with thrombin (3.3 NIH units/ml), thrombomodulin 
(0.6 units/ml) and CaCl2 (20 mM) in the presence of r-tPA (0.10 µg/ml). PCI was 
included (30 µg/ml), where stated. Closed squares, normal plasma. Closed circles, 
normal plasma diluted 20-fold in TAFI-depleted plasma. Open circles, normal 
plasma diluted 20-fold in TAFI-depleted plasma with PCI. Closed triangles, TAFI-
depleted plasma. Open triangles, TAFI-depleted plasma with PCI. The baseline OD 
value was subtracted for each curve (about 0.4).
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Figure 2. Dilution profile of pooled normal plasma in the functional assay 
of TAFI. Variable TAFI concentrations were obtained by performing serial dilutions 
of normal plasma in TAFI-depleted plasma. TAFI in each plasma sample was then 
activated during clotting with thrombin (3.3 NIH units/ml), thrombomodulin 
(0.6 units/ml) and CaCl2 (20 mM) in the presence of r-tPA (0.10 µg/ml). Each 
sample was measured in the absence and in the presence of PCI and TAFI-
related retardation was plotted against the TAFI antigen concentration. Each point 
represents the mean of seven independent experiments and bars indicate SEM.
the associations between the TAFI functional assay parameters and the 
TAFI Electroimmunoassay. Linear regression analysis was performed to 
evaluate the between-assay relationships in the TAFI genotype subgroups. 
Multivariate regression analysis was performed to assess the effect of 




A typical example of the clot lysis profiles obtained is shown in Fig.1. The lysis 
times (LT) of TAFI-depleted plasma in the absence and presence of PCI were 
essentially identical (30.2 ± 3.6 min and 31.6 ± 4.0 min, respectively, mean 
± SD, n = 25 with two batches of TAFI-depleted plasma). Normal plasma 
diluted 20-fold in TAFI-depleted plasma showed a 1.5-fold prolonged lysis 
time, which was abolished by the addition of PCI. Undiluted normal plasma 
showed a 2-fold prolonged lysis time. Figure 1 also demonstrated that the 
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levels of other constituents of plasma essential for clot formation and lysis 
were not appreciably altered by the immunoadsorption procedure, as the 
LT+ PCI of the plasma remained constant before and after TAFI depletion.
Dilution profile
From serial dilutions of pooled normal plasma in TAFI-depleted plasma we 
obtained the dilution profile for the TAFI-related retardation, shown in Fig.2. 
Increasing TAFI concentrations produced an increase in retardation up to 
about 0.20 U/ml. At higher TAFI concentrations a plateau in the response 
was reached.
TAFI functional assay
On the basis of the dilution profile of pooled normal plasma (Fig.2) we 
used a 20-fold dilution of plasma samples in TAFI-depleted plasma in order 
to determine TAFI-related retardation in a relatively sensitive range. Lysis 
Figure 3. Frequency distribution of the TAFI-related retardation in the 
1040 CT genotype subgroups of 92 healthy individuals. The TAFI-related 
retardation presented a normal distribution in each genotype subgroup.
times (LT) were derived for each sample in the absence and presence of PCI. 
Normal distributions were obtained for all assay parameters determined 
in plasma from 92 healthy individuals. Mean values for LT- PCI and LT+ PCI 
and for TAFI-related retardation are presented in Table I. No associations 
were found between the LT- PCI or LT+ PCI or the TAFI-related retardation and 
gender. There was also no relationship between TAFI-related retardation or 
the LT- PCI and age. The LT+ PCI, on the other hand, progressively decreased 
with age (r = 0.311; P = 0.003). In the genotype subgroups, normal 
distributions were observed for the LT- PCI, LT+ PCI (not shown) and the TAFI-
related retardation (Fig.3, for 1040 CT genotype). The TAFI functional 
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assay parameters were not associated with TAFI genotypes (- 438A/G and 
1040C/T, tested by ANOVA).
Influence of other plasma components on the TAFI functional assay
We investigated the influence of a number of plasma components, namely 
fibrinogen, plasminogen, plasmin inhibitor and PAI-1, on the TAFI functional 
assay parameters. The assay was performed essentially as described under 
methods. Each of the purified components was added in increasing amounts 
to normal plasma which was then diluted 20-fold in TAFI-depleted plasma. 
As shown in Fig.4, fibrinogen (Fig.4A), plasminogen (Fig.4B) or plasmin 
inhibitor (Fig.4C) had no effect on the TAFI functional assay parameters 
(p > 0.05 for all, repeated measurements test) in a wide concentration 
range, up to a 3-fold increase of the component concentration in the normal 
plasma. An increase in PAI-1 concentration in normal plasma up to 2000 
Figure 5. Effect of TAFI genotype 
on the relationship between 
the TAFI-related retardation 
and the TAFI antigen levels 
(Electroimmunoassay) for a group 
of 92 healthy individuals. A, -438 A/
G genotype: (□) -438 G/G, (●) -438 A/
G, () -438 A/A. B, 1040 C/T genotype: 
(□) 1040 C/C, (●) 1040 C/T, () 1040 
T/T. Depicted lines were obtained 
by linear regression analysis of 
each of the genotype sub-groups.
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Figure 6. Box plots depicting 
the effect of - 438A/G and 
1040C/T TAFI genotypes 
on the TAFI-specific 
antifibrinolytic activity 
in a group of 92 healthy 
individuals. A, - 438 A/G, 
*P = 0.004. B, 1040 C/T, **P 
= 0.003. The TAFI-specific 
antifibrinolytic activity was 
defined as the ratio between 
the TAFI-related retardation 
(min) and TAFI antigen level 
(U/ml) and was expressed in 
arbritary units (AU). P values 
for relations between TAFI-
specific antifibrinolytic activity 
and TAFI genotypes were 
calculated by ANOVA – post-
test for linear trend.
ng/ml (100-fold) had no effect on the TAFI functional assay parameters 
(Fig.4D - p > 0.05 for all, repeated measurements test). Only at PAI-1 
concentrations of 10,000 ng/ml (500-fold increase) the TAFI functional 
assay parameters became considerably prolonged (96.6 ± 6.8 min against 
46.1 ± 2.4 min for LT- PCI, 54.7 ± 0.2 min against 30.3 ± 2.8 min for LT+ PCI, 
and 41.9 ± 6.8 min against 15.8 ± 3.7 min for TAFI-related retardation). 
Correlation of TAFI functional assay parameters with TAFI antigen – Both 
the LT-PCI and LT+PCI displayed a weak correlation with the TAFI antigen 
levels (Table I) determined with the Electroimmunoassay (r = 0.205; P = 
0.05 and r = - 0.245; P = 0.02, respectively). After correction for age, the 
association between LT+PCI and the TAFI antigen levels became weaker. TAFI 
antigen levels were not associated with age or gender. The TAFI-related 
retardation correlated significantly with the TAFI antigen levels(r = 0.357; 
P = 0.0005).
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Figure 7. Dilution profile of a CC and a TT individual (1040C/C and 1040T/T, 
respectively) in the functional assay of TAFI. Variable TAFI concentrations were 
obtained by performing serial dilutions of individual plasmas in TAFI-depleted plasma. 
TAFI in each plasma sample was then activated during clotting with thrombin (3.3 NIH 
units/ml), thrombomodulin (0.6 units/ml) and CaCl2 (20 mM) in the presence of r-tPA 
(0.10 µg/ml). Each sample was measured in the absence and in the presence of PCI 
and TAFI-related retardation was plotted against the TAFI antigen concentration. Each 
point represents the mean of at least two experiments. () CC individual plasma, (□) 
TT individual plasma.
When the different genotypes were taken into account the correlation of 
the TAFI-related retardation with the TAFI antigen increased in strength 
for the -438GG (r = 0.497, P = 0.0003), -438AG (r = 0.517, P = 0.0011) 
and the 1040CC (r = 0.430, P = 0.003), 1040 CT (r = 0.490, P = 0.0015) 
genotypes (Fig.5A and 5B). For the -438AA and 1040TT genotype subgroups 
no correlation was found between the TAFI-related retardation and the TAFI 
antigen levels, which may be due to the small sample sizes. The regression 
lines (Fig. 5B) are consistent with the notion that individuals with the 1040T 
allele (TAFI-325Ile) have higher TAFI activity (TAFI-related retardation) per 
TAFI antigen concentration than individuals with the 1040C allele (TAFI-
325Thr).
Multivariate regression analysis illustrated that the TAFI antigen on its 
own explained 13% of the variation in the TAFI-related retardation and 
that the TAFI antigen together with the - 438AG and 1040CT genotypes 
clarified around 22% of the variation. Furthermore, the assay variability 
could explain roughly 50% of the variation in the TAFI-related retardation. 
This leaves nearly 30% of variability unexplained and points to additional 
differences between TAFI functional activity and TAFI level.
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TAFI-specific antifibrinolytic activity
The TAFI-specific antifibrinolytic activity was defined as the ratio between 
the TAFI-related retardation (min) and the TAFI antigen level determined 
with the Electroimmunoassay (U/ml) and values are given in arbitrary units 
(AU) (Table I). The box plots in Fig.6 depict the association of the TAFI-
specific antifibrinolytic activity with the - 438 A/G (Fig.6A) and 1040 C/T 
(Fig.6B) TAFI genotypes. From these results we concluded that individuals 
who are heterozygous or homozygous for the - 438A allele or for the 1040T 
allele have an increased TAFI-specific antifibrinolytic activity (by ANOVA, 
post-test for linear trend: r = 0.291; P = 0.004 and r = 0.306; P = 0.003, 
respectively). In addition, from the mean TAFI-specific antifibrinolytic 
activities in the TAFI genotype subgroups we can estimate the increase 
in antifibrinolytic activity due to the 1040 C/T TAFI SNP. On average, 
the subgroup with 325Thr/Ile (1040CT) and 325Ile/Ile (1040TT) showed 
respectively 14% and 34% greater specific antifibrinolytic activity than the 
subgroup with 325Thr/Thr (1040CC).
Dilution profile of TAFI variants
Dilution profiles were constructed with plasma from individuals with the 
1040CC genotype and 1040TT genotype (Fig.7) in order to further examine 
the difference in TAFI-specific antifibrinolytic activity. Plasma of the CC 
individual displayed a response similar to that of the pooled normal plasma 
(Fig.2), in agreement with the high frequency of the C-allele in a normal 
population (Table I). Plasma of the 1040TT individual, on the other hand, 
exhibited a considerably higher response and plateau than that of the 
1040CC individual, corroborating a higher specific antifibrinolytic activity of 
the 325Ile-isoform.
This distinct response means that pooled normal plasma cannot be used 
for the calibration of this TAFI functional assay.
Discussion
Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B 
zymogen present in plasma, which has the capacity to suppress fibrinolysis. 
This is accomplished by removing newly plasmin-generated C-terminal 
lysine and arginine residues in fibrin that function as high affinity binding 
sites for plasminogen [28,29], thus leading to the downregulation of 
plasmin generation [11,12,30].
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To incorporate this role of TAFI in fibrin clot lysis into functional TAFI 
measurements, a novel assay was developed for the determination of TAFI 
functional activity in plasma. In order to mimic physiological conditions as 
much as possible, a high plasma concentration was used in the assay (80% 
plasma, final concentration). Fibrin generation and simultaneous TAFI 
activation were achieved by the addition of thrombin, thrombomodulin and 
calcium. The conditions for optimal TAFI activation, i.e. maximal retardation 
of clot lysis, have been described previously [9]. The lysis of the plasma 
clot is mediated by r-tPA that is included in the reaction mix and not in 
the plasma sample in order to minimise its inhibition by plasma proteinase 
inhibitors (such as PAI-1) prior to the assay measurements. Subsequently, 
the lysis profile is obtained by monitoring the OD at 405 nm while incubating 
the microtitre plate at 37oC. Finally, every sample is diluted 20-fold in TAFI-
depleted plasma and determined in the absence and in the presence of 
potato carboxypeptidase inhibitor (PCI). The difference between clot lysis 
times in the absence and in the presence of PCI is thus specific to the 
contribution of TAFI. In order to study the assay performance we executed 
the TAFI functional assay in samples from 92 healthy individuals.
As shown in Fig.4, the 20-fold dilution in TAFI-depleted plasma ensures 
a minimal interference of other plasma components on the determination 
of TAFI functional activity in different individuals. In the particular case of 
PAI-1 (Fig.4D), it would be expected that when a 1:1 molar ratio between 
PAI-1 added and r-tPA used in the assay is reached an effect would be 
observed in the lysis times. To our surprise, at a PAI-1 concentration as 
high as 2000 ng/ml no effect was detected. The explanation possibly lies 
in the particular conditions of the TAFI functional assay. The presence of 
thrombin/thrombomodulin in the assay will activate protein C, which will 
form a tight 1:1 complex with PAI-1. The presence of an excess of thrombin 
may also lead to inactivation of PAI-1 via the formation of a ternary complex 
with vitronectin. Moreover, the assay is performed close to physiological 
conditions (pH 7.4 and 37oC), conditions under which PAI-1 is known to 
rapidly lose activity.
We also determined the TAFI antigen levels and genotyped the 92 healthy 
individuals for the - 438A/G and 1040C/T TAFI SNPs. Recently, it was shown 
that some anti-TAFI IgG preparations have different affinities towards the 
two TAFI isoforms (Thr325Ile) of the 1040C/T SNP [24,31]. This leads 
to a concentration- and genotype-dependent artefact in the TAFI antigen 
measurement. However, we have previously shown that some assays, 
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among which the TAFI Electroimmunoassay used in the present study, are 
insensitive to this artefact. By the use of such assays it was confirmed that 
the TAFI concentration in plasma is associated with the TAFI genotype, 
although TAFI antigen levels in 1040CC carriers were only 20 to 30% higher 
than in 1040 TT carriers [24].
A weak correlation was found between the TAFI-related retardation and 
TAFI antigen levels (r = 0.357). Taking into account the TAFI genotype 
improved the relationship between the TAFI-related retardation and TAFI 
antigen. The genotypes comprising the stable TAFI variant (TAFI-325Ile) 
displayed the highest response (upper line - Fig.5B). The dispersion found 
here between assays can only partially be accounted for by assay variability 
or by known TAFI variability (SNPs). This points to additional differences 
between TAFI molecules and/or their activity as well as to the need for 
more detailed information concerning the role of TAFI in distinct assays.
We studied the response of pooled normal plasma (Fig.2) as well as two 
genotype-specific individual plasmas (1040 CC and TT genotype, Fig.7). 
The genotype-specific plasma samples confirm a distinct response of 
samples with known differences in stability and activity with the more 
stable 325Ile-variant presenting a higher response and plateau than the 
325Thr-variant. On the other hand, these results also indicate that pooled 
normal plasma cannot be used as the calibrator, as a combination of TAFI 
forms will generate an intermediate curve and will lead to under- or over-
estimation of the individual samples. 
Schneider et al [14] have shown that different isoforms of TAFI lead 
to different retardation profiles with distinct plateaux. Using purified 
recombinant variants they reported that the 325Ile-variant displayed a 30-
50% higher antifibrinolytic effect, compared to the 325Thr-variant. We also 
found an increased TAFI-specific antifibrinolytic activity for the more stable 
325Ile-variant (Fig.7) and accordingly, the specific TAFI antifibrinolytic 
activity was associated with the TAFI genotype (Fig.6). On average, the 
subgroup with 325Thr/Ile (1040C/T) and 325Ile/Ile (1040T/T) showed 
respectively 14% and 34% higher TAFI specific antifibrinolytic effect than 
the subgroup with 325Thr/Thr (1040C/C). This is consistent with the results 
of Schneider et al [14], especially when we take into account that here 
individual plasmas are being studied. The mechanism behind the distinct 
plateaux found by Schneider et al with recombinant TAFI variants and in 
this study with native TAFI variants from plasma remains unclear. During 
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the preparation of this manuscript Leurs et al [32] and Walker and Bajzar 
[33] demonstrated that TAFIa influenced clot lysis through a threshold-
dependent mechanism. They showed that according to this mechanism not 
only the TAFI concentration, but also the time course of TAFI activation, 
the stability of TAFIa and the tPA concentration are determinant factors for 
the clot dissolution. This might help to elucidate the distinct retardation 
profiles observed in the present work (Fig.7 and in Ref.[14]) as the more 
stable variant will remain longer above the threshold.
It is interesting to note that the 325Ile-variant with the higher specific 
TAFI antifibrinolytic activity is present at a slightly lower concentration in 
plasma (Table I). This is explained by the linkage between the functional 
TAFI SNP (1040C/T) and SNPs in the TAFI promoter region. The two effects 
compensate for each other and, as a result, the TAFI functional activity 
(TAFI-related retardation) did not differ in the genotype subgroups (Table 
I). Accordingly, if TAFI functional activity is found to be associated with 
risk for some cardiovascular disease, it will be interesting to perform TAFI 
genotyping and TAFI antigen determination in order to investigate the 
contribution of these factors to the risk.
Thus, the TAFI functional parameter of this new assay (TAFI-related 
retardation) seems to be related to a particular combination of factors (e.g. 
concentration, stability, activity) for each individual. The understanding of 
these particular combinations and their relation to disease states will be 
necessary to further elucidate the involvement of TAFI in cardiovascular 
disease.
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Summary
Background and objective: Several studies have suggested that thrombin-
activatable fibrinolysis inhibitor (TAFI) levels are associated with the risk 
of arterial thrombosis, but results have been contradictory. We studied 
functional TAFI levels and TAFI gene polymorphisms in 124 patients with a 
recent ischemic stroke and 125 age and sex-matched controls to establish 
the role of TAFI in ischemic stroke. Methods and results: Functional TAFI 
levels, defined as TAFI-related retardation, the difference in clot lysis time 
in the absence or presence of a specific activated TAFI inhibitor potato 
carboxypeptidase inhibitor (PCI), were higher in patients than controls 
(19.5 ± 4.2 vs. 17.7 ± 3.7 min, p <0.005). Clot lysis times in the presence 
of PCI, which were independent of TAFI, were also increased in ischemic 
stroke patients. This indicates that in these patients fibrinolysis is impaired 
not only by high TAFI levels, but also by other mechanisms. Individuals 
with functional TAFI levels in the highest quartile had an increased risk 
of ischemic stroke compared to the lowest quartile (OR 4.0, CI 1.6-9.8). 
In an unselected group of 36 of the 125 stroke patients functional TAFI 
levels were also measured at 3 months, and were persistently high. This 
indicates that increased functional TAFI levels after stroke are not caused 
by an acute phase reaction. No difference was found between patients and 
controls with respect to TAFI genotype distribution. Conclusions: Increased 
functional TAFI levels, resulting in decreased fibrinolysis, are associated 
with an increased risk of ischemic stroke.
Introduction
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a fibrinolysis inhibitor of 
which the role in the pathogenesis of ischemic stroke is not yet clear. The 
known physiological role of activated TAFI is the inhibition of fibrinolysis 
by removing C-terminal lysine and arginine residues of partially degraded 
fibrin, thereby slowing the rate of tissue plasminogen activator-induced 
plasminogen activation [1,2]. A role of TAFI in arterial thrombosis, including 
unstable angina pectoris and myocardial infarction, has been suggested. 
In patients with symptomatic coronary heart disease (CHD) contradictory 
results concerning TAFI antigen levels have been reported, some studies 
showed elevated levels in CHD [3-5], while others found decreased levels 
[6,7]. So far at least 14 polymorphisms in the TAFI gene have been 
identified, and some of these are strongly associated with plasma TAFI 
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antigen levels [8-10]. It has been suggested that TAFI gene polymorphisms 
may also be associated with the risk of acute myocardial infarction [7].
Studies on the role of TAFI in ischemic stroke are limited. One recent study 
found increased generated TAFI activity levels in patients with a history 
of ischemic stroke [11]. In addition, one other study in a small series of 
patients, showed increased TAFI antigen levels shortly after ischemic stroke 
[12]. Thus far, no studies have reported on the association between TAFI 
genotype and the risk of ischemic stroke. We studied functional TAFI levels 
and TAFI gene polymorphisms in patients with a recent acute ischemic 




We performed a case-control study with prospective inclusion of the 
participants. Cases were consecutively recruited patients with first ischemic 
stroke, admitted to the department of Neurology of our hospital. We used 
population controls, i.e neighbours or friends of the patients. They were 
age- and sex- matched, did not have a history of stroke and were not 
related to the patient. 
Inclusion and exclusion criteria
Patients, controls and their parents had to be born in Northern Europe and 
be of the Caucasian race. Patients with a definite non-atherosclerotic cause 
of the stroke, such as a mechanical heart valve, endocarditis or dissection, 
as well as patients above 75 years or using oral anticoagulants were 
excluded. 
Definitions and measurements
Ischemic stroke was defined as the acute onset of focal cerebral dysfunction 
due to cerebral ischemia with symptoms lasting more than 24 hours. Patients 
with TIA (symptoms lasting less than 24 hours) were included only if the 
neurological deficit was witnessed by a neurologist. In all patients a CT of 
the brain was made to confirm the diagnosis of ischemic stroke and to rule 
out hemorrhagic stroke. Clinical stroke subtypes were classified according 
to the OCSP (Oxford Community Stroke Project) criteria, modified by CT 
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[13]. Etiologic stroke type was classified according to the TOAST (Trial of 
Org 10172 in Acute Stroke Treatment) criteria [14]. We defined large artery 
atherosclerosis as a stenosis of presumed atherosclerotic origin in the 
symptomatic cervical artery of more than 50%, as determined by duplex 
ultrasonography and if necessary with angiography (NASCET method). 
Stroke severity was assessed with the Barthel index and the modified 
Rankin Scale [15]. Hypertension was defined as systolic blood pressure 
above 160 mm Hg or diastolic blood pressure above 90 mm Hg 5 days after 
the event, or the use of antihypertensive medication. Hypercholesterolemia 
was defined as fasting cholesterol level above 5.0 mmol/l or use of lipid 
lowering drugs. Diabetes mellitus was defined as the use of antidiabetic 
medication or glyco-Hb >6.5%.
In patients and controls detailed information about cardiovascular risk factors 
was collected. Patients were screened for cardiac abnormalities by means 
of standard twelve-lead ECG examination. A cardiologist was consulted in 
female patients aged 55 years or less, in male patients aged 45 years or 
less and in patients with ECG abnormalities or a history of cardiac disease. 
In these patients, 24 hours ECG monitoring and echocardiography was 
carried out. Screening for large vessel disease included duplex ultrasound 
or angiography of the carotid or vertebral arteries. Also information on 
medicaton was obtained: All patients used low dose aspirin (38 mg) at the 
time of first blood sample, 96 % of the patients at the time of second blood 
sample. The patients that were included were not treated with heparin, 
oral anticoagulants, clopidogrel, nor had they been previously treated with 
thrombolytic therapy.
Blood samples and procedures
Between 7-14 days after the stroke, venous blood samples were taken under 
strictly standardized conditions. The patients were in fasting condition, with 
no exposure to cigarette smoking or alcohol for at least the preceding 8 
hours and blood was drawn after 15 minutes rest. Cholesterol levels and 
glyco-Hb were also measured 7-14 days after the ischemic stroke. In a 
random subgroup of 36 of the 124 stroke patients a second blood sample for 
functional TAFI and CRP measurement was collected when they visited our 
outpatient department three months after the stroke in the convalescence 
phase.
Blood was collected in citrate (0.105 M) using a Vacutainer system (Bekton 
Dickinson, Plymouth, UK.)
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Blood was centrifuged (2000xg for 30 min at 4°C) and plasma was stored 
in aliquots at -80°C until use. Genomic DNA was isolated according to 
standard salting-out procedures. 
Laboratory assays and TAFI genotyping
Recombinant tPA (Actilyse) was kindly supplied by Boehringer Ingelheim 
(Germany). Human thrombin and potato carboxypeptidase inhibitor (PCI), 
an inhibitor of TAFIa, were purchased from Sigma (St Louis, MO, USA) and 
Calbiochem (La Jolla, CA, USA), respectively. Rabbit lung thrombomodulin, 
with a specific activity towards thrombin of 1.2 units/μg, was acquired from 
American Diagnostica (Greenwich, CT, USA). TAFI-depleted plasma was 
prepared from a pool of normal plasma by using rabbit anti-TAFI antibodies 
immobilized with CNBr-activated Sepharose-4B. TAFI functional assay 
based on clot lysis was performed as described elsewhere [16]. Briefly, 100 
µl of diluted plasma samples (20-fold dilution of individual plasmas in TAFI-
depleted plasma) were added to the wells of a microtitre plate containing 
25 µl of a reaction mix composed of thrombin, thrombomodulin, CaCl2 and 
r-tPA (final concentrations in the assay: 3.3 NIH units/ml, 0.6 units/ml, 20 
mM, and 0.10 µg/ml respectively), after which clots were formed. A control 
with addition of PCI was tested for each sample (final concentration 30 
µg/ml). The wells were immediately covered with paraffin oil and the plate 
was placed in a pre-warmed incubation chamber (37oC, TECAN Sunrise® 
Microplate-reader). The optical density at 405 nm was monitored for 150 
min. Lysis time (LT) was defined as the time point corresponding to a 50% 
decrease in optical density. Functional TAFI levels were calculated as TAFI-
related retardation (RT), defined as the difference between the lysis time 
in the absence and in the presence of PCI, (LT-PCI - LT+PCI).  The variation 
coefficients are 5.3% for LT-PCI , 6.8% for - LT+PCI  and 12.9% for RT [16]. 
To exclude assay variation, plasma samples taken after 7-14 days were 
remeasured in the same run as the samples taken at three months.
Plasminogen activator inhibitor-1 (PAI-1) was measured using a 
commercially available ELISA (TintElize®PAI-1, Biopool, Umea, Sweden). 
Fibrinogen was measured according to the von Clauss method on a Sysmex 
automated coagulation analyzer (Dade Behring, Leusden, The Netherlands) 
(variation coefficient 3.5%). CRP was measured using a turbidometric 
assay obtained from Roche Diagnostics on a Hitachi 917 analyzer (Roche 
Diagnostics, Almere, The Netherlands) with a variation coefficient of 4%.
Determination of the TAFI -438A/G, 505A/G (Ala147Thr) and 1040 C/T 
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(Thr325Ile) genotype was performed using polymerase chain reaction (PCR) 
and subsequent restriction analysis, as previously described [6].
Statistics
For the TAFI 1040C/T (Thr325Ile) polymorphism with an expected 
prevalence of the TT genotype of 10% in the control group, the minimal 
detectable odds ratio (OR) associated with the TT genotype would be 
2.8 (with an α=0.05, β=0.80). The relationship between the TAFI gene 
polymorphisms and ischemic stroke was calculated using logistic regression 
with adjustment for smoking, hypertension and diabetse and expressed 
as an OR with a 95% confidence interval (CI). The clot lysis times (LT) 
and TAFI-related retardation (RT) were divided into quartiles, based on 
the measurements in both cases and controls. The relationship between 
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LT and RT and ischemic stroke was estimated by odds ratio per quartile 
relative to the quartile with the lowest levels. The association between TAFI 
haplotypes and the risk of stroke was investigated using (weighted) logistic 
regression with a modification of the method described by Tanck et al [17]. 
In addition to the effects of combined alleles, the effect of a single allele 
substitution was examined by pair-wise comparison of haplotype effects 
and this comparison was repeated for the different haplotypic backgrounds. 
Differences in functional TAFI levels among TAFI genotypes and among the 
Figure 1. A, Clot lysis times 
(LT-PCI); B, Clot lysis times 
(LT+PCI) and C, functional TAFI 
levels (TAFI-related retardation, 
RT = (LT-PCI-LT+PCI) in patients with 
ischemic stroke and controls. The 
horizontal lines indicate mean 
value. 
CHAPTER 5 
Functional TAFI levels in ischemic stroke
92 
Figure 2. Functional TAFI levels 
(TAFI-related retardation, RT 
= (LT-PCI-LT+PCI) in patients 
with ischemic stroke at 7-14 
days after ischemic stroke 
(acute phase) and after 3 
months (convalescence phase). 
No significant difference was found 
(paired student’s t-test, p =0.22).
groups were tested by one-way analysis of variance (ANOVA). The TAFI 
multilocus haplotype effects on functional TAFI levels were estimated using 
weighted linear regression [17]. The student’s t-test was used to compare 
two groups and a p-value of <0.05 was considered significant.
Results
Patient population
The baseline characteristics of patients, including stroke subtypes, and 
controls are given in Table 1. Smoking, hypertension and diabetes occurred 
more frequently in the patients compared to controls. As expected, the risk 
of stroke (odds ratio, OR) for the classical risk factors in our study population 
were 2.3 (95% CI 1.4-3.9) for smoking, 3.9 (2.2-8.9) for hypertension, 4.1 
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(1.5-10.9) for diabetes, 0.8 (0.5-1.4) for hypercholesterolaemia, and 1.4 
(0.6-3.6) for oral contraceptive use.
Functional TAFI levels in ischemic stroke
Functional TAFI levels were increased in ischemic stroke patients compared 
to controls (figure 1). Both clot lysis times (LT-PCI  and LT+PCI) were significantly 
increased in patients with ischemic stroke compared to controls, which 
indicates less efficient fibrinolysis in patients with ischemic stroke compared 
to controls (figure 1, Table 2). We subdivided the individuals according 
to quartiles of functional TAFI levels. A significant association between 
functional TAFI levels and the risk of ischemic stroke was found. Individuals 
with the highest functional TAFI levels (highest quartile) had a markedly 
increased risk of ischemic stroke: OR of 4.0 (95% confidence interval (CI) 
1.6-9.8) compared to the lowest quartile. Similar findings were obtained 
for LT-PCI (OR 8.2, CI 3.2-21.3, highest quartile vs. lowest quartile).
Functional TAFI levels and the possible relation with acute phase response
The median CRP level was 5 mg/l (range 1-215 mg/l) in patients one week 
after the stroke and 3 mg/l (range 1-21 mg/l) in controls (p <0.05). After 
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three months CRP values were decreased (median 2 mg/l, ranges 1-19mg/l) 
compared to the first blood sample, and were not significantly different from 
the controls. In our study population there was no correlation between CRP 
and functional TAFI levels (r= 0.06, n=199, n.s.). Plasminogen activator 
inhibitor-1 (PAI-1) antigen levels were not significantly different between 
cases (22.9 ± 13.5 ng/ml) and controls (25.1 ± 15.0 ng/ml) (p =0.23). 
A significant correlation was present between PAI-1 levels and functional 
TAFI levels (r= 0.18, p <0.01). There was no correlation between PAI-1 
and LT+PCI (r=0.02, n.s). A significant correlation was also present between 
functional TAFI levels and fibrinogen (r=0.19, p =0.01). Functional TAFI 
levels were also measured in the convalescence phase after three months in 
36 patients. Functional TAFI levels were not significantly different between 
the acute and convalescence phase (RT was 22.25 ± 4.0 min vs. 22.33 ± 3.9 
min, respectively, n.s.) (figure 2). Also LT+PCI was still increased after 3 months 
31.4 ± 0.3 min in patients and 26.4 ± 0.24 min for controls (p <0.0001).
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TAFI gene polymorphisms
Functional TAFI levels were not associated with the -438A/G, the 505A/G 
and the 1040C/T polymorphisms (Table 3). No association was observed 
between the three studied polymorphisms in the TAFI gene and the risk 
of ischemic stroke (Table 4). Also in subgroup analysis no association 
between TAFI polymorphisms and specific etiological subtypes of stroke, as 
mentioned in Table 1, was found (not shown).
Because there is a high degree of linkage disequilibrium between the three 
polymorphisms, it is not possible to estimate the effect of one single SNP 
on stroke risk by analyzing the single polymorphisms separately. Therefore 
haplotype analysis was performed to estimate more precise the contribution 
of a three individual polymorphisms on stroke risk. The effect of haplotypes 
on functional TAFI levels is shown in figure 3. The eight haplotypes did not 
differ in respect to functional TAFI levels in patients with ischemic stroke 
(Figure 3). In the controls the GGC and AGT haplotypes had significantly 
lower functional TAFI levels compared to the haplotype with the highest 
TAFI levels (AAT), which was taken as reference, although this was only a 
small difference (Figure 3). The risk of stroke was not significantly different 
Figure 3. The effect of TAFI haplotypes 
on plasma functional TAFI levels 
(TAFI-related retardation) in controls 
(A) and patients with ischemic stroke 
(B) (levels are expressed as mean 
and 95% CI). The alleles in the 
haplotype are given in the following 
polymorphism order: -438G/A, 505G/
A, and 1040C/T. Asterisks indicate 
haplotypes whose average effects are 
significantly different from the group 
with the highest functional TAFI 
level as the reference group (AAT). 
Haplotypes with a frequency below 
2% were not included in the figure.
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between the various TAFI haplotypes (not shown).
Association of functional TAFI levels and baseline characteristics
Functional TAFI levels were not different between males and females, 
individuals with and without diabetes and smokers and non-smokers. 
Individuals with hypertension had higher functional TAFI levels (RT 20.0 ± 3.8 
vs 18.0 ± 4.1 min; p =0.0007). Also individuals with hypercholesterolemia 
(19.2 ± 3.7 vs 17.6 ± 4.5 min; p =0.0058) and of higher age (>45 years) 
(19.1 ± 4.0 vs 16.7 ± 4.0 min; p =0.0005) had increased functional TAFI 
levels. Both in young (<45 years) and elderly individuals functional TAFI was 
higher in stroke patients compared to controls (17.7 ± 4.2 vs. 15.4 ± 3.4 
min, p = 0.06, and 20.0 ± 4.2 vs. 18.2 ± 3.6 min, p <0.005, respectively). 
The observed odds ratio’s of clot lysis times (LT-PCI) and functional TAFI 
levels did not change after adjustment for possible confounding variables 
including hypertension, diabetes, smoking, age and hypercholesterolemia 
(not shown). All other odds ratios given above are adjusted for these 
classical risk factors.
Discussion
In this study we found that increased functional levels of TAFI are associated 
with an increased risk of ischemic stroke. Clot lysis times in the presence 
of PCI, which were independent of TAFI, were also increased in ischemic 
stroke patients. This indicates that in these patients fibrinolysis is impaired 
not only by high functional TAFI levels, but also by different mechanisms.
Only two previous studies on TAFI levels in stroke patients have been 
reported so far. Montaner et al showed in a small study including 30 patients 
that TAFI antigen levels were increased in patients with ischemic stroke 
[12]. Plasma samples were taken within 24 hours of onset of the symptoms. 
Therefore the high TAFI antigen levels may be caused by an acute phase 
response, and may not reflect a causative role of TAFI in the development 
of ischemic stroke [3,18]. Santamaria et al performed a case-control study, 
comparable with our study design [11]. The patients were included at least 
one month after the event. They found that increased TAFI activity levels, 
measured using a synthetic substrate based assay, were associated with 
a 6-fold increased risk of ischemic stroke. The study population consisted 
of patients with at least one previous ischemic event, which may result 
in a selection of patients with recurrent thrombotic events, whereas in 
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our study only patients with a recent first episode of ischemic stroke were 
included. Despite these differences in patient population our study confirms 
the finding that increased functional TAFI levels are associated with an 
increased risk of ischemic stroke. By measuring functional TAFI levels at 
two different time points, and by including CRP in our analysis, we could 
establish that high functional TAFI levels are not due to an acute phase 
response.
The mechanism by which increased functional TAFI levels may result in 
ischemic stroke is still unknown. Hypothetically a decreased fibrinolytic 
potential will result in more stable thrombi, that are less prone to lysis. The 
relationship between PAI-1 and stroke supports such a mechanism and our 
findings on functional TAFI levels are in concordance with previous studies 
on the role of PAI-1 [19].
The role of TAFI in arterial thrombosis is still unresolved. Juhan-Vague et 
al showed that reduced TAFI antigen levels are found in patients with a 
history of acute myocardial infarction (AMI) [7]. We have previously shown 
in patients with unstable angina pectoris that lower TAFI antigen levels 
were found in patients who were refractory to medical treatment (more 
severe cases) compared to non-refractory patients [6]. On the contrary, 
other studies found increased levels of TAFI antigen in patients with arterial 
thrombosis, measured both in plasma of patients with symptomatic coronary 
heart disease or angina pectoris [3,5], or in blood obtained intracoronary 
during angiography [4]. A major difference between the various studies was 
the method of determination of TAFI antigen levels. It has become evident 
that some antigen assays have a variable antibody reactivity towards the 
different isoforms of TAFI [20,21]. The discrepancy between the studies 
may therefore (in part) be attributed to the various assays that have been 
used in the past. Because of the problems with TAFI antigen measurement, 
and the difficulties of interpretation of the various results, measurement of 
functional TAFI seems to be of utmost importance. In addition, genotype-
independent TAFI antigen assays will be of value to establish the role of 
TAFI in arterial thrombotic disease.
There have been relatively few studies performed measuring TAFI activity 
levels in arterial thrombosis [11,22]. The tests used in previous studies were 
based on synthetic substrates. Several TAFI activity assays have recently 
been developed [23,24]. A clot lysis based assay is a more physiological 
method to study the impact of TAFI on fibrinolysis. However, a clot lysis–
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based TAFI activity assay may be influenced by other plasma components 
[23,25]. The method that we have used is therefore very specific for 
TAFI activity. TAFI-related retardation (RT), calculated by the difference 
in clot lysis time in the absence and presence of a TAFIa inhibitor PCI, 
is a specific parameter for functional TAFI and is not influenced by other 
plasma components, including fibrinogen and PAI-1 [21]. The finding that 
TAFI-related retardation was significantly higher in patients compared to 
controls, indicates that functional TAFI levels are a risk factor for ischemic 
stroke. However, also clot lysis times in the presence of PCI are significantly 
higher in patients with ischemic stroke. This suggests that variables other 
than TAFI may also contribute to the increased risk of ischemic stroke. 
We adjusted for other potential confounders in our study population, such 
as hypercholesterolemia, age, and smoking, but these did not influence 
the association of clot lysis times with the risk of ischemic stroke. In the 
total study group, functional TAFI levels were higher in individuals with 
hypercholesterolemia, higher age and hypertension.
We found a weak, but significant correlation between PAI-1 antigen levels 
and functional TAFI (r = 0.18). However, PAI-1 antigen levels were not 
significantly different in patients and controls, and it is therefore unlikely 
that the increased risk of stroke associated with high functional TAFI levels 
is caused by a difference in PAI-1 [26]. In addition, in vitro experiments 
have shown that even extremely high levels of PAI-1 (up to 2,000 ng/ml) 
do not influence clot lysis times in our assay [16]. This indicates that PAI-1 
levels will not influence the measurement of the functional TAFI levels in 
our stroke patients. A weak correlation was found between functional TAFI 
levels and fibrinogen (r = 0.19, p <0.05). In vitro experiments however 
showed also that addition of high concentrations of fibrinogen did not alter 
clot lysis times and functional TAFI levels [16]. The weak correlations found 
between functional TAFI levels and both PAI-1 and fibrinogen, suggest 
a biological mechanism that influences functional TAFI levels, PAI-1 and 
fibrinogen in a similar way.
We studied three TAFI gene polymorphisms, one SNP in the promoter region 
and two SNP in the coding region. The -438 A/G was selected because 
it is a promoter gene polymorphism that is associated with TAFI antigen 
levels. The 505 A/G SNP was selected because it is also associated with 
TAFI antigen levels and with the risk of arterial thrombosis [7], and the 
1040 C/T SNP was selected because this polymorphism encodes for two 
different isoforms of TAFI, with a difference in activity and half-life [10]. We 
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could not demonstrate a difference in the risk of ischemic stroke between 
the various genotypes. The -438 AA genotype seemed to be more frequent 
in patients compared to controls, however this is not significant, possibly 
because of the limited number of individuals in our study. Previous studies 
showed that the 505G/A SNP (Ala147Thr) in the TAFI gene is associated 
with the risk of acute myocardial infarction [7]. Individuals carrying the 
“TAFI antigen decreasing allele” (505G, Ala147) had an increased risk of 
acute myocardial infarction in a combined analysis of three case control 
studies. In our study we could not find this association between the TAFI 
505G/A gene polymorphism and the risk of ischemic stroke. We could also 
not detect an association between the 1040 C/T polymorphism (Ile325Thr) 
and the risk of ischemic stroke. Because of the strong linkage between the 
three studied polymorphisms, haplotype analysis was performed to assess 
the effects of the individual polymorphisms, while excluding the effects of 
associated polymorphisms [17]. Only a small difference between functional 
TAFI levels in the different haplotypes was found (GGC and AGT versus AAT) 
in the controls. Since the AGT haplotype had significantly lower functional 
TAFI levels than AAT haplotype, it is suggested that the 505G (Ala147) 
allele may be associated with low functional TAFI levels. However, no 
significant difference was found between the GGC and the GAC haplotype. 
Further studies in larger cohort are required to establish these findings. No 
association was found between TAFI haplotypes and the risk of ischemic 
stroke.
One of the limitations of our study is the size of the study population, 
especially, as already mentioned above, for assessing the association 
between TAFI gene polymorphisms and ischemic stroke. It has therefore 
limited power to detect moderately high odds ratio’s. In addition stroke 
is a more heterogeneous disorder than coronary heart disease. By using 
strict inclusion criteria for ischemic stroke patients, for instance excluding 
patients with a definite non-atherosclerotic cause for stroke, we cannot 
exclude the possibility that other specific etiological subtypes of stroke 
may be associated with TAFI genotypes. Based on the confidence intervals, 
however, TAFI gene variations will probably not be a strong risk factor for 
ischemic stroke. 
Recently, it was reported that high TAFI antigen levels are associated with 
symptomatic hemorrhagic transformation in stroke patients treated with 
thrombolytic therapy (rt-PA) [27]. Patients with hemorrhagic transformation 
were found to have higher TAFI levels. This illustrates that TAFI may not 
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only be associated with risk, but also with outcome of ischemic stroke, 
albeit with a paradoxal mechanism [27].
We conclude that high functional TAFI levels are associated with an increased 
risk of ischemic stroke. The reduced fibrinolysis in stroke patients in our 
study, as shown by a prolongation of clot lysis times, can only partially be 
explained by TAFI. Other factors influencing fibrinolysis may be involved, 
for which additional studies should be performed. For future studies on TAFI 
it is important to study functional levels, antigen levels using genotype-
independent assays, as well as genotype.
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Summary
TAFIa was shown to attenuate fibrinolysis. In our in vitro study, we 
investigated how the inhibitory effect of TAFIa depended on the type and 
concentration of the plasminogen activator (PA). We measured PA-mediated 
lysis times of plasma clots under conditions of maximal TAFI activation 
by thrombin-thrombomodulin in the absence and presence of potato 
carboxypeptidase inhibitor. Seven different PAs were compared comprising 
both tPA-related (tPA, TNK-tPA, DSPA), bacterial PA-related (staphylokinase 
and APSAC) and urokinase-related (tcu-PA and K2tu-PA) PAs. We derived 
the lysis time and the retardation factor which we plotted against the PA 
concentration. The retardation factor plots were bell-shaped. At low PA 
concentrations, the retardation factor was low, probably due to the limited 
stability of TAFIa. At intermediate PA concentrations the retardation factor 
was maximal (3-6 depending on the PA), with TNK-tPA, APSAC and DSPA 
exhibiting the strongest effect. At high PA concentrations, the retardation 
factor was again low, possibly due to inactivation of TAFIa by plasmin or 
to a complete conversion of glu-plasminogen into lys-plasminogen. Using 
individual plasmas with a reduced plasmin inhibitor activity (plasmin 
inhibitor Enschede) the bell-shaped curve of the retardation factor shifted 
towards lower tPA and DSPA concentrations, but did not decrease. In 
conclusion, TAFIa delays the lysis of plasma clots mediated by all the 
plasminogen activators tested. This delay is dependent on the type and 
concentration of the plasminogen activator, but not on the fibrin specificity 
of the plasminogen activator. Furthermore, plasmin inhibitor does not play 
a significant role in the inhibition of plasma clot lysis by TAFI.
Abbreviations
TAFI, thrombin activatable fibrinolysis inhibitor; TAFIa, activated thrombin 
activatable fibrinolysis inhibitor; TM, thrombomodulin; PCI, potato 
carboxypeptidase inhibitor; PA, plasminogen activator; tPA, tissue-type 
plasminogen activator; TNK-tPA, tenecteplase; DSPA, Desmodus rotundus 
salivary plasminogen activator; STA, staphylokinase; APSAC, anisoylated 
plasminogen-streptokinase activator complex; tcu-PA, two-chain urokinase-
type plasminogen activator; K2tu-PA, amediplase; PI, plasmin inhibitor, 
previously α2 –antiplasmin.
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Introduction
Thrombin activatable fibrinolysis inhibitor (TAFI) is a zymogen present 
in plasma that can be activated (TAFIa) by thrombin or plasmin [1-4]. 
Thrombomodulin (TM) acts as a cofactor stimulating over 1000-fold the 
activation by thrombin [5-7]. Plasmin not only acts as an activator but can 
also inactivate TAFI and TAFIa by proteolytic cleavage at Arg302, Lys327 or 
Arg330 [8]. TAFIa can cleave C-terminal lysine and arginine residues that 
become available when plasmin partially degrades fibrin [9-13]. These 
residues are binding sites for plasminogen and plasmin and essential for the 
upregulation of fibrinolysis as the activation of plasminogen is accelerated 
[14-16]and fibrin bound plasmin becomes more resistant to inactivation by 
plasmin inhibitor (PI), previously α2-antiplasmin [17,18]. TAFIa blocks this 
upregulation and causes, possibly in this way, a prolongation of lysis times 
[9,10,12].
Given what is currently known about the mechanism of action of TAFI, 
we speculated that TAFIa would lead to variable inhibition of plasminogen 
activator (PA)-induced thrombolysis, depending not only on the concentration 
of the PA but also on the type of the PA. Different PAs operate through 
distinct mechanisms that rely to various extents on fibrin binding, on the 
C-terminal lysine-residues, on the conversion of glu- to lys-plasminogen 
and on the cofactor effect of soluble fibrin degradation products and of 
(DD)E [19-24].
Up to now, tissue-type PA (tPA) has been the PA of choice to study the 
effect of TAFI on fibrinolysis. TAFI-related retardation of tPA-mediated lysis 
has been described in purified systems [25], in clots prepared from diluted 
[10,12,26-28] and undiluted plasma [11], in whole blood clots [29] and in 
several animal models [9,30-32]. Walker et al [23] have recently studied 
the DSPA cofactor activities of TAFIa-treated soluble fibrin degradation 
products but still more insight is needed to understand the mode of action 
of TAFI with different plasminogen activators. Under our in vitro model 
conditions, we investigated how internal plasma clot lysis is affected by the 
PA concentration and how TAFIa changes the lytic activities of different PAs. 
Additional models, such as a model of external clot lysis, will be necessary 
to fully understand the multiple inter-linked mechanisms of TAFI and allow 
extrapolations to clinical practice of thrombolytic therapy.
A variety of plasminogen activators was tested in this study, from tPA-
related plasminogen activators such as tPA itself, Tenecteplase (TNK-tPA) 
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and Desmodus rotundus salivary plasminogen activator (DSPA) to bacteria-
related PAs such as staphylokinase (STA) and anisoylated plasminogen-
streptokinase activator complex (APSAC), and urokinase-related PAs such 
as two-chain urokinase-type PA (tcu-PA) and Amediplase (K2tu-PA). The 
properties of these plasminogen activators have been described before 
[33,34]. To study the role of plasmin inhibitor in the TAFI-related retardation 
of lysis we used citrated plasma from a homozygous and a heterozygous 
individual for plasmin inhibitor Enschede [35,36]. This is a dysfunctional 
plasmin inhibitor molecule, which exhibits no inhibition of plasmin.
We demonstrated that TAFI delays clot lysis for all the PAs tested. No 




The tcu-PA (Ukidan) preparation was purchased from Serono. Staphylokinase 
(recombinant Sak42D) was a gift from Dr. H.R. Lijnen (University of 
Leuven). Other PAs were kindly supplied by the companies listed below: tPA 
(Actilyse), by Boehringer Ingelheim; TNK-tPA, by Genentech Inc; K2tu-PA 
(Amediplase), by Menarini; DSPA, by Schering AG; Anistreplase (Eminase), 
by Tramedico BV. Anistreplase concentration in mg/ml was calculated by 
using 1 IU/mg as specific activity. The tcu-PA concentration was determined 
spectrophotometrically using A 2801%, 1 cm = 13.6 and its specific activity was 
175,000 IU/mg. Human thrombin and potato carboxypeptidase inhibitor 
(PCI) were acquired from Sigma and Calbiochem, respectively. Rabbit lung 
TM, with a specific activity towards thrombin of 1.2 units/μg, was supplied 
by American Diagnostica Inc. Citrated platelet-poor plasma from ten healthy 
volunteers was obtained from the blood bank. A plasma pool was prepared 
and used in all normal plasma experiments. Citrated platelet-poor plasmin 
inhibitor (PI) deficient plasma from both a heterozygous and a homozygous 
individual with plasmin inhibitor Enschede was used when indicated.
TAFI Activation by Thrombin-TM Complex
Pooled blood bank plasma was dialysed against 50 mM Hepes, 100 mM 
NaCl, 20 mM tri-sodium citrate, pH 7.4 to remove phosphate ions and 100 
μl were added to the wells of a microtitre plate containing 25 μl of a mix 
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per well. The mix was composed of thrombin (3.3 NIH units/ml), tPA (0.20 
μg/ml), CaCl2 (20 mM), PCI (0 or 30 μg/ml) and variable TM concentrations 
(0-1.8 units/ml) in a 50 mM Hepes buffer, pH 7.4 containing 0.1% w/v BSA. 
The concentrations between brackets refer to the final concentrations in the 
clotted plasma. The clots, prepared at room temperature, were immediately 
covered with 50 μl paraffin oil (Merck-107162) and the microtitre plate 
was placed in the incubation chamber pre-warmed at 37oC of a TECAN 
Sunrise Microplate-reader. The optical density was measured continuously 
at 405 nm. Lysis time is defined as the time point corresponding to a 50% 
decrease in optical density. The lysis time was determined by fitting lysis 
profiles with a sigmoidal regression equation.
TAFIa effect on PA-mediated clot lysis
Dialysed pooled blood bank plasma was added to the wells of a microtitre 
plate according to the procedure described above. A final concentration of 
0.60 u/ml of TM was chosen in order to obtain maximal retardation of clot 
lysis under the assay conditions and the concentration of each of the seven 
PAs used was varied. The antifibrinolytic effect of TAFIa was described with 
the retardation factor, defined as lysis time in the absence of PCI divided 
by the lysis time in the presence of PCI. All the data result from the mean 
values of 3 independent measurements.
TAFIa effect on PA-mediated clot lysis in plasmin inhibitor Enschede plasma
Citrated plasmas from a heterozygous and a homozygous individual with PI 
Enschede were used in the procedure described above using both tPA and 
DSPA as plasminogen activators.
Plasmin inhibitor activity
Plasmin inhibitor activity was determined as described by Billing Clason et 
al [37] and expressed in % pooled plasma.
TAFI antigen concentration
A sandwich-type enzyme-linked immunosorbent assay (ELISA) was used 
to determined TAFI antigen levels in dialysed pooled blood bank plasma 
and in plasma of PI Enschede individuals. This ELISA made use of sheep 
polyclonal antibodies against TAFI (Affinity Biologicals Inc.). The levels were 
expressed in % pooled plasma, using as calibrator a citrated plasma pool 
composed of 40 normal individuals.
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Results
TAFI Activation by Thrombin-TM Complex
The tPA-mediated lysis of plasma clots prepared in the presence of variable 
TM concentrations is depicted in Fig.1A. Prolongation of lysis times by TM 
was dose-dependent in the absence of PCI. Even the lowest TM concentration 
tested (0.01 unit/ml) produced a considerable prolongation of lysis time. 
At a TM concentration of 0.06 unit/ml the maximum effect was achieved, 
resulting in a 3-fold prolongation of lysis time (Fig.1B). A small retardation 
of clot lysis by PCI was observed in the absence of TM that is probably due 
to TAFI activation by thrombin. In the presence of PCI there was no effect 
of the TM concentration on lysis time (Fig.1B). The prolongation of lysis 
Figure 1.Thrombomodulin-
induced delay of clot lysis 
by tPA (0.20 μg/ml). Citrated 
plasma with or without PCI 
(30 μg/ml) was clotted with 
3.3 NIH units/ml thrombin and 
variable TM concentrations. A, A 
selection of clot lysis profiles in 
the absence of PCI: () No TM; 
(+) 0.01 unit/ml TM; () 0.02 
unit/ml TM; (X) 0.06 unit/ml TM; 
(□) 0.45 unit/ml TM; () 0.60 
unit/ml TM; (∆) 1.20 unit/ml 
TM. The baseline OD value was 
subtracted for each curve (about 
0.37). B, Clot lysis times in the 
absence () and presence (□) 
of PCI. Lysis time was defined as 
the time point corresponding to 
a 50% decrease in OD 405 nm 
and the retardation factor as the 
lysis time in the absence of PCI 
divided by the lysis time in the 
presence of PCI. The error bars 
represent the SD.
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Figure 2. Effect of TAFIa on the internal lysis of plasma clots induced by seven 
PAs in the absence () and in the presence (□) of potato carboxypeptidase 
inhibitor (PCI). A, Tissue-type PA (tPA); B, Tenecteplase (TNK-tPA); C, Desmodus 
rotundus salivary PA (DSPA); D, Staphylokinase (STA); E, Anisoylated plasminogen-
streptokinase activator complex (APSAC); F, Two-chain urokinase-type PA (tcu-
PA); G, Amediplase (k2tu-PA). Retardation factor variations with PA concentration. 
H, tPA; I, TNK-tPA; J, DSPA; K, STA; L, APSAC; M, tcu-PA; N, k2tu-PA. Lysis time 
was defined as the time point corresponding to a 50% decrease in OD 405 nm 
and the retardation factor as the lysis time in the absence of PCI divided by the 
lysis time in the presence of PCI. (line) Retardation factor baseline.
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time that could be quantitatively inhibited by PCI was attributed to TAFIa. 
The TAFI antigen concentration of the plasma pool was 96.4 ± 13.7%.
TAFIa effect on PA-induced lysis of plasma clots
Fig.2 shows the dependence of lysis times on the PA concentration in the 
internal clot lysis model with maximal TAFI activation. Seven different 
PAs were tested in the presence and absence of PCI (Fig.2A - G). For 
all the PAs, a decrease in lysis time with increasing PA concentrations 
was observed. The difference between the dose-response curves, in the 
absence and presence of PCI, depicts the potency of TAFIa antifibrinolytic 
activity, which was quantified through the retardation factor (Fig.2H - N). 
At low PA concentrations, long lysis times (100-500 min) were found and 
low retardation factors were derived. At intermediate PA concentrations the 
Figure 3. Effect of PI activity 
on the retardation of clot 
lysis by TAFIa. Normal plasma 
(squares), heterozygous PI 
Enschede plasma (triangles) 
and homozygous PI Enschede 
plasma (circles). Lysis of plasma 
clots induced by: A, t-PA and B, 
DSPA, in the absence (,,●) 
and in the presence (□,∆,) of 
potato carboxypeptidase inhibitor 
(PCI). Inset, Retardation factor 
variation for normal plasma 
(□), heterozygous PI Enschede 
plasma (∆) and homozygous 
PI Enschede plasma (). Lysis 
time was defined as the time 
point corresponding to a 50% 
decrease in OD 405 nm and 
the retardation factor as the 
lysis time in the absence of 
PCI divided by the lysis time 
in the presence of PCI. (line) 
Retardation factor baseline.
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retardation factor became maximal. The retardation factor declined again 
at high PA concentrations, in particular when short lysis times (<10 min) 
were obtained. All PAs generated bell-shaped retardation factor curves 
over variable concentration ranges. The maximal retardation factors were 
between 3-6. A powerful TAFI-related retardation (factor 5.8) was observed 
for TNK-tPA. The APSAC and DSPA-mediated plasma clot lysis was also 
considerably influenced by TAFIa (factor 5.1 and 5.0, respectively). tPA, the 
most common PA used to study the effects of TAFI on clot lysis, and tcu-
PA showed an intermediate maximal TAFIa-dependent retardation factor 
(factor 3.4 for both). The weakest effect of TAFIa was observed for STA and 
K2tu-PA (factor 3.1 and 2.9, respectively).
The effect of TAFIa on PA-mediated clot lysis in plasmin inhibitor 
Enschede plasma
By using plasmin inhibitor Enschede plasma the role of plasmin inhibitor in 
the antifibrinolytic effect of TAFI was examined. Citrated plasma from both 
a heterozygous and a homozygous individual for PI Enschede was used. 
The PI functional activity was 7 ± 4 % for the homozygous individual and 
51 ± 2 % for the heterozygous individual (% normal pool plasma). TAFI 
antigen levels did not differ significantly for the two individuals (73 ± 4 and 
79 ± 9 %, respectively). Figure 3 shows that replacement of the pooled 
normal plasma by the PI Enschede heterozygous or homozygous individual 
plasma resulted in a shift towards shorter lysis times, both in the presence 
and in the absence of PCI and both for tPA (Fig.3A) and for DSPA (Fig.3B). 
Employment of the PI Enschede plasmas also resulted in a shift of the bell-
shaped curves of the retardation factors towards lower tPA concentrations 
(inset, Fig.3A and 3B). The maximal retardation factor remained constant 
when pooled normal plasma was replaced by PI Enschede heterozygous 
plasma for both tPA and DSPA. When PI Enschede homozygous plasma 
was used the maximal retardation factor increased somewhat for both PAs 
tested (3 to 4.5 for tPA and 5 to 8 for DSPA). These results indicated that 
PI does not play a major role in the retardation of the clot lysis by TAFI.
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Discussion
TAFIa, the activated form of thrombin activatable fibrinolysis inhibitor (TAFI), 
a plasma basic procarboxypeptidase, which is able to cleave C-terminal 
lysine and arginine residues from partially degraded fibrin [1-4]. These C-
terminal lysine residues act as binding sites for plasminogen, and as fibrin 
is degraded by plasmin their number increases, enhancing plasminogen 
activation. TAFIa can delay lysis by preventing this enhancement of 
plasminogen activation. It has also been shown that the binding of plasmin 
to fibrin renders plasmin less susceptible to inactivation by plasmin inhibitor 
[17,18]. Yet, it is not known whether TAFI can delay lysis by preventing the 
protection of plasmin from inactivation by plasmin inhibitor.
Information concerning the effect of TAFI on clot lysis with different PAs is 
limited as most observations were done in systems with tPA-mediated lysis. 
Therefore, we performed this study to assess the antifibrinolytic potential 
of maximally activated TAFI in the lysis of plasma clots mediated by several 
types and concentrations of plasminogen activators. In addition, we were 
also interested in the role of plasmin inhibitor in TAFIa-related retardation 
of the internal lysis of a plasma clot.
Maximal TAFI activation was achieved by clotting plasma with thrombin and 
an optimal concentration of thrombomodulin in the presence of calcium 
ions (Fig.1) [11]. Seven different PAs (tPA, TNK-tPA, tcu-PA, APSAC, DSPA, 
K2tu-PA and STA) were tested with this model revealing that the presence 
of TAFIa prolonged lysis times for all PAs. The maximal retardation factor 
varied between 3- and 6-fold depending on the plasminogen activator. 
Moreover, we found that the effect of TAFIa was dependent on the PA 
concentration (bell-shaped curves in Fig.2H-N).
The effect was small at low PA concentrations (lysis times > 100 min), 
which we attributed to the restricted stability of TAFIa. Indeed, we have 
previously investigated the stability of TAFIa activity under similar conditions 
[11]. TAFIa activity declined rapidly, falling back to baseline levels within 
60 min. Recently, low concentrations of PCI were shown to stabilize TAFIa, 
in particular at low tPA concentrations [27,38]. However, here we used a 
considerably higher PCI concentration which fully inhibits TAFIa. Altogether, 
this leads us to conclude that at low PA concentrations other fibrinolysis 
inhibitors play a more prominent role in our plasma clot lysis system than 
TAFI.
At high PA concentrations (lysis times < 10 min) the effect of TAFIa was 
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also low. We hypothesised that at these high PA concentrations elevated 
amounts of plasmin were generated. In our system, TAFI is activated by 
the thrombin/TM, which makes TAFIa available for proteolytic inactivation 
by plasmin [8]. Another possibility is that at high PA and high plasmin 
concentrations glu-plasminogen is fully converted into lys-plasminogen. 
Lys-plasminogen is produced by plasmin cleavage of the NH2-terminal part 
of glu-plasminogen and presents a more open conformation than native glu-
plasminogen. Moreover, the rate of activation of lys-plasminogen to plasmin 
is greater than that of glu-plasminogen. TAFIa seems to be specific to the 
glu-form of plasminogen [13]. The finding that in the absence of plasmin 
inhibitor activity and hence higher plasmin concentration the decrease in the 
effect of TAFIa occurred at lower tPA and DSPA concentrations corroborates 
the attribution of this decrease to a high plasmin activity (Fig.3).
The strongest TAFIa effects were observed for TNK-tPA and DSPA, two highly 
fibrin specific plasminogen activators. A moderate effect was, however, 
found for STA, which is also highly fibrin specific. Moreover, APSAC, which 
has low fibrin specificity, was amongst the PAs that displayed the strongest 
effect. This suggests that the magnitude of the inhibitory effect of TAFIa on 
internal plasma clot lysis does not depend strongly on the fibrin specificity 
of the plasminogen activator used.
Plasmin bound to C-terminal lysine residues is partially protected from 
inhibition by PI. TAFIa eliminates these binding sites and might therefore 
be able to modulate plasmin activity. Hence, TAFIa might rely on the rapid 
inhibition of unbound plasmin by PI to achieve its maximal lysis retardation 
effect. If this is the case, decreasing PI activity would lead to an increase 
in the plasmin concentration and to a faster lysis as well as a smaller TAFIa 
effect.
Keeping this in mind, we studied the role of PI in the mechanism of 
TAFIa retardation of clot lysis using plasmas from a heterozygous and a 
homozygous individual for PI Enschede. This dysfunctional PI molecule 
displays complete immunological identity with normal PI and has normal 
plasminogen-binding properties, but an abnormal functional activity 
resulting in a fully defective inhibition of plasmin [35,36].
The bell-shaped retardation factor curves shifted towards lower PA 
concentrations for both tPA and DSPA (Inset, Fig.3A and 3B, respectively). 
The maximal TAFIa-related retardation factor remained constant for the 
heterozygous PI Enschede individual and increased somewhat for the 
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homozygous individual. So, we can conclude that PI does not play a 
significant role in the inhibition of plasma clot lysis by TAFI.
The increase in maximal TAFIa-related retardation factor might be 
explained if this individual was also homozygous for the more stable and 
active variant of TAFI (325 Ile/Ile) [39]. Therefore, TAFI antigen for the 
PI Enschede individuals was determined by two immunological assays 
previously described by Gils et al [40] (not shown). The results showed that 
both the homozygous and the heterozygous PI Enschede individuals were 
not homozygous for Ile325. Another possible explanation would consist of 
TAFIa being able to remove the C-terminal lysine present in PI, interfering 
in this way with the rapid inactivation of plasmin [41]. However, recent 
work  has demonstrated that Lys 436 in the plasmin inhibitor and not the 
C-terminal lysine residue (Lys 452) is necessary for the interaction with 
plasmin [42]. This implies that the increase in retardation factor remains 
still unexplained.
In conclusion, TAFI was found to affect the lysis of plasma clots mediated 
by all the PAs tested in broad concentration intervals. Also, the extent of 
the inhibitory effect of TAFI in the internal lysis of plasma clots was not 
determined by the fibrin specificity of the plasminogen activator. Moreover, 
the inhibitory effect of TAFIa on clot lysis did not depend on the presence 
of PI.
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Summary
In this study, the in vitro fibrinolytic efficacy of Tenecteplase, Amediplase and 
scu-PA was investigated in different external lysis models by measuring the 
lysis of human plasma clots after the addition of the plasminogen activators 
(PAs) to the surrounding plasma. The effect of TAFI was examined for each 
PA by neutralising TAFIa with potato carboxypeptidase inhibitor (PCI).
The lytic efficacy of Amediplase was lower than that of Tenecteplase at 
low PA concentrations but slightly higher at therapeutic concentrations. 
The activity of scu-PA was clearly lower than that of either Tenecteplase 
or Amediplase. The TAFI system inhibited external clot lysis mediated 
by all the PAs, when thrombomodulin was present in the model. In the 
therapeutic range (5-10 µg/ml) however, the TAFIa effect was negligible for 
both Amediplase and Tenecteplase. At lower PA concentrations the effect of 
TAFI on Amediplase was slightly stronger than that on Tenecteplase. Under 
static conditions the lysis rates were lower than with stirring. The role of 
TAFI was similar under both conditions.
In conclusion, at therapeutic concentrations Amediplase was slightly more 
active than Tenecteplase and scu-PA under all conditions used. Therefore 
Amediplase might possibly be a more potent thrombolytic agent at these 
concentrations and increase the efficacy of thrombolysis. The potential 
of TAFI for inhibiting thrombolytic therapy is probably low. However in 
conditions where the local PA concentrations are sub-optimal TAFI might 
affect the lysis rate.
Abbreviations
TAFI, thrombin activatable fibrinolysis inhibitor; TAFIa, activated thrombin 
activatable fibrinolysis inhibitor; TM, thrombomodulin; PCI, potato 
carboxypeptidase inhibitor; PA, plasminogen activator; tPA, tissue-type 
plasminogen activator or Alteplase; TNK-tPA, Tenecteplase (Metalyse); 
K2tu-PA, Amediplase; scu-PA, single-chain urokinase-type plasminogen 
activator or pro-urokinase.
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Introduction
Plasminogen activators (PAs) comprise the serine proteinases, which are 
responsible for the conversion of plasminogen, the inactive precursor 
circulating in blood, into plasmin required for the proteolytic degradation 
of fibrin (1). The elucidation of the molecular mechanisms of physiological 
fibrinolysis has led to the development of new thrombolytic agents 
(engineered PAs) that constitute the current standards for thrombolytic 
therapy.
Tenecteplase is a genetically engineered tissue-type plasminogen activator 
(t-PA or Alteplase) variant with a few substitutions in the amino acid sequence, 
which exhibits a prolonged half-life in the circulation and a decreased 
sensitivity to plasminogen activator inhibitor-1 (2) while maintaining affinity 
to fibrin (3). Amediplase (K2tu-PA) is a single-chain hybrid PA, comprising 
the kringle 2 of t-PA and the protease domain of single-chain urokinase-
type plasminogen activator (scu-PA or pro-urokinase) (4). t-PA has a 
strong affinity to fibrin (5), which is ascribed to the finger domain and to a 
lesser extent to its kringle 2 domain (6,7) whereas scu-PA has hardly any 
affinity for fibrin (8). Due to the presence of kringle 2 of t-PA, Amediplase 
has a moderate affinity to fibrin (4,9). scu-PA can be inactivated by direct 
cleavage of the protein chain by thrombin (10). Moreover, this reaction is 
accelerated by thrombomodulin (11). Amediplase, on the other hand, does 
not contain the thrombin-sensitive site of scu-PA and is probably not directly 
inactivated by thrombin. Tenecteplase and Alteplase are nowadays widely 
used for thrombolytic therapy, while Amediplase is currently undergoing a 
phase III clinical trial in patients with myocardial infarction (12).
In the present study, we compared the lytic efficacy of three distinct PAs 
(Tenecteplase, Amediplase and scu-PA) in external plasma clot lysis, which 
is a model for thrombolytic therapy. In such a model, the PA is applied 
outside the plasma clot and proteolytic degradation occurs in a sharp active 
zone on the exterior edge of the clot (13). This active zone reflects the 
accumulation of plasminogen and PA from the plasma clot exterior (14). 
The accumulation of PA varies for different PAs according to their affinity 
for fibrin.
Thrombin activatable fibrinolysis inhibitor (TAFI) is an inhibitor of the 
fibrinolytic system (15) although its part in thrombus resistance to thrombolytic 
therapy is still rather unclear. TAFI is a plasma procarboxypeptidase B, 
which is activated to TAFIa by thrombin. Thrombomodulin works as 
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a cofactor for this reaction resulting in a 1000-fold acceleration of TAFI 
activation (16). TAFIa then eliminates carboxyterminal lysine residues from 
partially degraded fibrin, thereby inhibiting the binding of plasminogen 
to partially degraded fibrin as well as the lysis rate (17). Recently, we 
described an internal plasma clot lysis model where the PA is incorporated 
into the plasma clot during clot formation and demonstrated that all PAs 
tested are sensitive to the inhibitory action of TAFIa (18). Maximal TAFI 
retardation of the clot lysis occurred at intermediate PA concentrations 
and varied between 3- and 6-fold. At low PA concentrations lysis times 
were long and the inhibitory effect of TAFIa was low probably due to the 
limited stability of TAFIa. At high PA concentrations, the inhibitory effect of 
TAFIa was low and possibly related to the inactivation of TAFI/TAFIa by the 
elevated amounts of plasmin generated under these conditions.
The sensitivity of Tenecteplase, Amediplase and scu-PA to the inhibitory 
action of TAFIa was investigated in a modified external plasma clot lysis 
model, which is sensitive to TAFI. Variable stirring conditions were applied, 
striving to accomplish variable transport rates of the fibrinolytic proteins.
Materials and Methods
Materials
Amediplase (batch P003/03) was supplied by Menarini Biotech (Rome, 
Italy). Tenecteplase (Metalyse) was from Boehringer Ingelheim (Ingelheim, 
Germany). scu-PA from a transformed human kidney cell line was 
provided by Sandoz (Vienna, Austria) and biochemically characterised 
previously (19). Potato carboxypeptidase inhibitor (PCI) was acquired 
from Calbiochem (EMD Biosciences, Merck, Darmstadt, Germany). Rabbit 
lung thrombomodulin (TM), with a specific activity towards thrombin 
of 1.2 units/μg, was supplied by American Diagnostica Inc (Greenwich, 
CT, USA). Batroxobin maranhao was from Pentapharm (Kordia, Leiden, 
the Netherlands). Recombinant hirudin (Refludan/Lepirudin) and human 
thrombin were purchased from Aventis Behring (ZLB Behring, King of 
Prussia, PA, USA) and Sigma (St Louis, MO, USA), respectively. Trasylol 
(aprotinin) was obtained from Bayer (Leverkusen, Germany). Human 
fibrinogen (plasminogen, von Willebrand factor and fibronectin depleted) 
was supplied by Enzyme Research Laboratories (Kordia BV, Leiden, the 
Netherlands) and labelled with fluorescein isothiocyanate (FITC) (Sigma) 
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as described elsewhere (14). A plasma pool was prepared with citrated 
apheresis plasma from 12 healthy donors from the local blood bank.
Defibrinated plasma
Plasma was dispensed into plastic tubes containing 2.5 BU/ml batroxobin, 
final concentration. After incubation for 2 hours at room temperature, the 
clots were disconnected from the walls of the tubes and centrifuged at 
5000g for 30 min. The resulting plasma supernatant was pooled into a 
tube and subsequently subdivided into 1 ml aliquots, which were kept at -
80oC. Batroxobin is a thrombin-like proteolytic enzyme isolated from snake 
venom which splits the 16 Arg-17 Gly bond in Aα-chain of fibrinogen. 
Batroxobin only causes release of fibrinopeptide A and no TAFI activation 
occurs during this plasma preparation [20].
External plasma clot lysis model
External plasma clot lysis was measured essentially as previously described 
(9) with some modifications. Plasma was supplemented with FITC-labelled 
fibrinogen and aliquots of 0.2 ml were clotted with calcium chloride (20 mM) 
and thrombin (1 NIH U/ml) for 30 min at 37ºC. The clots were disconnected 
from the tube wall and immersed in 1.0 ml of plasma supplemented with 
hirudin (0 or 20 ATU/ml) and with Amediplase, Tenecteplase or scu-PA (0-
10 μg/ml). Concentrations between brackets refer to final concentrations. 
The clots were incubated for 6 hours at 37ºC on a shaker. At regular 
intervals samples were taken from the plasma and diluted in 50 mM Hepes 
buffer, pH 7.4 containing 0.1% w/v BSA. The released FITC-labelled fibrin 
degradation products were immediately determined in a spectrofluorometer 
and the extent of lysis calculated for each time point. The signal of the 
FITC-labelled fibrinogen supplemented to plasma was considered as 100%. 
The extent of lysis was plotted against the sampling time and the half-
maximal lysis time was determined by fitting these lysis profiles with a 
sigmoidal regression equation.
External plasma clot lysis model sensitive to TAFI
Plasma (125 µl) was supplemented with FITC-labelled fibrinogen and 
clotted by the addition of calcium chloride (20 mM) and thrombin (0.3 NIH 
units/ml) for 30 min at room temperature. Then the plasma clots were 
disconnected from the wall and immersed in defibrinated plasma (125 µl) 
supplemented with calcium chloride (20 mM), thrombomodulin (0.1 units/
ml) and Amediplase, Tenecteplase or scu-PA (0-10 µg/ml). Concentrations 
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between brackets refer to final concentrations. Control experiments with 
potato carboxypeptidase inhibitor (PCI, 30 µg/ml), a specific inhibitor 
of TAFIa, both incorporated in the clot and added to the surrounding 
plasma, were performed in parallel. The incubation was performed at 
room temperature with or without a shaker to create different stirring 
conditions. Sample collection and calculations were performed as for the 
external plasma clot lysis model described above. Values for extent of lysis 
represent the mean of six repeats. An unpaired t-test was used to test 
for differences between half-maximal lysis times of distinct PAs at specific 
concentrations. P values < 0.05 were considered statistically significant.
Fibrin content
The external plasma clot lysis model sensitive to TAFI was used to reinforce 
the results obtained in the presence of PCI. Plasma clots were prepared 
without addition of FITC-labelled fibrinogen and external lysis was induced 
as described above using 5 µg/ml of either Tenecteplase or Amediplase. 
After 30 min plasma clot lysis was stopped by transferring the remaining 
plasma clot into a well containing 250 µl of Trasylol (100 units/ml) in 
50 mM Hepes, pH 7.4. The clot was incubated on an orbital shaker for 
60 min, time after which the Trasylol solution was refreshed. During the 
next 24 hours, the clots were thoroughly washed with 50 mM Hepes, 1.5 
M NaCl, pH 7.4 (refreshed 3 times) and afterwards with 50 mM Hepes, 
pH 7.4 (refreshed 3 times). The buffer was then removed and the clots 
squeezed to minimize buffer content. The clot was dissolved in 200 µl 
2.5 M NaOH (80oC, 4 hours) and the protein content (21) estimated with 
sodium carbonate and Folin-Ciocalteu’s phenol reagent. The fibrin content 
of plasma clots treated in the same way but not subjected to external lysis 
was considered as 100% (mean, n = 6). The variation coefficient for these 
clots was 4.8 %. An unpaired t-test was used to compare the remaining 
fibrin content in the plasma clot after external lysis mediated by either 
Tenecteplase or Amediplase. P values < 0.05 were considered statistically 
significant.
Results
External plasma clot lysis model
Fig.1 shows the time-dependent results of external plasma clot lysis, in which the 
PAs were added to the external plasma in increasing concentrations (0-10 µg/ml). 
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Figure 1. Profiles for the extent of 
external plasma clot lysis mediated 
by: A, Tenecteplase; B, Amediplase; 
C, scu-PA. Preformed plasma clots 
labelled with FITC-fibrin were immersed 
in citrated plasma containing the 
thrombin inhibitor hirudin (20 ATU/
ml) and increasing amounts of the 
plasminogen activators: () 0 µg/ml; 
() 0.031 µg/ml; (∆) 0.078 µg/ml; (□) 
0.156 µg/ml; () 0.31 µg/ml; () 0.63 
µg/ml; (∆) 1.25 µg/ml; () 2.5 µg/ml; 
() 5 µg/ml; (+) 10 µg/ml. The time-
dependent release of FITC-labelled 
fibrin degradation products into the 
external plasma was determined with a 
fluorometer, expressed as a percentage 
of lysis and plotted against the sampling 
time.
The PAs showed sigmoidal lysis curves. The half-maximal lysis times were 
derived for each lysis profile and presented in Fig.2 as a function of the PA 
concentration. Amediplase was less active (i.e. longer half-max lysis times) 
than Tenecteplase at low PAs concentrations, but slightly more active than 
Tenecteplase at high, therapeutic concentrations. scu-PA (pro-urokinase) 
was less active than both Amediplase and Tenecteplase. Moreover, lysis 
experiments were performed with (Fig.1 and Fig.2) and without (not shown) 
the thrombin inhibitor hirudin (Refludan 20 ATU/ml). The purpose of this 
was to study the effect of thrombin generation/activity and TAFI activity, 
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but no significant differences were observed in the absence or presence of 
hirudin. This indicates that the amounts of thrombin in the system were 
too low for substantial TAFI activation. In addition, this indicated that the 
direct inactivation of scu-PA by thrombin was also minor.
Figure 2. Comparison of the half-
maximal lysis times obtained for 
Tenecteplase (squares), Amediplase 
(circles) and scu-PA (triangles) in 
the presence of hirudin (20 ATU/ml).
External plasma clot lysis model sensitive to TAFI
To be able to compare the sensitivity of the different PAs towards the 
inhibitory action of TAFI the external plasma clot lysis set-up was modified, 
as described under methods. To enhance TAFI activation and to increase the 
half-life of TAFIa, thrombomodulin was added to the external defibrinated 
plasma and experiments were performed at room temperature, respectively. 
Stirring increased the extent of plasma clot lysis both in the absence and 
in the presence of PCI and shifted the dose-response curves at each time 
point towards lower PA concentrations. Inclusion of PCI resulted in a clear 
acceleration of external plasma clot lysis for each of the three PAs.
The time-dependent lysis profiles were constructed and used to determine 
the half-maximal lysis time, which was then plotted against the PA 
concentration both with (Fig.3) and without (not shown) stirring. At low 
PA concentrations, long half-maximal lysis times were observed as well as 
the high inhibitory effects of TAFIa. These effects were more pronounced 
for Amediplase and scu-PA than for Tenecteplase. The inhibitory effect 
of TAFIa decreased with increasing PA concentrations. In the therapeutic 
range (5-10 µg/ml), the TAFIa effect was negligible for both Amediplase 
and Tenecteplase.
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Figure 3. Half-maximal lysis times 
obtained for increasing concentrations 
of Amediplase (A), Tenecteplase (B) 
and scu-PA (C) with stirring, using 
an external plasma clot lysis model 
sensitive to TAFI. (mean, n = 6) Half-
maximal lysis times were determined 
from the clot lysis profiles with (open 
symbols) or without (closed symbols) 
a specific TAFIa inhibitor (PCI) and 
plotted against the PA concentration.
In the presence of PCI (Fig.4A), Amediplase was more effective than 
Tenecteplase at PA concentrations between 1-10 µg/ml (1.25 µg/ml, p 
= n.s.; 2.5 µg/ml, p = 0.009; 5 µg/ml, p = 0.009 and 10 µg/ml, p = 
0.04) while, at lower concentrations, Tenecteplase was more effective 
than Amediplase. This corresponded well to the results in the first model 
that was insensitive to TAFI (Fig.2). A similar external plasma clot lysis 
model sensitive to TAFI was used to confirm the results obtained in the 
presence of PCI. Plasma clots were prepared without addition of FITC-
labelled fibrinogen and external lysis was performed with 5 µg/ml of each 
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PA, as earlier described. After 30 min plasma clot lysis was stopped and 
the fibrin content in the remaining plasma clot determined. The plasma 
clots subjected to external lysis mediated by Tenecteplase contained 51.6 
± 3.1 % (mean ± SD, n = 4) of the initial fibrin content while the plasma 
clots treated with Amediplase contained 13.6 ± 7.3 % of the initial fibrin 
content (p = 0.008), corroborating the differences observed in the model 
containing FITC-labelled fibrinogen.
In the absence of PCI (Fig.4B) Amediplase still appeared to be more effective 
than Tenecteplase at 5 and 10 µg/ml but this did not reach statistical 
significance (5 µg/ml, p = 0.05 and 10 µg/ml, p = n.s.). This confirmed 
that Amediplase was slightly more sensitive to TAFIa than Tenecteplase. 
scu-PA was less effective than Amediplase or Tenecteplase.
Figure 4. Comparison of the half-
maximal lysis times obtained for 
Tenecteplase (squares), Amediplase 
(circles) and scu-PA (triangles) in 
the absence (A) or presence (B) of 
PCI with stirring, using an external 
plasma clot lysis model sensitive 
to TAFI. Differences between half-
maximal lysis times of Tenecteplase 
and Amediplase were tested with 
an unpaired t-test. p values <0.05 
were considered statistically 
significant. A, 1.25 µg/ml, p = n.s.; 
2.5 µg/ml, p = 0.009; 5 µg/ml, p = 
0.009 and 10 µg/ml, p = 0.04. B, 5 
µg/ml, p = 0.05 and 10 µg/ml, p = 
n.s..
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Discussion
In this study, we compared the lytic activity of Tenecteplase, Amediplase and 
scu-PA in external plasma clot lysis models taking into account factors that 
may influence clot dissolution such as TAFIa activity, thrombin generation 
in the exterior plasma, and stirring conditions.
In the first model, we showed that Amediplase was more active than 
Tenecteplase at therapeutic concentrations. For lower concentrations, 
Amediplase exhibited a lower lytic activity than Tenecteplase (Fig.2). The 
activity of scu-PA was clearly lower than that of both Tenecteplase and 
Amediplase. The addition of hirudin to the exterior plasma did not lead to 
differences in the lysis rates, which probably reflects negligibly low thrombin 
generation in citrated plasma without recalcification.
Thereafter, we investigated the inhibitory effect of TAFIa on these three 
PAs using an external plasma clot lysis model modified for this purpose. 
In this model, plasma clots were immersed in recalcified plasma to allow 
the activation of TAFI. This exterior plasma was defibrinated by treatment 
with batroxobin, a snake-derived enzyme, which leads to fibrin formation 
but not to TAFI activation (20,22). Thrombomodulin was added to the 
defibrinated plasma and experiments were performed at room temperature 
instead of 37oC to enhance the activation of TAFI and the stability of TAFIa, 
respectively.
The addition of a specific TAFIa inhibitor increased the percentage of lysis 
under all conditions corroborating an inhibitory effect of TAFIa on all PAs 
tested, both with (Fig.3) and without stirring. Previously, we compared the 
inhibitory effect of TAFIa on seven different PAs using an internal lysis model, 
in which the PA is incorporated into the plasma clot (18). TAFIa was able 
to inhibit internal lysis mediated by all PAs tested and a dependence on the 
type and concentration of the PA used was observed. The inhibitory effect 
of TAFIa strongly decreased at high PA concentrations. Recently, Cruden 
et al (23) also showed that tPA-mediated fibrinolysis was accelerated by 
the inhibition of TAFIa when tPA concentrations supplemented to blood 
corresponded to plasma concentrations in the range of 0.1-0.2 µg/ml but 
not when higher tPA concentrations (1-5 µg/ml) were used. A concentration-
dependence was also observed for the effect of TAFIa in the external lysis 
model, described here. The inhibitory effect of TAFIa was high at low PA 
concentration and decreased with increasing PA concentrations (Fig.3). 
In the therapeutic range (5-10 µg/ml), the TAFIa effect was negligible for 
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both Amediplase and Tenecteplase. This agreed with previous findings for 
Alteplase using in vitro external lysis (24) and in vivo thrombolysis (25) 
models. Using model thrombi, Mutch et al. (26) observed a significant 
effect of TAFIa in external lysis mediated by two chain u-PA, scu-PA and tPA 
when the model thrombi were surrounded by plasma (30%). Interestingly, 
the inhibitory effect of TAFIa became less obvious by increasing the 
plasminogen concentration in the surrounding plasma. All findings concur 
with the fact that the loss of the TAFIa effect coincides with plasminogen or 
PA concentrations at which a high plasmin concentration is achieved. It is 
thus possible that these high plasmin concentrations inhibit TAFI and TAFIa 
by proteolytic cleavage (27). In addition, the loss of fibrin specificity at 
therapeutic concentrations makes plasminogen activation less dependent 
on the availability of C-terminal lysines on fibrin, as suggested by Colucci 
et al. (24). Mutch et al. did not observe a decreased TAFIa effect at high PA 
concentrations (26). Their highest PA concentration was, however, 1 µg/ml, 
i.e. 10-fold lower than the highest PA concentration in our study.
In addition to Tenecteplase and Amediplase, scu-PA represents a potentially 
new thrombolytic agent. In the PROACT trial, the safety and recanalisation 
efficacy of recombinant pro-urokinase (rpro-UK), Prolyse, in acute 
ischaemic stroke was investigated (28). In the models used here, scu-PA 
was less effective than the other two PAs and a TAFIa effect was seen even 
at 10 µg/ml scu-PA. When comparing the results for scu-PA in the first 
external lysis model with those obtained in the second external lysis model 
in the presence of PCI, we observed a further decrease in lytic activity in 
the second model. It is likely that the presence of thrombomodulin in the 
second external lysis model increases the direct inactivation of scu-PA by 
thrombin (10,11).
We conclude that Amediplase was slightly more active than either 
Tenecteplase or scu-PA at therapeutic concentrations under all conditions 
(with/without hirudin, with/without TAFIa activity and with/without stirring) 
using two different external clot lysis models. In a phase II clinical trial, 
over 75% of the patients with acute myocardial infarction treated with 
Tenecteplase achieved coronary artery patency (TIMI 3 flow grade) at 90 
min after administration, corresponding to an average plasma concentration 
of 3.6 µg/ml during this 90 min interval (29,30). In acute myocardial 
infarction patients, administration of Amediplase achieved a similar TIMI 
3 flow grade at 60 min (3K2 trial) (31). For Amediplase higher weight-
adjusted doses were used in comparison to Tenecteplase and the average 
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plasma concentration during treatment was 7.9 µg/ml (Menarini Ricerche, 
unpublished). Our results (Fig.2 and 4) show that this is the concentration 
range where Amediplase was slightly more active than Tenecteplase 
resulting in a lower half-maximal lysis time.
Finally, the role of TAFI during optimal and successful thrombolytic therapy 
is probably low. Nevertheless, depending on the thrombus composition 
and architecture, haemodynamic conditions and distinct physiological 
interactions of plasminogen and PAs in the vascular environment, it is 
conceivable that the local PA concentration does not reach optimal levels 
creating conditions, in which TAFI might affect the lysis rates during 
thrombolytic therapy.
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Summary
Besides having a key role in fibrinolysis, the plasminogen system has also 
been implicated in cell migration and angiogenesis. A common mechanism 
is the binding of plasminogen to carboxy-terminal lysine residues in partially 
degraded fibrin or on cellular surfaces. Here we examined the involvement 
of TAFI, a plasma procarboxypeptidase B, and pancreatic CPB in capillary 
tube formation using an in vitro system, which was largely plasminogen-
dependent. Human microvascular endothelial cells (hMVECs) were seeded 
on a 3D plasma clot matrix and subsequently stimulated with bFGF/TNF-α. 
Tube formation was analyzed and fibrin degradation products (FbDP) were 
determined in the medium. Supplementation of the matrix with additional 
TAFI or with CPB produced a reduction in tube formation. Pretreatment 
of hMVECs with CPB before seeding resulted in a similar effect. FbDP-
levels indicated a concomitant reduction in matrix proteolysis. The addition 
of a TAFIa inhibitor increased tube formation and FbDP release into the 
medium. In a wound assay, CPB impaired the migration of hMVECs in a 
dose-dependent manner. Overall, these results demonstrate that TAFI and 
CPB in these systems modulate the plasminogen system both in the matrix 
and on the cell surface, thus leading to the inhibition of endothelial cell 
movement and tube formation.
Introduction
Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is a basic 
carboxypeptidase that inhibits fibrinolysis by preventing the positive 
feedback in plasmin generation. The proenzyme TAFI, is synthesized in 
the liver and present in plasma and can be activated by trypsin, plasmin 
and thrombin [1,2] by a single cleavage at Arg-92. The efficiency of 
TAFI activation by thrombin is increased by the endothelial cell receptor 
thrombomodulin [3]. In addition, the activation of TAFI by plasmin is 
stimulated by glycosaminoglycans [4], which are synthesized by endothelial 
cells. Activated TAFI (TAFIa), also described as plasma carboxypeptidase B, 
carboxypeptidase U and carboxypeptidase R [1,5-7], is intrinsically unstable 
[8] with a half-life of about 8 min at 37oC [9]. TAFIa cleaves carboxy-
terminal basic residues from proteins with a preference for carboxy-terminal 
arginine residues over carboxy-terminal lysine residues [5]. Pancreatic 
carboxypeptidase B (CPB), a digestive basic carboxypeptidase displays 
high homology with TAFI [10] but in contrast to TAFIa, CPB is a stable 
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protease.
The conversion of plasminogen into active plasmin is initiated either by the 
tissue-type plasminogen activator (tPA) or the urokinase-type plasminogen 
activator (uPA). tPA is mainly involved in the dissolution of fibrin in the 
circulation and uPA in the induction of pericellular proteolysis [11]. The 
interaction between plasminogen and fibrin is dependent on lysine binding 
sites on plasminogen. Plasmin is able to generate new carboxy-terminal 
lysine and arginine residues in fibrin enhancing its own binding as well as the 
binding of plasminogen [12]. This enhanced binding results in an increased 
catalytic efficiency of plasmin formation [13,14] and can be blocked by 
TAFIa [15]. TAFIa was shown to inhibit tPA and uPA in vitro plasma clot 
lysis [16,17]. In addition, in vivo inhibition of TAFIa by a specific inhibitor, 
i.e. potato carboxypeptidase inhibitor (PCI), was shown to enhance tPA-
induced thrombolysis [18-22].
Besides the key role that these carboxy-terminal lysine residues play in 
fibrinolysis they have also been implicated in cell migration, wound healing 
and angiogenesis where they function as binding sites for plasminogen 
[23]. Lysine analogs, such as epsilon-amino-caproic acid (ε-ACA) and 
tranexamic acid (Cyclokapron) efficiently prevent plasmin formation [24-
26] and inhibit tumor cell metastasis and primary tumor growth [27,28]. 
Moreover, binding of plasminogen to the cell surface can be abrogated by 
treatment with pancreatic CPB as well as with TAFIa [29].
It is therefore possible that TAFI functions as a broad modulator of the 
plasminogen system in its various functions. Although an TAFI-/- mice 
did not present an overt phenotype [30], recently Swaisgood et al. [31] 
demonstrated an in vivo role for TAFI as a modulator of the plasminogen 
system during fibrinolysis and during cell migration. Furthermore, te Velde 
et al. [32] showed that TAFI-deficient mice present an impaired healing 
of cutaneous wounds and of colonic anastomoses. However, little is 
known about the possible effects of TAFI on endothelial cell migration and 
neovascularization.
Here, we investigated the participation of TAFI in the formation of capillary-
like tubular structures in vitro using a model for tube formation that relies 
mainly on the plasminogen/uPA system [33,34]. The addition of antibodies 
against uPA, aprotinin or uPA receptor (uPAR) completely inhibited bFGF/
TNF-α stimulated tube formation, while the addition of anti-tPA antibody or 
of a general MMP-inhibitor resulted only in a moderate inhibition. Frequently, 
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neovascularization occurs in adults under conditions, in which a fibrinous 
exudate is formed and this can facilitate the angiogenesis process [35]. 
In this study, we sought to mimic the formation of capillary-like structures 
in vitro using a three-dimensional plasma clot matrix covered by human 
microvascular endothelial cells (hMVECs).
To our knowledge, this is the first time that TAFI has been demonstrated to 
have an effect on in vitro capillary-like tube formation. Moreover, this effect 
could not be solely ascribed to the cleavage of carboxy-terminal lysine 
residues from partially degraded fibrin, which composes the known substrate 
for TAFIa and rather points to the existence of additional physiological 
substrates. We propose that TAFI might be involved in neovascularisation 




Cell culture reagents were purchased as previously described [34]. Human 
serum (HS) was obtained from a local bloodbank and was prepared from 
freshly obtained blood from 10-20 healthy donors, pooled and stored at 
4oC. Newborn calf serum (NBCS) was obtained from Life Technologies 
(Grand Island, NY, USA). NBCS and HS were heat-inactivated before use. 
Basic fibroblast growth factor (bFGF) was purchased from Prepro Tech EC 
(London, UK) and human recombinant tumor necrosis factor-α (TNF-α) was 
a gift from Dr. J. Travernier (Biogent, Gent, Belgium) and contained 2.45 x 
107 U/mg protein and less than 40 ng lipopolysaccharide per mg protein. 
Aprotinin was purchased from Pentapharm Ltd. (Basel, Switzerland). Heparin 
and bovine thrombin were obtained from Leo Pharmaceutics Products 
(Weesp, the Netherlands) and potato carboxypeptidase inhibitor (PCI) was 
acquired from Calbiochem (La Jolla, CA, USA). Pancreatic carboxypeptidase 
B was purchased from Sigma-Aldrich (St. Louis, MO, USA) and TAFI was 
isolated as described previously [38]. Citrated platelet-poor plasma from 
ten healthy volunteers was obtained from the blood bank, pooled and 
stored at -80oC. TAFI-depleted plasma was prepared using an anti-TAFI IgG 
sepharose column essentially as previously described [39]. The monoclonal 
u-PA receptor (uPAR)-blocking antibody H-2 was a kind gift from Dr. U. 
Weidle (Boehringer Mannheim, Penzberg, Germany) [40]. Rabbit polyclonal 
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anti-u-PA antibodies were prepared in our laboratory [41]. Horseradish 
peroxidase (HRP) conjugates of sheep anti-human TAFI IgG and rat anti-
mouse IgG were from Affinity Biologicals (Hamilton, Ontario, Canada) and 
DAKO (Glostrup, Denmark), respectively. The CD31 murine IgG (clone 
1A10) was from Monosan (Sanbio, Uden, The Netherlands).
Cell culture
Human foreskin microvascular endothelial cells (hMVECs) were isolated, 
cultured and characterized as previously described [42,43].
Preparation of the three-dimensional (3D) plasma clot matrix
Plasma clot matrices were prepared by the addition of 1 U/mL thrombin 
to citrated platelet-poor plasma. Immediately afterwards, 300 µL aliquots 
of this mixture were added to the wells of a 48-well plate. The plasma clot 
matrices were left at room temperature for at least 30 minutes and then 
equilibrated at 37ºC, under humidified 5% CO2/ 95% air atmosphere with 
serum-containing culture medium (Medium 199 - M199, supplemented 
with 10% (v/v) HS, 10% (v/v) NBCS, 100 IU/ml penicillin and 0.1 µg/ml 
streptomycin). During the next 24 hours, the matrices were thoroughly 
washed with serum-containing culture medium (3 to 4 times).
Pre-treatment of hMVECs with CPB
The hMVECs were detached by treatment with trypsin/EDTA and suspended 
in serum-containing culture medium. After washing, the hMVECs were 
incubated with 50 units/ml of pancreatic CPB in serum-containing culture 
medium at 4oC. After 30 min the CPB-containing medium was removed 
and the hMVECs were washed by centrifugation. These pre-treated hMVECs 
were resuspended in serum-containing culture medium and seeded at a 
split ratio of 2:1 on top of the plasma matrices. Non-treated cells were 
submitted to the same procedure with serum-containing medium, in the 
absence of CPB.
In vitro tube formation assay
The formation of capillary-like tubes was evaluated essentially as previously 
described in fibrin matrices [33]. Confluent hMVECs were seeded at a split 
ratio of 2:1 on top of the plasma matrices and cultured growth factor free 
for 24 hours in serum-containing culture medium. Then, the cells were 
stimulated with stimulation medium composed of serum-containing culture 
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medium supplemented with bFGF (10 ng/ml) and TNF-α (10 ng/ml). 
The reagents to be tested were either added to plasma before preparing 
the matrix or added to the stimulation medium. Every second day the 
stimulation medium was collected and renewed. After seven days the 
formation of tubular structures was analyzed by phase-contrast microscopy. 
Quantification of the length of the structures formed was performed 
essentially as previously described [33], by measuring in six randomly 
chosen microscopic fields (7.3 mm2/field) using a Nikon FXA microscope 
equiped with a monochrome CCD camera (MX5) connected to a computer 
with Optimas image analysis software.
Wound assay [44]
Confluent hMVECs were seeded on fibronectin-coated dishes of a 48-wells 
plate in serum-containing culture medium with 150 µg/ml crude endothelial 
cell growth factor (ECGF) and 5 U/ml heparin. Subsequently, hMVECs were 
growth factor deprived for 24 hours. A scratch was applied to the confluent 
monolayer and the cells were washed for three times with M199 to remove 
the detached cells. Immediately, the stimulation medium (serum-containing 
culture medium with 10 ng/ml bFGF and 10 ng/ml TNF-α) supplemented 
with the compounds of interest was added to the wells and the cells were 
incubated at 37ºC, under humidified 5% CO2/ 95% air atmosphere. During 
the following 24h, photographs of the wound were taken every 2h and 
wound analyses were performed by calculating the diameter of the wound 
for each time point (4 measurements/well) for duplicate wells.
Proliferation assay
hMVECs were seeded 1:8 on a fibronectin-coated 24-well plate in serum-
containing culture medium (0.5 ml/well). After 24 hours, the cells were 
stimulated with bFGF (10 ng/ml) alone or in combination with CPB (1, 
10 or 100 U/ml) and incubated at 37°C under humidified 5% CO2/ 95% 
air atmosphere for 96 hours. After the incubation period, the cells were 
washed for three times with M199 with 100 IU/ml penicillin and 0.1 mg/ml 
streptomycin and fixed for 10 minutes with 2% glutaraldehyde. The cell 
membrane was rendered permeable by fixation with 70% ethanol for 10 
minutes. The cells were stained with crystal-violet for 2h, washed for four 
times with MilliQ and dried overnight at room temperature. Cell counting 
was performed by the computer program Optimas. The experiment was 
performed in duplicate and the data was based on six countings per well.
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Fibrin degradation products (FbDP) EIA and uPA ELISA
The FbDP EIA was performed essentially as previously described [45]. 
Calibration was performed using whole-blood clot lysate [46] and pooled 
normal plasma was used as control. FbDP levels were calculated from 
duplicate measurements.
uPA antigen was measured essentially as previously described [33].
Immunohistochemistry
Tissue sections (5 µm) of human atherosclerotic plaques with an incorporated 
mural thrombus were dewaxed by immersion in xylene and rehydrated in 
decreasing concentrations of ethanol. For HPS staining, the sections were 
counterstained with Mayer’s hematoxylin, phloxin and saffron. After dehydration 
in a reversed ethanol-xylene series, the sections were prepared for microscopy. 
Inhibition of endogenous peroxidase was accomplished by immersion in 1% 
hydrogen peroxidase in absolute methanol for 20 min. The sections were 
washed in deionized water and equilibrated in phosphate-buffered saline (PBS, 
pH 7.4). For antigen retrieval, sections were incubated in 0.1 M sodium-citrate 
in a microwave at 700 Watt until boiling point was reached, followed by a period 
of 10 min at 180 Watt. Subsequently, all the sections were blocked by 5% BSA 
in PBS to prevent nonspecific binding. Different antibodies were applied to the 
sections overnight at 4ºC. After washes with PBS, the sections were exposed 
to the second antibody, the biotinylated horse anti-mouse IgG diluted in 1% 
BSA/PBS in a concentration of 1:400, for 1 hour at room temperature. Then 
after further washes with PBS, the sections were incubated for 30 min at room 
temperature with the HRP Avidin Biotinylated Complex (ABComplex). The 
signal was amplified by biotinylated tyramides as described [47] for 10 min at 
room temperature, followed again by the HRP ABComplex for 30 min at room 
temperature. The sections were washed with PBS and stained with Novared 
for a period of 5 to 10 min. Finally, the sections were washed in aquadest, 
counterstained with hematoxylin, washed in running water and dehydrated in 
a reversed ethanol-xylene series and prepared for microscopy.
Statistical analysis
Tube formation results were expressed as the mean percentage ± SEM of the 
results obtained in the bFGF/TNF-α condition. For statistical analysis, we used 
one-way ANOVA followed by the Dunnett’s test as post-test. The Dunnett’s 
test is a modified t-test that takes into account multiple comparisons with a 
control condition. Statistical significance was accepted at P<0.05.
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Results
Involvement of TAFI in tube formation in a 3D plasma clot matrix
To study the involvement of TAFI during tube formation, we used a 3D 
in vitro model where a plasma clot is used to mimic the provisional 
wound matrix. hMVECs were seeded on top of the plasma clot matrix and 
stimulated with bFGF and TNF-α to form capillary-like structures (Fig.1A). 
Figure 1B demonstrates that addition of the TAFIa-specific inhibitor PCI 
stimulated the formation of tubular structures by 57% (p<0.01) while 
increasing TAFI concentration (by 50 nM) in the plasma clot matrix inhibited 
tube formation (42%, p<0.05). In agreement with previous findings, the 
plasma inhibitor aprotinin caused a strong inhibition of tube formation 
(80%, p<0.01) confirming the dependency of the model on the activity of 
plasmin. Similarly, inhibition of uPA by anti-uPA and of uPAR by anti-uPAR 
(MoAb H2) also reduced tube formation corroborating the involvement of 
cell-bound u-PA on tube formation (both over 80%, p<0.01) (not shown).
Pancreatic CPB was incorporated into the plasma clot matrix to compare 
the effect of this active and stable basic carboxypeptidase with that of TAFI. 
Addition of CPB (1-10 units/ml) to the matrix induced a significant and 
dose-dependent inhibition of tube formation, which was significant at 5 and 
10 units/ml CPB (both p<0.01; Fig.1C).
The inhibitory effect of TAFI during tube formation might emerge from its 
known downregulation of fibrin matrix degradation or from an effect on hMVECs 
themselves. To further explore this, the hMVECs were pre-treated with CPB. 
Subsequently, the hMVECs were washed and seeded on top of the plasma 
clot matrix. After 24 h they were stimulated with bFGF/TNF-α alone (CPB+) 
or combined with the addition of CPB to the medium (25 units/ml, CPB++). 
This pre-treatment (CPB+) resulted in an inhibition of tube formation (58%, 
p<0.01) pointing to a direct effect on the hMVECs (Fig.1C). Furthermore, when 
CPB was also added to the stimulation medium (CPB++) a supplementary 
inhibition in tube formation was observed (73%, p<0.01). It is interesting 
to notice that either supplementation of the matrix with 10 units/ml CPB 
or treatment of hMVECs with CPB in combination with CPB in the medium 
(CPB++) resulted in an inhibition of tube formation comparable to the 
addition of aprotinin. This suggests that the observed effects reflected 
complete interference with the uPA/plasmin system.
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Figure 1. Formation of capillary-like structures in a 3D plasma clot matrix. hMVECs 
were cultured on top of a 3D plasma clot matrix in serum-containing culture 
medium. (A) Phase-contrast photomicrographs of tube formation with stimulation with 
bFGF (10 ng/ml) and TNF-α (10 ng/ml) were made at (a) day 1, (b) day 3 and (c) day 6 
(original magnification 20x). (B) hMVECs were cultured with and without stimulation with 
bFGF and TNF-α. Additionally, purified TAFI (50 nM) or potato carboxypeptidase inhibitor 
(PCI, 30 µg/ml) was added to the plasma clot matrix. Aprotinin (200 KIU/ml), a plasmin 
inhibitor, was added to the stimulation medium. (C) Pancreatic carboxypeptidase B (CPB) 
was either incorporated into the plasma clot matrix (CPB 1, 5, 10 units/ml) or hMVECs 
were pre-treated with CPB (CPB+) or pre-treated with CPB and 25 units/ml CPB added to 
the medium (CPB++). After 6 days of culture the tube length per cm
2 was expressed as 
% of the bFGF/TNF-α control as described. The data represent mean percentage ± SEM 
of 3 independent experiments performed in duplicate wells. The dotted line indicates the 
extent of tube formation that can be inhibited by a plasmin inhibitor, aprotinin.
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Fibrin degradation products (FbDPs) accumulation during tube formation
The amount of FbDPs accumulated in the conditioned medium markedly 
increased during tube formation, as evaluated during two 48h periods 
after initial stimulation by bFGF/TNF-α (Fig.2A). This accumulation was 
largely inhibited by aprotinin (81%, p<0.01). Addition of PCI enhanced 
FbDP accumulation in the medium (87%, p<0.01) whereas addition of TAFI 
(Fig.2A) inhibited the release of FbDPs compared to bFGF/TNF-α stimulation 
only (57%, p<0.01). Moreover, when the matrix was supplemented with 
CPB (Fig.2B), FbDP levels decreased (71% CPB1, 86% CPB5 and 89% CPB10, 
all p<0.01) pointing to a downregulation of fibrinolysis. Pre-treatment of 
hMVECs with pancreatic CPB also inhibited FbDPs release (87% CPB+ and 
93% CPB++, both p<0.01).
uPA accumulation during tube formation
The accumulation of uPA in the stimulation medium during tube formation 
was significantly decreased when hMVECs were pre-treated with CPB (46% 
Figure 2. Release of fibrin degradation 
products (FbDP) during the formation 
of capillary-like structures in a 3D 
plasma clot matrix. The stimulation 
medium was renewed at 48 h intervals 
and the conditioned media of the first 
two stimulation periods were collected 
for assay of FbDPs. The two values were 
added to obtain the FbDP accumulatioon 
over the 96 h period. (A) hMECs were 
cultured with and without stimulation 
with bFGF/TNF-α. In addition, the matrix 
was supplemented with PCI (30 µg/ml), 
aprotinin (200 KIU/ml) or additional 
purified TAFI (50 nM) where stated. (B) 
CPB was either incorporated into the 
plasma clot matrix (CPB 1, 5, 10 units/
ml) or hMVECs were pre-treated with 
CPB (CPB+) or pre-treated with CPB and 
25 units/ml CPB added to the medium 
(CPB++). The data represent mean ± 
SEM of 3 independent experiments 
performed in duplicate wells. The FbDP 
level for the bFGF/TNF-α condition 
corresponds to 30 µg/ml).
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CPB+ and 48% CPB++ compared to bFGF/TNF-α, both p<0.01) (not shown). 
The amount of uPA found in the medium under bFGF/TNF-α stimulation 
corresponded to about 16 ng/ml. The addition of CPB, PCI or TAFI to the 
matrix, did not alter the uPA accumulation compared to bFGF/TNF-α.
TAFI concentration in the plasma clot matrix and consequences for tube formation
We examined the effect of reducing TAFI concentration in the plasma 
clot matrix by testing serial dilutions of normal pooled plasma in TAFI-
depleted plasma. Reduction of the TAFI content of the plasma clot matrix 
caused an acceleration of the tube formation (Fig.3A) and an increase in 
FbDP accumulation (Fig.3B). Depletion of TAFI in the plasma clot matrix or 
addition of PCI to normal plasma clot matrix had similar results (Fig.3A,B).
Figure 3. Effect of decreasing TAFI 
concentrations in the plasma clot 
matrix on the tube formation. Serial 
dilutions of normal plasma in TAFI-
depleted plasma were performed and 
these mixtures were used to prepare 
the 3D plasma clot matrix (open bars). 
hMVECs were cultured on top of this 
matrix and stimulated with bFGF (10 ng/
ml) and TNF-α (10 ng/ml). Additionally, 
potato carboxypeptidase inhibitor (PCI 
- 30 µg/ml) was added to the plasma 
clot matrix where stated (black bar). (A) 
After 6 days of culture the tube length per 
cm2 was expressed as mean percentage 
of the bFGF/TNF-α control ± SEM of a 
representative experiment. (B) Release of 
FbDP during the formation of capillary-like 
structures in a 3D plasma clot matrix. The 
stimulation medium was renewed at 48 h 
intervals and the conditioned media of the 
first two stimulation periods were collected 
for assay of FbDPs. The two values were 
added to obtain the FbDP accumulatioon 
over the 96 h period. The data represent 
the mean percentage of the bFGF/TNF-α 
control ± SEM of 3 independent experiments 
(FbDP level for the bFGF/TNF-α condition 
corresponds to 5 µg/ml). The dotted line 
indicates the amount of tube formation 
under normal conditions, i.e. plasma 
containing the normal amount of TAFI.
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The reduction of TAFI content not only caused an increase in capillary tubes 
but also modified their structure. The tubes formed in matrices containing 
less TAFI displayed a more extensive network and were accompanied by 
wider tubes, often in the upper area of the plasma clot matrix, suggesting 
increased fibrin degradation (Fig.4A-C) and also possibly an altered 
migration.
Figure 4. Formation of capillary-like tubular structures by hMVECs at decreasing 
TAFI concentrations. hMVECs were cultured on top of a 3D plasma clot matrix and 
stimulated with bFGF (10 ng/ml) and TNF-α (10 ng/ml). The plasma clot matrices were 
prepared by serial dilutions of normal plasma in TAFI-depleted plasma. Histological cross-
sections of the plasma clot matrices containing 75% (A), 5% (B) and 2.5% (C) of TAFI. 
Tubular structures are indicated by arrowheads and the asterisks indicate areas where 
extensive lysis of the plasma clot matrix has occurred, original magnification 40x.
CPB affects the migration of hMVECs in a concentration dependent way
Pre-treatment of hMVECs with CPB resulted in the inhibition of tube formation 
(Fig.1). Moreover, decreasing TAFI concentrations in plasma resulted 
not only in an increase in fibrinolysis (Fig.3B) but also in an increased 
hMVECs infiltration (Fig.3A; Fig.4). These results suggest that these basic 
carboxypeptdases are able to modulate hMVECs functions, probably via the 
regulation of the uPA/plasmin system. We therefore used CPB to study the 
effect of basic carboxypeptidase activity on the proliferation and migration 
of hMVECs. The proliferation of hMVECs was not affected in the presence 
of CPB (1, 10 and 100 U/ml), as estimated by cell counting (not shown). 
A wound assay was used to investigate the effect of carboxypeptidase B 
activity on hMVECs migration under similar stimulation conditions as used 
for the tube formation assay, namely stimulation by bFGF/ TNF-α. In this 
assay the migration of hMVECs was impaired in a dose-response manner 
by increasing CPB concentrations in a 24-hour period (Fig.5). The uPA/
plasminogen system was also involved during the migration of hMVECs, 
under bFGF/TNF-α stimulation, as the addition of anti-uPAR, anti-uPA or 
aprotinin delayed the migration of hMVECs.
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Figure 5. Pancreatic carboxypeptidase B inhibits migration of hMVECs 
in a concentration-dependent way. Confluent hMVECs were seeded on a 
fibronectin coated well to obtain a cobblestone monolayer. (A) Scratches were 
made through the monolayer and photomicrographs of the migrating hMVECs were 
taken at regular intervals. (a), 0 hours; (b), 12 hours and (c), 24 hours (original 
magnification 20x). (B,C) Immediately after wounding, the cells were stimulated 
with bFGF (10 ng/ml) and TNF-α (10 ng/ml) (striped bars). (B) A negative control 
without stimulation was included (open bars). Some wells were exposed to 
combined stimulation with bFGF/TNF-α and increasing concentrations of CPB (B) 1 
unit/nl (light grey bar), 10 units/ml (dark grey bar) and 100 units/ml (black bar) or 
(C) anti-uPA antibody (30 µg/ml) (black bar), anti-uPAR antibody (25 µg/ml) (dark 
grey bar) and aprotinin (200 U/ml) (light grey bar). Data represent mean ± SEM 
of 3 experiments performed in duplicate wells. P-values for comparisons between 
the different compounds tested and the bFGF/TNF-α condition were calculated by 
ANOVA with the Dunnett’s test as post-test; * P<0.05 and ** P<0.01.
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Localization of TAFI in an atherosclerotic plaque
To investigate the presence and localization of TAFI in new vascular 
structures formed in a fibrinous environment, immunohistochemical analysis 
of TAFI was performed in tissue sections of atherosclerotic plaques with 
organized thrombi. The neointima with incorporated thrombus contained 
new capillaries. The endothelial cells of the newly formed microvessels 
were visible after staining for CD31 (PECAM-1) (Fig.6A). Staining with an 
antibody against TAFI (Fig.6B,C) revealed that TAFI was, as expected, 
present in the fibrinous exudate, and accumulated in many of the vascular 
structures in this thrombus. This occurred possibly by the colocalization of 
TAFI with the endothelial cells lining the vessels.
Figure 6. Localization of TAFI and endothelial cell marker CD31 (PECAM-1) in 
neovessels formed in a human atherosclerotic plaque that had incorporated 
a mural thrombus. Immunohistochemistry was performed on paraffin sections as 
described under materials and methods. (A) Immunostaining of endothelial cells by 
CD31; arrows indicate examples of positive endothelial cells. (B,C) Two examples 
of immunostaining of TAFI with a polyclonal IgG, arrows indicate presence of TAFI. 
Original magnification 400x.
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Discussion
Currently, TAFI is primarily seen as an inhibitor of the plasminogen system 
during fibrinolysis. Yet, there is increasing evidence that TAFI function may 
not be restricted to fibrinolysis but that TAFI may also act as a regulator of 
inflammation and as a modulator of the plasminogen system during tissue 
remodeling and cell migration. In this report we have provided evidence 
for the involvement of TAFI in the formation of capillary-like tubular 
structures by hMVECs in a 3D plasma clot matrix. To our knowledge, these 
results represent the first attempt to investigate the role of TAFI in tissue 
remodeling processes in vitro.
Different groups have recently generated and characterized TAFI knockout 
mice and corroborated the absence of an overt phenotype [30-32]. In 
addition, no anomalous response to a number of acute challenges was found 
for TAFI-/- mice compared to TAFI+/+ wild-type mice. However, this lack of 
a dramatic phenotype is shared with deficiencies of other components of 
the fibrinolytic system [48-52] and does not necessarily mean that TAFI 
does not fulfil a physiologic role. Supporting this notion, te Velde et al. [32] 
have shown that TAFI-/- mice have impaired wound healing and abnormal 
keratinocyte migration. Swaisgood et al. [31] combined TAFI deficiency 
with a plasminogen heterozygous deficiency background demonstrating 
that TAFI regulates the functions of the plasminogen system both in 
fibrinolysis and in cell migration in vivo. Moreover, it should be noted that 
during in vivo tissue remodeling a functional overlap between the functions 
of the plasminogen/uPA system and of the MMP system occurs [53]. It has 
been elegantly shown that wound healing is impaired both in plasminogen-
deficient mice and in wild-type mice treated with the MMP inhibitor galardin. 
Complete arrest of wound healing is only achieved when plasminogen-
deficient mice were treated with a MMP inhibitor [53].
On the basis of present knowledge, different mechanisms by which TAFI 
may play a role in our in vitro model of capillary-like tube formation can 
be envisaged. First, in this model the plasminogen/uPA system localizes 
the proteolytic activity to specific sites on the cell surface, facilitating 
matrix degradation and the invasion into the matrix. Therefore, TAFI might 
inhibit tube formation by removing carboxy-terminal lysines in the plasma 
clot matrix, preventing the upregulation of plasminogen activation in the 
matrix and in this way decreasing proteolysis. This mechanism fits with our 
observations as increasing TAFI or CPB concentrations in the matrix impaired 
tube formation and decreased proteolysis of the matrix (decrease in FbDP 
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release). Adding of a TAFIa inhibitor (PCI) or decreasing TAFI concentration 
in the matrix resulted in the oposite effect that is, the acceleration of tube 
formation and of matrix proteolysis.
Second, it has been shown previously that the treatment of cells with 
pancreatic CPB [23,54-56] and with TAFI [29] results in a striking inhibition 
of plasminogen binding to cells. This binding relies on cell surface receptors 
which have as common characteristcs their relatively low affinity (Kd~1 
µmol/L), high density (104 to 107 sites/cell) and requirement of free 
lysine binding sites of plasminogen. To investigate whether TAFI could be 
involved in the regulation of these receptors we pretreated the hMVECs 
with CPB before seeding them on top of the plasma clot matrix. Our results 
show that pretreatment of the cells efficiently inhibits tube formation and 
downregulates proteolysis suggesting that the modulation of the cell-
associated functions of the plasminogen system by TAFI occurs on several 
levels.
Third, impaired wound healing with a decreased rate of keratinocyte 
migration has been found in plasminogen-deficient mice [52] and recently 
a disturbed keratinocyte migration was also reported in TAFI-/- mice [32]. 
Decreasing TAFI concentration in the plasma clot matrix in our model 
also altered the magnitude of tube formation and the morphology of the 
capillary structures formed suggesting alterations of the migration pattern 
of the hMVECs. In the wound assay, the migration of hMVECs was inhibited 
in a dose-dependent manner by pancreatic CPB, under the same conditions 
as used for the tube formation model. The plasminogen/uPA system (uPAR, 
uPA and plasmin) proved to be involved during the migration of hMVECs, 
under these conditions as well. In agreement with the in vivo results from 
TAFI-/- mice [31,32], TAFI seems to be able to modulate cell migration.
Finally, modulation of the binding of plasminogen and uPA to cell-surfaces 
or the proteolysis of cell surface receptors that change the internalization, 
may cause the activation of signal transduction pathways in the cell [57]. We 
observed a decrease in the accumulation of uPA in the conditioned medium 
when hMVECs were pretreated with pancreatic CPB. Although these results 
are preliminary it has been previously shown that uPA-induced monocyte 
adhesion requires a carboxy-terminal lysine in a pathway in which cAMP-
dependent signal transduction is involved [58].
It should be noted that our results are confined to neovascularization in a 
plasma clot matrix. We can best perceive this in vitro system as a model 
of wound healing angiogenesis and it can be compared to pathological 
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conditions such as the neovascularization of a thrombus incorporated in an 
atherosclerotic plaque. Indeed, TAFI was clearly present both in the matrix 
and in the endothelial cell lining of the newly formed microvessels in the 
thrombus that we analysed by immunohistochemistry.
In the in vitro model of capillary-like tube formation, the 3D plasma clot 
matrix was prepared by the addition of thrombin to plasma. Therefore, 
one may suppose that thrombin and/or thrombin/thrombomodulin were 
responsible for TAFI activation in this model. The complex between 
thrombin and thrombomodulin, the endothelial cell receptor of thrombin, 
is usually depicted as playing a major role in TAFI activation, while the 
physiological role of plasmin-mediated TAFI activation remains limited. 
On the other hand, in a cellular environment plasmin-catalyzed activation 
of TAFI can be stimulated by glycosaminoglycans [4] (15-fold), but the 
catalytic efficiency of plasmin remains lower than that of thrombin/
thrombomodulin. Some characteristics of the assay set-up argue against 
the idea of thrombin-dependent TAFI activation. Namely, after the plasma 
clot matrix was prepared it was incubated for 24 hours at 37oC. This will 
inactivate thrombin and due to the temperature sensitivity, any TAFIa will 
be readily inactivated, as well. Therefore, it seems more likely that the 
activation of TAFI in this model might be mediated by plasmin, but this has 
to be further explored.
In conclusion, our results provide evidence that TAFI is a skilfull modulator 
of the cellular functions of the plasminogen/uPA system. TAFI regulates 
at several levels the fine tuning of capillary tube formation and of matrix 
proteolysis by controling the upregulation of plasminogen binding to the 
plasma clot matrix and to the cell surface and by controling the migration 
of hMVECs.
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THESIS  MODULATION OF THE PLASMINOGEN SYSTEM BY THROMBIN  ACTIVATABLE 






Physiological haemostasis is an exquisitely controlled process, essential 
for blood vessel patency. Haemostasis requires the fast formation of an 
impermeable platelet and fibrin plug at the site of injury but also demands 
the local restriction of the active procoagulant substances to the site of 
injury. The platelet plug rapidly covers the exposed subendothelium and 
creates the ideal surface for the amplification of thrombin generation, as 
well as a physical barrier between the active procoagulant substances and 
the circulating blood [1]. Simultaneously, the fibrinolytic system reacts by 
binding plasminogen and tissue plasminogen activator to fibrin, the target 
substrate of plasmin. The localisation of proteolytic and inhibitory activity 
to this environment allows for selective protection and/or inhibition of 
the active components, resulting in the efficient regulation of fibrinolysis 
(reviewed in [2]). Cell surfaces also regulate the binding of the components 
of the plasminogen system by the expression of a variety of cell surface 
receptors, which are implicated in the spatial organisation, the activation 
and the inhibition of fibrinolytic components. Plasminogen receptors are 
characterised by their low affinity, high density and ubiquitous distribution 
(reviewed in [3]) and provide a tool for localised proteolytic activity. 
Accordingly, the plasminogen/plasmin system is associated with processes, 
in which pericellular fibrinolysis is required for extracellular matrix 
degradation and in cell migration.
Thrombin activatable fibrinolysis inhibitor (TAFI) bridges the coagulant and 
fibrinolytic systems (Chapter 1, reviewed in [4-8]) since it is one of the 
many substrates of thrombin (reviewed in [9]) and when active inhibits 
the amplification of plasminogen activation, thus inhibiting fibrinolysis. 
Carboxy-terminal basic amino acids (C-terminal lysines and arginines) that 
are so critical for the upregulation of plasminogen activation [10,11] also 
mediate other protein-protein interactions. Consequently, these C-terminal 
residues and TAFI fulfil additional roles in inflammation, vascular tone and 
cellular migration [12-17].
This chapter encloses the general conclusions provided in this thesis along 
with a discussion of our results and the literature in an attempt to provide 




TAFI determination in plasma
In this thesis we have studied the determination of TAFI levels and activity 
in plasma, which may be useful for the clarification of the pathophysiological 
mechanisms of TAFI and the evaluation of the diagnostic value of TAFI as 
a cardiovascular risk indicator. Until recently the migration of the activation 
peptide of TAFI during SDS-PAGE was not clear, as the peptide cannot be 
stained in standard staining procedures. In Chapter 2 [18], the migration 
behaviour of the activation peptide of TAFI during SDS-PAGE was established 
along with its detection by Western blotting. This knowledge was used to 
characterise the reactivity of monoclonal anti-TAFI antibodies against either 
TAFIa or the activation peptide of TAFI. New immunological methods that 
use these monoclonal antibodies have been, in the meanwhile, developed 
and constitute a helpful asset for measuring specific fractions of TAFI (e.g. 
TAFI, TAFIa, TAFI activation peptide) [19]. These assays provide a way to 
track TAFI activation in both in vitro and in vivo experimental set-ups. They 
may also have value in assessing the role of TAFI as a cardiovascular risk 
indicator but this has still to be established in clinical and epidemiological 
studies. Until now only one study has been performed concerning the 
elimination of TAFI and TAFIa from the circulation [20] little information 
is available regarding the fate of different TAFI fragments (e.g. TAFI 
activation peptide) in vivo. This may pose a problem when attempting to 
draw conclusions from epidemiological studies, but ultimately such studies 
will provide valuable information regarding in vivo TAFI activation along 
with the fate of the TAFI fragments following activation.
TAFI variability in plasma – Functional activity
The function of TAFI in fibrinolysis is derived from its ability to cleave C-
terminal lysine residues from partially degraded fibrin. A functional TAFI 
activity determination may bring further insight into the anti-fibrinolytic 
performance of TAFI in different individuals. Therefore, a new clot lysis-
based assay for the determination of the TAFI functional activity in plasma 
was developed (Chapter 4, [21]). Such a functional assay should be able to 
trace abnormal molecules with altered activation or inactivation kinetics and/
or with diverse activity. Using this assay the TAFI functional variants (TAFI 
Thr325Ile), which differ slightly in concentration were found to be similar in 
activity. However, when the activity was corrected for the amount of TAFI 




individuals expressing the more stable TAFI variant, TAFI 325Ile (Chapter 
4, [21]), in agreement with findings with recombinant proteins [22]. This 
demonstrates the ability of our assay to detect functional differences in 
TAFIa activity. Moreover, combining the information obtained from different 
assays, which evaluate both TAFI concentration and TAFI functional 
activity, may help to further characterise TAFI heterogeneity. In addition, 
the inactive fragments of TAFI (TAFIai, activation peptide or proteolytic 
fragments) do not interfere in the determination and the activity measured 
is specific to the natural substrate of TAFIa during fibrinolysis. Nevertheless, 
it is important to realise that the assay determines the functional activity 
of maximally activated TAFI in a plasma sample and that the measurement 
represents a composed determination of TAFI concentration and activity 
and of the activity of TAFIa under fixed assay conditions.
TAFI variability in plasma – Issues with assays
The plasma concentration of TAFI was shown to vary considerably in the 
human population and this variability is poorly explained by environmental 
factors (reviewed in [23]). A strong association was reported between TAFI 
levels and TAFI gene polymorphisms suggesting a genetic background 
[24]. In Chapter 3 [25], we established that a lower antibody reactivity 
towards the TAFI Ile-325 variant of the functional SNP 1040 C/T (Thr325Ile) 
resulted in an overestimation of the magnitude of the association between 
TAFI levels and genotypes comprising this SNP. This was also established 
by Gils et al. [26] who developed two distinct ELISAs using specific 
monoclonal combinations with different immunoreactivity towards the 1040 
C/T TAFI SNP (Thr325Ile). In addition, we demonstrated a true association 
between TAFI levels and TAFI gene polymorphisms by using artefact-free 
assays (Chapter 3, [25]). Subsequently, the contribution of the TAFI gene 
variability to the variation in TAFI levels was studied by detailed haplotype 
analysis (-2599C/G, -2345 2G/1G, -1690A/G, -1102G/T, -438G/A, 505A/G 
(Ala147Thr), 1040C/T (Thr325Ile), 1542C/G and 1583T/A) and was found 
to explain only up to 25% of TAFI level variability [27]. This also implies that 
the remaining variability in TAFI levels ought to be the result of additional 
factors, some of which might still be assay-related.
Until now, the epitopes of the antibodies used for the majority of the TAFI 
antigen assays have not been characterised and most assays determine 
total antigen (Chapter 1) although different reactivities have been observed 




besides variable reactivity towards different TAFI genotypes, a variable 
recognition of TAFI fragments can also contribute to the observed TAFI 
antigen differences. These fragments can certainly be expected to appear 
in variable amounts in patients in whom coagulation and fibrinolysis have 
been systemically activated.
Another problem regarding TAFI assays has to do with the standardisation 
of the various assays. Commonly used calibrators consist of pooled plasma 
or purified preparations, which are often poorly characterised and in which 
the TAFI concentration and activity decay are influenced by the particular 
haplotype combination in the calibrator (Chapter 3, [25]).
TAFI variability in plasma – Gene expression control
Current knowledge provides some additional factors that might further 
elucidate the assay-independent variability in TAFI levels. Recently the 
regulation of mRNA stability was revealed to constitute a mechanism for 
controlling gene expression [29]. The intrinsic stability of TAFI mRNA in 
HepG2 cells decreased after combined administration of IL-6 and IL-1 [30]. 
Hence, the regulation of the mRNA transcript stability in relation to the 
location of alternative polyadenylation sites in the 3’UTR of the TAFI gene 
was investigated [31]. The regulation of the TAFI gene expression mediated 
by cytokines took place through the modulation of transcript stability and 
polyadenylation site selection. Thus, this variable transcript stability may 
contribute to the relative abundance of TAFI in the presence of specific 
stimuli.
Moreover, it has been suggested that TAFI is a positive acute-phase 
reactant [23,32,33], which creates the possibility that the TAFI gene 
expression, and particularly TAFI transcription, may be under the control of 
inflammatory stimuli. In addition, sex hormones seem to play a role in TAFI 
gene expression [24,34-37]. Therefore an additional mechanism for the 
regulation of TAFI gene expression may involve the molecular structure of 
the TAFI promoter or the binding of specific transcription factors although 
this remains to be elucidated. In fact, a C/EBP-binding site between position 
-53 and -40 has been identified in the promoter of the TAFI gene and 
elimination of this site strongly decreased the level of promoter activity in 
HepG2 cells but did not abolish it completely [38]. This can be explained 
either by a lower level of promoter activity without the involvement of C/




TAFI promoter. Inspection of the TAFI 5’-flanking region revealed additional 
potential C/EBP-binding sites [38] some of which are located in the 
proximity of putative HNF-3 binding sites (TFSEARCH [39]). HNF-3 and 
C/EBP sites have been described as mutually affecting each other in the IL-
6-induced fibrinogen β expression [40]. Interestingly, the promoter region 
of the C-reactive protein and of fibrinogen α genes, which are also acute 
phase proteins, enclosed a putative HNF-3 site located adjacent to IL-6 
responsive C/EBP elements as well (TFSEARCH). It is well established that 
C/EBP acts as a critical mediator of immune and inflammatory responses 
including the acute phase response [41] and this could constitute another 
mechanism regulating the expression of the TAFI gene. Furthermore, a 
functional glucocorticoid response element has been identified in the TAFI 
promoter close to the C/EBP-binding site [38]. Glucocorticoids are required 
for maximal stimulation of many acute phase genes indicating another 
possible mechanism by which the transcription of the TAFI gene is activated 
during inflammatory processes.
TAFI as a risk factor for venous and arterial thrombosis
The hypothesis that TAFI constitutes a risk for thrombotic disorders seems 
plausible in view of its role as a link between coagulation and fibrinolysis. 
However, it is well established that the aetiology of venous versus arterial 
thrombotic disease presents important differences, which may influence 
the relevance of the TAFI pathway in these two types of thrombosis.
Deep-vein thrombosis (DVT) usually originates in venous valve pockets, 
within which flow separation results in recirculation [42]. The outcome 
is a thrombus with a laminar structure consisting of layers of platelets, 
leukocytes and fibrin, where the main red cell mass is present [43]. In 
the laminar structure of venous thrombi the platelet-rich layers release, 
upon activation, the coagulation and fibrinolytic factors present in their α-
granules (e.g. FVIII, FXI, PAI-1 and TAFI). Thus, these platelet-rich layers 
effectively amplify the procoagulant signal driving thrombin generation into 
the propagation phase. This large-scale thrombin generation will in turn 
increase TAFI activation, further stabilising the thrombus in these areas by 
making them resistant to fibrinolysis.
One of the earliest studies focusing on the role of TAFI in venous thrombosis 
was the LETS study (Leiden Thrombophilia Study). In this case-control 




determined [37] using an artefact-free antigen assay (Chapter 1, Chapter 
3 [25]). Patients with TAFI levels above the 90th percentile of the controls 
had a two-fold higher risk of venous thrombosis. In this same study, 
elevated levels of TAFI increased the risk of thrombosis in individuals with 
elevated circulating factor VIII concentrations whereas elevated TAFI levels 
did not increase the risk in factor V Leiden carriers. Another study focussed 
on the role of TAFI levels as a risk factor in factor V Leiden carriers with 
venous thromboembolism [44], by determining TAFI with an activity-based 
assay. Elevated TAFI and factor VIII levels resulted in an increased risk 
of venous thromboembolism in factor V Leiden carriers. These clinical 
studies corroborate earlier findings, which indicate a role for the intrinsic 
coagulation system in the activation of TAFI through the generation of high 
quantities of thrombin [45-49].
Up to the present only one prospective, multicentre cohort study has 
investigated the role of TAFI in the recurrence of venous thromboembolism 
(Austrian Study on Recurrent Venous Thromboembolism, AUREC) [50] by 
determining the TAFI antigen levels (American Diagnostica, see Chapter 
1). A high TAFI level (above the 75th percentile in patients) was associated 
with a 2-fold higher risk of recurrent venous thromboembolism, though we 
should keep in mind that this TAFI antigen assay is not well characterised 
regarding genotype-related artefacts.
The effect on TAFI levels of different heparin regimens, which influence 
the thrombin generation, was examined in a randomised trial for venous 
thromboembolism (chromogenic assay, see chapter 1) [51]. The authors 
suggest that the significant reduction in TAFI levels found in different 
heparin regimens was related to a more effective regulation of thrombin 
generation by some of the heparins tested. However, if this were the case a 
lower thrombin concentration would result in a decrease in TAFI activation 
and therefore in a relative increase in the TAFI level in plasma.
Finally, the influence of the genetic variation of TAFI gene expression 
(TAFI genotype and haplotype) on the risk of venous thrombosis was also 
investigated. However, the results are rather conflicting as some studies 
found a genotype effect [52] while others found only a trend [53,54] or no 
effect of the genetic component of TAFI [55-57].
In conclusion, the current data support a contribution of elevated TAFI 
antigen levels to the risk of venous thrombosis, though larger studies are 




component of TAFI as well as the relation of TAFI to other known risk 
factors.
Arterial thrombosis usually occurs under high shear stress and is accompanied 
by significant modification or damage to the vessel wall (atherosclerosis) 
leading to the formation of a typical thrombus consisting of a platelet-rich 
“head” followed by a fibrin-rich “tail” [42]. The role of platelets in arterial 
thrombosis is certainly different from that in venous thrombosis. During 
arterial thrombosis the platelet plug constitutes the first response to injury 
while the subsequent decrease of blood flow promotes the formation of 
fibrin. TM redirects the activity of thrombin towards TAFI activation. The 
TAFI activation promotes the stabilisation of the fibrin network and possibly 
prevents embolisation. 
The relationship between TAFI and arterial thrombosis has also been 
examined using both antigen- and activity-based assays, previously 
described in Chapter 1. Discussing the role of TAFI in arterial thrombosis 
is intricate in view of the controversial results previously published. Some 
of these studies found TAFI to be a risk factor for arterial disease [32,58-
66], whereas others found it to be protective [67-69] or to have no 
effect [70-76]. These discrepancies might arise from the lack of proper 
characterisation of the assays used as was discussed above and as shown 
by the results of the Prospective Epidemiological Study of Myocardial 
Infarction (PRIME study) [68,75,77]. Therefore, here we will restrict our 
discussion to clinical studies, which have been performed with antigen 
assays, free from genotype-related artefacts (Chapter 1, Chapter 3 [25] 
and [19,26,27]) or with activity-based assays (Chapter 4 [65] and [32,60-
62,72,73]). The studies with various set-ups (case-control, prospective) 
were conducted in patients with either a cerebral (ischaemic stroke, IS) or 
a cardiac (myocardial infarction, MI; angina pectoris, AP; coronary artery 
disease, CAD) ischaemic event.
Two case-control studies investigated the association between TAFI 
levels and the risk of ischaemic stroke [60,65]. In both studies elevated 
TAFI resulted in an increased risk of ischaemic stroke (TAFI levels in 
patients>120%, OR 5.7; 95%CI 2.3-14.1 and TAFI levels in patients in 
the highest quartile, OR 4.0; 95%CI 1.6-9.8, respectively). Moreover, TAFI 
levels remained elevated in ischaemic stroke patients even 3 months after 
the event [65] whereas CRP levels decreased after 3 months, suggesting 




Silveira et al. [32] determined TAFI levels in patients requiring coronary 
artery bypass grafting (CABG) due to stable angina pectoris. They showed 
that TAFI levels declined from their preoperative level three days after 
surgery but rose in relation to the preoperative level six days after surgery. 
These variations may be related to the consumption of TAFI after surgery 
and to increases in TAFI gene expression during the inflammatory stage. 
Though TAFI was found to be an acute phase protein very little is known 
about its fluctuation upon the onset of inflammation and the relation 
between the inflammatory response profile of TAFI and other acute phase 
proteins, such as fibrinogen, α1-antitrypsin and CRP. The role of TAFI levels 
in acute CAD [62] was also investigated and again a significant increase in 
risk with high TAFI levels (TAFI levels in patients>126%, OR 3.5; 95%CI 
1.3-8.7) was encountered. On the other hand, no difference in TAFI levels 
was found either in a case-control acute MI study [72] or in a study aiming 
to predict reperfusion after acute MI [73] whereas a significant increase 
in TAFI levels was observed in young patients with acute MI [61]. In the 
PRIME study (MI and angina pectoris) no association between TAFI levels 
and the risk of coronary heart disease was found.
A role for TAFI in arterial thrombosis might arise from the differential 
expression of thrombomodulin (TM), which is modulated through a variety 
of factors [78]. TM is down regulated in the presence of oxidised LDL, 
increased shear stress conditions and under inflammatory conditions where 
oxidation of methionine 388 of TM occurs, conditions which are typical of 
the atherosclerosis process and thus are somehow involved during arterial 
thrombosis. This down-regulation may result in the inhibition of APC 
pathway while TAFI activation is preserved. This together with an enhanced 
transcription of the TAFI gene under inflammatory conditions may lead to 
an increased risk of developing arterial thrombosis.
Modulation of the plasminogen system by TAFI
At present, any thrombolytic therapy regimen relies on the activation of 
the fibrinolytic system in the patient by the administration of plasminogen 
activators (PAs) [79]. These PAs convert the precursor plasminogen into 
plasmin, the active enzyme responsible for the proteolytic degradation of the 
fibrin fibres of the thrombus. It follows that the efficiency of thrombolysis is 
influenced by the properties of the PA, the thrombus structure, the supply 
of plasminogen and PA to the boundary and interior of the thrombus and by 




system. These inhibitors are directed towards the inhibition of the PAs (PAI-
1), the direct inhibition of plasmin (plasmin inhibitor, previously named α2-
antiplasmin and to a lesser extent α2-macroglobulin) and the inhibition of 
the cofactor activity of partially degraded fibrin on plasminogen activation 
(TAFI). Up to now, tPA has been the PA most widely used for investigating 
the effect of TAFI on fibrinolysis both in vitro [46,80-87] and in vivo [88-
93]. However, it still remains unclear whether TAFI contributes to the sub-
maximal efficacy observed during thrombolytic therapy. In Chapter 6 [94] 
we investigated the inhibitory effect of TAFI in an internal plasma clot lysis 
model mediated by a variety of PAs, which represent all major classes of 
currently available thrombolytic drugs. In such a model, plasminogen and 
the PA are distributed throughout the plasma clot. TAFIa inhibited clot lysis 
mediated by each PA in a PA concentration-dependent manner. The effect 
of TAFI was small at low PA concentrations, which we attributed to the 
restricted stability of TAFIa. The maximal TAFIa-related inhibition varied for 
different PAs but was not related to the fibrin specificity of the PA. As TAFIa 
eliminates the newly formed binding sites for plasminogen and plasmin 
on fibrin, it might be able to modulate plasmin activity. It is known that 
fibrin-bound plasmin becomes more resistant to inactivation by plasmin 
inhibitor (PI) [95,96]. We studied the role of PI in the mechanism of TAFIa 
retardation of clot lysis (Chapter 6, [94]). In our model, PI did not play 
a significant role in the inhibition of plasma clot lysis by TAFI. Recently, 
TAFIa was shown to eliminate the protection of plasmin from PI by cleaving 
the exposed C-terminal residues on partially degraded fibrin, in a purified 
system [97]. This apparent discrepancy might result from the differences 
between the two systems used.
In addition, we investigated the fibrinolytic efficacy of three PAs 
(Tenecteplase, Amediplase and scu-PA) in external plasma clot lysis models 
examining the inhibitory effect of TAFI as well (Chapter 7). External plasma 
clot lysis resembles more thrombolytic therapy as the PA reaches the clot 
after its formation. TAFIa also displayed an inhibitory effect in external 
lysis, when thrombomodulin was present. This effect was again dependent 
on the type and concentration of the PA used. The inhibitory effect of 
TAFIa was high at low PA concentration and decreased at increasing PA 
concentrations.
The TAFIa effect became negligible in the therapeutic range, both in the 
internal and external plasma clot lysis model (Chapter 6 and 7). Our 




and PA concentrations at which a high plasmin concentration is achieved. 
This may be the outcome of the inhibition of TAFI and TAFIa by proteolytic 
cleavage by plasmin or arise from the loss of fibrin specificity that makes 
plasminogen activation less dependent on the availability of C-terminal 
lysines on fibrin. This is in agreement with previous findings [80,85,98]. 
These results suggest that the role of TAFI during optimal and successful 
thrombolytic therapy is probably low. Nevertheless, depending on the 
thrombus composition and architecture, haemodynamic conditions and 
distinct physiological interactions of plasminogen and PAs in the vascular 
environment, it is conceivable that the local PA concentration does not 
always reach optimal levels. This creates conditions, in which TAFI might 
affect the lysis rates during thrombolytic therapy.
The role of the plasminogen system in cardiovascular disease is not restricted 
to the degradation of fibrin as this system is also involved in the degradation 
of other matrix proteins, the activation of matrix metalloproteinases, the 
regulation of growth factor and chemokine pathways and in directed cell 
migration (reviewed in [99]). Plasminogen is activated to plasmin during 
wound healing [100] and a delayed reepithelisation of cutaneous wounds is 
observed in plasminogen-deficient mice [101]. In physiological plasminogen 
activation tPA seems to function mostly intravascularly, whereas uPA acts 
predominantly in extravascular spaces as a major player in cell migration 
and matrix remodelling [102]. In Chapter 8, we investigated the role of TAFI 
during in vitro capillary tube formation by human microvascular endothelial 
cells (hMVECs) in a 3D plasma clot matrix. In this in vitro model of wound 
healing, the plasminogen system plays a pivotal role and activation is mainly 
mediated by uPA [103]. TAFI is capable of preventing the upregulation of 
plasminogen activation not only on partially degraded fibrin but probably 
also on cell surfaces (shown with pancreatic carboxypeptidase B treatment, 
which is homologous to TAFIa [104-108]). We showed in vitro that this 
ultimately leads to the inhibition of cellular proteolysis and to a decreased 
and/or altered cell migratory response. This effect of TAFI on cellular 
migration was observed not only in our in vitro capillary tube formation 
experiments (Chapter 8) but also in an in vivo model of wound healing [16] 
and in a thioglycollate model of peritoneal inflammation [15]. These results 






During the initiation phase of coagulation the availability of thrombin 
substrates and of its cofactors directs the initial burst of thrombin activity 
affecting thrombus architecture and composition [9]. Thrombin substrate 
recognition involves the direct interaction between the substrate and 
thrombin’s exosites with or without the assistance of a cofactor, which increases 
considerably the efficiency of substrate cleavage. For substrate reactions 
assisted by cofactors, the reaction is rather inefficient in the absence of the 
cofactor and therefore unlikely to take place in vivo [9]. Hence it is believed 
that the complex between thrombin and thrombomodulin (TM) constitutes 
a physiologic activator of TAFI in the initiation phase of coagulation. The 
thrombin/TM complex is also the physiological activator of protein C [109]. 
This is important in the context of an injury or inflammatory stimulus where 
the cell-surface expression of TM is abrogated by various pathways [78]. 
Subsequently, the suppression of TM expression leaves thrombin activity 
uncontrolled resulting in the amplification of the inflammatory stimulus. 
Under these conditions, i.e. low TM, protein C activation is hampered while 
TAFI activation is relatively preserved [110], stabilising the thrombus at 
the site of injury and possibly also down-regulating inflammation [12-15]. 
Moreover, the ability of TAFIa to avoid precocious thrombus dissolution 
and thus prevent delayed rebleeding has provided an explanation for the 
bleeding tendency of factor XI-deficient individuals. The failure to produce 
high thrombin concentrations via a factor XI-dependent way was shown to 
decrease TAFI activation and to downregulate fibrinolysis in these individuals 
[111,112]. In fact, TAFI activation in the presence of TM, which requires 
only low thrombin concentrations, was able to correct the premature 
lysis of clots from factors X-, IX-, VIII-, and XI-deficient plasmas in vitro 
[84] (reviewed in [6,7]). Both tissue transglutaminases (TG) and FXIIIa 
catalysed the cross-linking of TAFI and TAFIa to fibrin [113]. The binding 
depended on the concentration of TG or FXIIIa and on the availibility of 
calcium. TAFI was cross-linked to a similar extent as was α2-antiplasmin, 
suggesting that the incorporation has biological significance. Interestingly, 
the cross-linking sites were located both in the TAFI activation peptide 
and in TAFIa suggesting that TAFIa remains associated with fibrin, which 
might increase its conformational stability and alter TAFI activation and 
inactivation kinetics significantly.
Glycosaminoglycans can enhance activation of the complement cascade as 




some components of the complement system [12-15]. Recently, it was 
shown that the activation of TAFI mediated by plasmin occurred during 
the final phase of internal plasma clot lysis [115]. In such a system this 
second burst of TAFI activity did not influence fibrinolysis as it occurred 
in the end stage of lysis. However, in the in vivo situation where external 
lysis takes place activation of TAFI by plasmin may occur and may 
have physiological relevance both in fibrinolysis and in inflammation 
management. If it is established that plasmin has the ability to modulate 
TAFI activation in vivo, the downregulation of inflammation by TAFIa may 
accompany the proteolytic activity of the plasminogen system. CPN, the 
other carboxypeptidase B, present in the circulation as an active enzyme 
that is also able to downregulate inflammation [116] fulfils a different role 
from TAFIa in the circulation.
Under normal conditions, the vasculature remains intact and the haemostatic 
balance is maintained. Howerver, chronic exposure of the vascular bed to 
a variety of subtle stimuli slowly but surely devises a state of endothelial 
dysfunction. Such a endothelial dysfunction state is often accompanied 
by increased vascular permeability followed by extravasation of plasma 
proteins and may result in a vicious circle where inflammation-induced 
coagulation leads to coagulation-induced inflammation [117].
Currently the understanding of the role of TAFI in the cross-talk between 
coagulation, complement system, fibrinolysis, pericellular fibrinolysis, 
atherosclerosis and inflammation is rather limited. The intricacy of TAFI 
provides additional challenges when investigating the role of TAFI in these 
processes. At present it is becoming clear that the functions of TAFI in the 
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THESIS  MODULATION OF THE PLASMINOGEN SYSTEM BY THROMBIN  ACTIVATABLE 
FIBRINOLYSIS INHIBITOR (TAFI)       
SUMMARY / SAMENVATTING




Haemostasis is an exquisitely controlled process, essential for blood vessel 
patency. Haemostasis requires the fast formation of an impermeable 
platelet and fibrin plug at the site of injury but also demands the local 
restriction of the active procoagulant substances to the site of injury. The 
platelet plug rapidly covers the exposed subendothelium and creates the 
ideal surface for amplification of thrombin generation, as well as a physical 
barrier between the active procoagulant substances and the circulating 
blood. Simultaneously, the fibrinolytic system reacts by binding plasminogen 
and tissue plasminogen activator to fibrin, the target substrate of plasmin. 
The localisation of proteolytic and inhibitory activity to this environment 
allows for selective activation, protection and/or inhibition of the active 
components, resulting in an efficiently regulated fibrinolytic system. Cell 
surfaces also regulate the binding of the components of the plasminogen 
system by the expression of a variety of cell surface receptors, which are 
implicated in the spatial organisation, the activation and the inhibition of 
these fibrinolytic components. Thrombin activatable fibrinolysis inhibitor 
(TAFI) bridges the coagulant and fibrinolytic systems since it can be 
activated to become TAFIa by thrombin formed via the coagulation 
cascade and TAFIa inhibits the amplification of plasminogen activation, 
thus inhibiting fibrinolysis. The mechanism of action of TAFI is related to 
the second phase of plasminogen activation. In this phase plasmin cleaves 
fibrin and generates carboxy-terminal lysine residues in the fibrin network, 
which represent additional binding sites for plasminogen. As a result of 
additional plasminogen binding, plasminogen activation and fibrinolysis 
are strongly accelerated. TAFIa, being a carboxypeptidase B, eliminates 
carboxy-terminal terminal lysine and arginine residues thus blocking the 
upregulation in the plasminogen activation.
The work presented in this thesis was structured in three sections. The 
first section deals with some biochemical properties of TAFI while the 
second section describes the assessment of TAFI assays along with the 
development, validation and implementation of new methodology for the 
functional determination of TAFI in plasma samples. Finally, the third section 
examines the involvement of TAFI in the modulation of the plasminogen 
system during fibrinolysis and during pericellular proteolysis.
In Chapter 1 the current knowledge in the TAFI field is reviewed and the 
characteristics of the currently available TAFI assays are considered in detail.
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The activation peptide of TAFI is heavily glycosylated with the carbohydrate 
content accounting for about 20% of the total mass of the zymogen. However, 
until recently the migration of the activation peptide of TAFI during SDS-
PAGE was not clear. In this thesis (Chapter 2), the migration behaviour 
of the activation peptide of TAFI during SDS-PAGE was established along 
with its detection by Western blotting. In addition, we used this knowledge 
to characterise the reactivity of monoclonal anti-TAFI antibodies against 
either TAFIa or the activation peptide of TAFI, facilitating the development 
of assays appropriate for tracking TAFI activation in vitro and in vivo.
In Chapter 3 we evaluated several assays for the determination of TAFI in 
plasma. The results in this chapter demonstrate a variable immunoreactivity 
of some antibodies towards TAFI Thr325Ile isoforms (TAFI 1040C/T SNP). 
The recognition of the TAFI 325Ile functional variant by these antibodies 
is impaired, leading to an underestimation in the determination of TAFI 
antigen levels and to a fictitious amplification of the genotype-related 
variation of TAFI concentration. Still, we showed a true association between 
TAFI levels and TAFI gene polymorphisms when using artefact-free assays. 
Chapter 4 covers the development and validation of a new TAFI functional 
activity assay, based on the retardation of plasma clot lysis by TAFIa. The 
TAFI-related retardation of clot lysis was determined in a group of healthy 
individuals and found to correlate with TAFI antigen level while the specific 
antifibrinolytic activity of TAFI was associated with the - 438A/G and 1040C/
T TAFI genotypes. Thereafter, in Chapter 5 we addressed the role of TAFI 
functional activity levels as well as TAFI genotype distribution in relation 
to ischaemic stroke. In a case-control study (COCOS study) no association 
was found between TAFI genotype or haplotype and the risk of stroke. 
However, increased TAFI functional activity was associated with a higher 
risk of ischaemic stroke even after adjustment for potential confounders.
TAFI is nowadays regarded as a potent inhibitor of fibrinolysis but its effect 
on the efficiency of thrombolysis which is influenced by the properties of 
the plasminogen activator (PA), the thrombus structure and the supply of 
plasminogen and PA to the boundary and interior of the thrombus, is not 
fully resolved. Therefore, in Chapter 6 we investigated the inhibitory effect 
of TAFI in an internal plasma clot lysis model mediated by a variety of PAs, 
which represent all major classes of thrombolytic drugs. TAFI inhibited clot 
lysis mediated by each PA in a PA concentration-dependent manner. In 
addition, in Chapter 7 we investigated the fibrinolytic efficacy of three 
PAs in external plasma clot lysis models, examining as well the inhibitory 
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effect of TAFI. TAFIa displayed an inhibitory effect in external lysis, when 
thrombomodulin was present. This effect was dependent on the type and 
concentration of the PA used. The inhibitory effect of TAFIa was high at 
low PA concentration and decreased with increasing PA concentrations. 
Both in the internal and external plasma clot lysis model the TAFIa effect 
became negligible in the therapeutic range. Our findings show that the loss 
of the TAFIa effect coincides with plasminogen and PA concentrations at 
which a high plasmin concentration is achieved. This may be the outcome 
of the inhibition of TAFI and TAFIa by proteolytic cleavage by plasmin or 
arise from the loss of fibrin specificity that makes plasminogen activation 
less dependent on the availability of C-terminal lysines on fibrin. There 
is growing evidence suggesting that TAFI behaves as a broad modulator 
of the plasminogen system. In Chapter 8, we studied the involvement 
of TAFI in an in vitro model of capillary-like tube formation, a wound-
healing angiogenesis model where a 3D plasma clot matrix is employed. 
Due to the composition of the matrix, the results may be extrapolated to 
the neovascularisation of a fibrinous exudate in vivo. TAFI modulated in 
vitro capillary tube formation by inhibiting plasminogen-dependent cellular 
proteolysis and decreasing and/or modifying endothelial cell migration.
Chapter 9 contains a general discussion of our work in relation to 
recent developments in TAFI research. Special attention is given to the 
determination of TAFI in plasma considering the role of different assays 
and of gene expression control on the variability of TAFI concentration 
as well as the repercussions to the evaluation of TAFI as a risk factor in 
venous and arterial thrombosis. Finally, the modulation of the plasminogen 
system by TAFI is discussed together with its role in the cross-talk between 
coagulation, complement system activation, fibrinolysis, pericellular 
fibrinolysis, atherosclerosis and inflammation. The intricacy of TAFI provides 
additional challenges when investigating the role of TAFI in this cross-talk. 
At present it is already becoming clear that the functions of TAFI in the 
vasculature go beyond the inhibition of fibrinolysis.




Hemostase is een uitermate nauwkeurig gereguleerd proces en van groot 
belang voor het intact en open houden van bloedvaten. Voor hemostase 
is de snelle vorming van een impermeabele trombocyten- en fibrineplug 
nodig, maar ook beperking van de actieve stollingsbevorderende factoren 
tot de beschadigde plek. De trombocytenplug bedekt het blootgelegde 
subendotheliale weefsel snel en vormt het optimale oppervlak voor 
amplificatie van trombinevorming en vormt bovendien een fysieke barrière 
tussen de actieve stollingsbevorderende factoren en het circulerende 
bloed. Tegelijkertijd reageert het fibrinolytisch systeem door de binding 
van plasminogeen en weefselplasminogeenactivator (tPA) aan fibrine, het 
substraat van plasmine. De concentratie van proteolytische en remmende 
activiteiten op deze plek zorgt voor selectieve activatie, bescherming en/of 
remming van de actieve componenten en dit resulteert in een efficiënte 
regulatie van de fibrinolyse. Celoppervlakken reguleren eveneens de binding 
van componenten van het plasminogeenactivatie systeem door de expressie 
van verschillende receptoren, die betrokken zijn bij de ruimtelijke organisatie, 
de activatie en de remming van deze fibrinolytische bestanddelen. De door 
trombine activeerbare fibrinolyse inhibitor (TAFI) vormt een brug tussen het 
stollings- en het fibrinolytisch systeem, doordat het geactiveerd kan worden 
tot TAFIa door trombine dat gevormd wordt in de stollingscascade en TAFIa 
de amplificatie van plasminogeenactivatie verhindert en zo fibrinolyse remt. 
Het werkingsmechanisme van TAFI is gerelateerd aan de tweede fase van 
plasminogeenactivatie. In deze fase wordt fibrine door plasmine gekliefd 
en ontstaan carboxy-terminale lysine residuen in het fibrine netwerk en 
deze vormen additionele bindingsplaatsen voor plasminogeen. Als gevolg 
van de additionele plasminogeenbinding worden plasminogeenactivatie en 
fibrinolyse sterk versneld. TAFIa is een carboxypeptidase B en verwijdert 
carboxy-terminale lysine en arginine residuen en blokkeert zo de toename 
van de plasminogeenactivatie.
Het onderzoek in dit proefschrift is verdeeld in drie secties. In het eerste 
gedeelte worden enkele biochemische eigenschappen van TAFI bestudeerd, 
terwijl in het tweede deel TAFI assays worden beoordeeld en de ontwikkeling, 
validatie en implementatie van een nieuwe methode voor de functionele 
bepaling van TAFI in plasma wordt beschreven. Tenslotte wordt in het derde 
deel de betrokkenheid van TAFI bij de modulering van het plasminogeen 
systeem tijdens fibrinolyse en tijdens pericellulaire proteolyse onderzocht.
In hoofdstuk 1 wordt een overzicht gegeven van de huidige kennis in het 
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onderzoeksgebied van TAFI  en worden de karakteristieken van de op dit 
moment beschikbare TAFI assays in detail besproken. Het activatiepeptide 
van TAFI is sterk geglycosyleerd waarbij de koolhydraat component ongeveer 
20% van de gehele zymogeenmassa vormt. Tot voor kort was echter de 
migratie van het activatiepeptide van TAFI tijdens SDS-PAGE niet duidelijk. 
In dit proefschrift (hoofdstuk 2) werden de migratie eigenschappen tijdens 
SDS-PAGE van het activatiepeptide van TAFI vastgesteld door de detectie 
ervan door Western blotting. Daarnaast werd deze kennis gebruikt om de 
reactiviteit van monoclonale antistoffen tegen TAFIa en het activatiepeptide 
van TAFI te karakteriseren, hetgeen de ontwikkeling van assays om TAFI 
activatie in vitro en in vivo te kunnen volgen, vereenvoudigde.
In hoofdstuk 3 worden verschillende assays voor de bepaling van TAFI in 
plasma geëvalueerd. De resultaten in dit hoofdstuk tonen een variatie aan van 
de immunoreactiviteit van enkele antistoffen tegen TAFI Thr325IIe isovormen 
(TAFI 1040C/T SNP). De herkenning van de TAFI 325IIe functionele variant 
door deze antistoffen is verminderd en dit leidt tot een onderschatting bij 
de bepaling van TAFI antigeen concentraties en tot een fictieve toename 
van de genotype-gerelateerde variatie in TAFI concentraties. Desondanks 
konden wij een echte associatie aantonen tussen TAFI concentraties en 
TAFI genpolymorfismen door gebruik van assays zonder deze artefacten. 
Hoofdstuk 4 omvat de ontwikkeling en validatie van een nieuwe assay voor 
de bepaling van de functionele activiteit van TAFI gebaseerd op de vertraging 
van de lysis van plasma stolsels door TAFIa. De aan TAFI gerelateerde 
vertraging van de stolsellysis werd bepaald in een groep gezonde individuen 
en bleek te correleren met TAFI antigeen concentraties terwijl de specifieke 
antifibrinolytische activiteit van TAFI geassocieerd was met de -438 A/G en 
1040 C/T TAFI genotypes. Daarna, in hoofdstuk 5, bestudeerden we de rol 
van de functionele TAFI activiteit in relatie tot ischemische herseninfarcten. 
In een case-control studie (COCOS studie) werd geen associatie gevonden 
tussen TAFI genotype of haplotype en het risico op een herseninfarct. 
Een toegenomen functionele activiteit van TAFI was daarentegen wel 
geassocieerd met een hoger risico voor een ischemisch herseninfarct, ook 
na correctie voor potentiële confounders.
TAFI wordt tegenwoordig beschouwd als een krachtige remmer van 
de fibrinolyse, maar het effect ervan op de efficiëntie van thrombolyse, 
welke beïnvloed wordt door de eigenschappen van plasminogeenactivator 
(PA), de structuur van de trombus en toevoer van plasminogeen en PA 
naar zowel de buitenkant en het binnenste van de trombus, is nog niet 
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geheel bekend. Daarom hebben we, in hoofdstuk 6, het remmende effect 
van TAFI onderzocht in een intern plasmastolsellysis model, gemedieerd 
door verschillende soorten PAs die alle grote klassen thrombolytische 
geneesmiddelen vertegenwoordigen. TAFI remde stolsellysis gemedieerd 
door elke PA op een PA concentratie-afhankelijke manier. Daarnaast 
bestudeerden we in hoofdstuk 7 zowel de fibrinolytische effectiviteit van 
drie PA’s als de remmende invloed hierop van TAFI in een extern stolsellysis 
model. TAFIa vertoonde een remmend effect in het externe lysis model 
in aanwezigheid van thrombomoduline. Dit effect was afhankelijk van de 
soort en de concentratie van de gebruikte PA. Het remmende effect van 
TAFIa was sterk bij een lage PA concentratie en nam af bij toenemende PA 
concentraties. Zowel in het externe als het interne plasmastolsellysis model 
werd het TAFIa effect verwaarloosbaar in de therapeutische range. Onze 
bevindingen tonen aan dat het verlies van het TAFIa effect samenvalt met 
plasminogeen en PA concentraties waarbij een hoge plasmine concentratie 
wordt bereikt. Dit zou het gevolg kunnen zijn van de remming van TAFI of 
TAFIa door proteolytische klieving door plasmine of zou het gevolg kunnen 
zijn van het verlies van fibrine-specificiteit dat plasminogeenactivatie 
minder afhankelijk maakt van de beschikbaarheid van C-terminale lysine 
residuen op fibrine. Er zijn steeds meer aanwijzingen dat TAFI zich gedraagt 
als een brede modulator van het plasminogeen systeem. In hoofdstuk 8 
hebben we de betrokkenheid van TAFI onderzocht in een in vitro model 
van capillair vorming, een wondhelings-angiogenese model waarin een 
3D plasma stollingsmatrix wordt toegepast. Door de samenstelling van 
de matrix zouden de resultaten geëxtrapoleerd kunnen worden naar de 
neovascularisatie van een fibrineus exsudaat in vivo. TAFI moduleerde de 
in vitro capillair vorming door remming van de plasminogeen-afhankelijke 
cellulaire proteolyse en door afname en /of verandering van de migratie van 
endotheelcellen.
Hoofdstuk 9 bevat een algemene discussie van ons werk in relatie tot 
recente ontwikkelingen in het TAFI onderzoek. Speciale aandacht wordt 
gegeven aan de bepaling van TAFI in plasma rekening houdend met de 
rol van de verschillende assays en van de controle door genexpressie op 
de variatie in TAFI concentraties evenals de repercussies op de evaluatie 
van TAFI als risicofactor voor veneuze en arteriële trombose. Tenslotte 
wordt de modulatie van het plasminogeen systeem door TAFI besproken 
samen met de rol van TAFI in de “cross-talk” tussen stolling, complement 
activatie, fibrinolyse, pericellulaire fibrinolyse, atherosclerose en ontsteking. 
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De complexiteit van TAFI leidt tot nieuwe uitdagingen voor het onderzoek 
naar de rol van TAFI in deze “cross-talk”. Momenteel wordt al duidelijk 
dat de functies van TAFI in het vaatstelsel verder gaan dan remming van 
fibrinolyse alleen.
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